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The use of skin-lightening products (SLPs) in an attempt to lighten the skin is a common 
practice among most African countries, with Nigeria making up the largest population in 
terms of sheer numbers.  These products are aimed at modulating melanogenesis through 
their active ingredients by acting on the tyrosinase enzyme in order to control unwanted 
skin pigmentation.  This in turn results in several health complications especially after 
their prolonged use.  The major concern is that most of these SLPs contain active 
ingredients that are either banned or exceed regulation limits and do not comply with 
labelling requirements.  This has resulted in the Nigerian Food and Drug Agency 
(NAFDAC) prohibiting all forms of bleaching agents in cosmetics and toiletries sold in 
Nigeria.  Nevertheless, products containing skin-lightening agents are still widely 
available. 
In this project, 35 skin-lightening formulations were sourced from Ilorin State in Nigeria.  
They were analysed in order to identify and quantify the organic active ingredients and 
heavy metals present in them.  
All of the 35 skin-lightening formulations were investigated for the presence of some 
selected organic active ingredients.  An appropriate extraction method was developed for 
these active ingredients, which included hydroquinone, benzoquinone, kojic acid, 
niacinamide, arbutin, clobetasol propionate, betamethasone dipropionate and 
clotrimazole.  The extracts were analysed by reversed-phase high performance liquid 
chromatography (HPLC) with photodiode array detection in an isocratic mode. 
Of the total samples analysed, 32 of the products were found to contain at least one or 
more of the active ingredients.  Hydroquinone was detected in 15 samples in 
concentrations ranging from 0.017 to 7.096% (m/m).  Some of the samples containing 
hydroquinone were also found to contain benzoquinone.  Hydroquinone is unstable in 
some formulations and hydrolyses to benzoquinone.  Of the six samples found to contain 
benzoquinone, its concentration ranged from 0.005 to 0.015% (m/m).  Kojic acid was 
detected in nine samples in the range of 0.017 to 1.412% (m/m).  Four samples were found 
to contain niacinamide.  The concentration of niacinamide in the samples ranged from 
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0.029 to 1.827% (m/m).  Arbutin was not detected in any of the products.  Steroid 
compounds were detected in 13 of the studied samples.  Eight samples were found to 
contain clobetasol propionate, two samples were found to contain both clobetasol 
propionate and clotrimazole, and three samples were found to contain betamethasone 
dipropionate.  The concentrations of clobetasol propionate, betamethasone dipropionate 
and clotrimazole were found in the range of 0.007 to 0.035, 0.019 to 0.027 and 0.007 to 
0.012% (m/m) respectively. 
The HPLC methods developed were validated by intra-day and inter-day reproducibility 
of standards, linearity of calibration lines, limits of detection and quantification, and 
recovery tests.  The linear correlation coefficients were found to be greater than 0.995, 
the acceptable recovery values ranged from 84.23 to 110.33%, and the percent relative 
standard deviation (%R.S.D.) for the intra-day precision ranged from 0.17 to 8.16% while 
that of the inter-day precision ranged from 0.14 to 4.78%.  This shows that the methods 
developed are reproducible with good precision. 
The second part of the study involved the analysis of the heavy metal content of the same 
products and also the assessment of the possible exposure risk due to the use of these 
products.  The heavy metals investigated included As, Al, Cd, Co, Cr, Co, Fe, Mn, Ni, 
Pb, Zn and Hg.  These elements were extracted into solution by acid-assisted microwave 
digestion.  The extracts were analysed for the metallic elements by inductively coupled 
plasma-optical emission spectrometry and cold-vapour atomic absorption spectrometry 
for Hg.  As, Cd and Co were not detected in any of the formulated SLPs.  Al was detected 
in all the samples and the maximum concentration found was 0.354 µg g-1.  Fe, Mn, and 
Cu were detected in most of the samples at levels not exceeding 1.252 µg g-1, 0.053 µg g-
1, and 0.056 µg g-1 respectively.  Zn was detected in all the samples but was relatively 
high in SLP 33 (76.33 µg g-1).  Cr was found in 21 samples at a maximum concentration 
of 0.217 µg g-1.  Pb was detected in all samples with concentrations not exceeding 0.026 
µg g-1 and nickel was detected in 26 samples at a maximum concentration of 0.433 µg g-
1.  One sample (SLP 6) was found to have a relatively high level of mercury (69.86 µg g-
1).  This level of mercury in a skin-lightening cream is alarming due to its high toxicity 
and that the presence of mercury in cosmetics is banned. 
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The systemic exposure dosage and margin of safety values for the studied SLPs show that 
the level of metal contents detected in these products are safe for use except in the case 
of one of the samples containing a relatively high level of Hg with a systemic exposure 
dosage of 2.07 × 10-2 mg kg-1 bw day-1 and a margin of safety value of 2.41.  The World 
Health Organization proposed the provisional tolerable daily intake for mercury to be 
7.14 × 10-4 mg kg-1 bw day-1 and the minimum margin of safety value of 100 for any 
heavy metal to be safe for use in skin-lightening products. 
It is evident from the results of the present study that banned and toxic ingredients, such 
as hydroquinone, mercury and very potent steroids, like clobetasol propionate and 
betamethasone dipropionate, are still found in skin-lightening products in the Nigerian 
market in spite of the NAFDAC prohibition.  This is worrisome as it can expose users to 
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INTRODUCTION AND LITERATURE REVIEW 
Skin-lightening, or in other words, skin-whitening, or skin-bleaching, has become a 
global concern.  Among the possible ways of achieving a lighter skin is through the use 
of cosmetic skin-lightening products (SLPs), which can take many forms, including 
creams, ointments, solutions, and gels.  The active ingredients in these products act on 
the tyrosinase enzyme to prevent melanin formation.  Melanin, a major dark pigment 
found in the skin, hair and eyes, serves to provide protection against harmful ultraviolet 
radiation capable of causing photoaging and photocarcinogenesis (1, 2).  Consequently, 
these products are aimed at modulating melanogenesis in order to control unwanted skin 
pigmentation such as freckles, melasma, age spots, acne, scars, or discoloration related to 
hormones, and most of all to lighten naturally dark skin.  However, the use of SLPs does 
come with some risk.  Several active ingredients in SLPs have been shown to be effective 
and non-detrimental, while some have proven to be toxic or have a questionable safety 
profile, adding to the controversy surrounding their use and impact on certain ethnic 
groups.  
In Nigeria, the use of SLPs to lighten skin is common especially among women.  The 
perception of a light skin signifying beauty, grace and high social ranking, encourages 
most women to indulge in the use of SLPs.  The use of these products cuts across all 
sociodemographic characteristics, including religious groups, rich or poor, single or 
married, literate or illiterate.  But, unfortunately, most of these women end up indulging 
in SLPs that bleach the skin, and they neglect any form of injury to their bodies or threat 
to their health.  A myriad of these products contain different kinds of skin-lightening 
agents (SLAs) that after prolonged use may eventually affect the users’ health through 
dermal absorption.  These include formulations containing mercury, corticosteroids, and 
hydroquinone.  However, the list of SLAs has now expanded as a result of some 
manufacturers introducing new chemicals of unknown safety profile such as kojic acid, 
niacinamide, arbutin, triethanolamine and many more.  In addition, there have been 
reports (3-6) on the presence of heavy metals, such as Cd, Cr, Cu, Ni, and Pb, in a variety 
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of cosmetic products including SLPs.  Since heavy metals bioaccumulate, they too can 
exert toxic health effects. 
The source of danger arises as a result of over exposure to certain chemicals. 
Hydroquinone, the gold standard in skin-lightening, is known to cause contact dermatitis, 
exogenous ochronosis and dyschromia (7-9).  Prolonged use of corticosteroids is 
associated with cutaneous, ophthalmologic and endocrinologic complications (10-13).  
Continuous exposure to mercury can lead to neurological damage (14).  Moreover, it has 
been established that diverse health effects, such as kidney, blood vessel and nervous 
system damage, miscarriage, infertility in men and women, hormonal changes and 
behavioural problems, can be induced by exposure to toxic metals (15).  
The cosmetic safety regulations of the European Union (EU) have prohibited the use of 
hydroquinone in cosmetics, while the United States Food and Drug Administration (US 
FDA) proposed a maximum of 1.5-2.0% hydroquinone as an active ingredient in over-
the-counter cosmetics (16).  In addition, the US FDA have also stated that mercury should 
be less than 1 µg g-1 under good production practice resulting from unavoidable impurities 
(16).  In spite of several efforts made by various health bodies to increase awareness of 
the dangers of skin-bleaching and governmental bans of harmful ingredients, the practice 
of skin bleaching and the use of potentially harmful ingredients in SLPs does not seem to 
slow down, rather it is ongoing and growing in most African countries and around the 
world. 
In this study, a number of SLPs were investigated and analysed in an attempt to identify 
and quantify the active organic SLAs and heavy metals in them. 
 
1.1  A general overview of skin-lightening practices 
From time immemorial and among the different races of people, and in various places 
around the world, a myriad of concoctions have been used to lighten the skin.  According 
to Blay (17), the practice of skin-lightening actually began in Europe and stems from 
Queen Elizabeth I’s efforts to make her skin appear ghostly white, and nearly transparent.  
This extremely pale skin became known as the Elizabethan ideal of beauty.  These ideals 
were later carried over to the Americans by female European settlers. 
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Another common propaganda that lead to the practice of skin-lightening was based on the 
dichotomy of white versus black and light versus dark as they were, and are still, viewed 
as pure and opposite to each other.  Glenn (18) explains that the concept of colourism in 
southern Africa is among the negative inheritance of European colonialism.  The white 
supremacy ideology that the European colonists brought associated blackness in natives 
with primitiveness, lack of civilisation, unrestrained sexuality, pollution and dirt.  This 
served as a potent type of threat against black people and also the group of darker skinned 
or brown people around the world (18).  In order to escape these negative associations in 
the form of discrimination and concrete oppression, ill-informed black people strived to 
attain a light skin through bleaching and various other ways. 
Blay (17) gives the most common reasons provided by Ghanaian and Tanzanian women 
for using SLPs.  They include to get rid of blemishes and to mitigate the effects of the 
sun, to appear and feel clean, to look beautiful, white and European, to please a partner, 
grab attention, or attract potential mates, and to impress peers, to appear sophisticated and 
modern and to gain economic and social mobility.  
With the rise of the internet, companies involved in the skin-bleaching market have 
become even more connected and have new easy ways for marketing and distribution of 
their products to their consumers via informational networks.  Mostly, skin-lighteners are 
manufactured in some countries and exported or smuggled into others.  For instance, the 
distribution of mercury soap has been illegal in the EU since 1989, but its manufacture 
has remained legal as long as it is for export only.  Although, the government and 
manufacturers in those countries know the dangers of mercury, they only focus on making 
a quick profit at the expense of people’s health in other nations (18).  
According to studies carried out by medical researchers on the prevalence of skin-
lightening practices among African women, they estimate that 25% of women in Bamaki, 
Mali; 35% in Pretoria, South Africa; 52% in Dakar, Senegal; and a staggering 77% of 
women traders in Lagos, Nigeria (12, 19-21) intentionally use SLPs for cosmetic reasons.  
In Asia, India is reported to consume the highest tonnage of bleaching products and in 
terms of sheer numbers, Indians make up the largest skin bleaching market.  In the 
Philippines, 50% of the population are reported to use skin-lighteners, and in places like 
Japan, China, Taiwan, and Korea users of skin-lighteners are reported to be within 20 - 
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50%.  Likewise, in some parts of Latin America and in the USA, women of all races, 
including Europeans, have long legacies of skin-lightening practices (18).  These statistics 
reiterate that the practice of skin-lightening is not a regional problem, but rather a global 
issue of significant concern. 
 
1.2  The human skin 
The skin is a complex organ, which covers the entire body surface as a flexible shield 
with the primary function to protect the organism and act as a permeability barrier to the 
external environment.  In terms of chemical composition the skin is made up from about 
70% water, 25% proteins and 3% lipids.  The remainder includes minerals, nucleic acids, 
glycosamines, proteoglycans and other chemicals (22).  The skin serves numerous 
protective functions (23): 
Ø A chemical barrier in two directions: controlling the loss of water, electrolytes, 
and other body constituents while barring the entry of harmful or unwanted 
compounds from the environment. 
Ø A radiation barrier against ultraviolet (UV) light as a result of the production of 
melanin by the melanocytes in the basal layer upon ultraviolet light stimulation.   
Ø A microbiological barrier preventing the penetration of microorganisms through 
the intact stratum corneum. 
Ø The skin is responsible for regulating the temperature of the body at 
approximately 37°C. 
The skin is made up of two layers: the outer epidermis and the underlying dermis.  They 
form a barrier that ranges in thickness from 0.8 mm on the palms and soles to 0.06 mm 
on the eyelids (23).  The basement membrane is what separates the epidermis and the 
dermis.  
The epidermis, as the outermost layer of the skin, provides the initial barrier of protection 
from the invasion of foreign substances into the body (24).  The epidermis consists of a 
stratified squamous epithelium with an underlying basement membrane.  The most 
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important cells of the epidermis are the keratinocytes.  Other constituents of the normal 
epidermis are Langerhans cells, melanocytes, Markel cells and sporadic T-lymphocytes.  
The dermis, which is 2-3 mm thick, contains numerous structures including blood vessels, 
nerves, hair follicles, smooth muscle, glands and lymphatic tissue.  The main cell types 
of the dermis are fibroblasts, macrophages, and mast cells. Fibroblasts are responsible for 
secreting collagen, elastin, and proteoglycans that give the support and elasticity of the 
skin.  Both the cells and the matrix have an influence on the rate and extent of 
differentiation of the keratinocytes and the formation of the epidermal layer (25, 26). 
Below the dermis is a subcutaneous layer, which is the third layer and composed mainly 
of adipocytes (fat cells) arranged in lobules, fibroblasts, lymphocytes and mast cells.  
Although this layer is not technically part of the skin, it plays an integral role by acting as 
a heat insulator, mechanical cushion and stores readily available high energy 
chemicals(23, 26).  
 
1.2.1  Variation in skin colour 
The human skin ranges in variety from the darkest brown to the lightest pinkish-white 
hues.  Primarily, the evolvement of skin pigmentation in humans is to regulate the amount 
of ultraviolet radiation (UVR) penetrating the skin and, thus, modify its biochemical 
effects (27).  There is a direct correlation between the geographical distribution of UVR 
and the distribution of indigenous skin pigmentation around the world.  Areas that receive 
a higher amount of UVR, generally located closer to the equator, tend to have a darker-
skinned population.  Areas that are far from the tropics and closer to the poles have a 
lower intensity of UVR, which is reflected in the lighter skinned population (28). 
A person’s natural skin colour has an impact on their reaction to the sun. Generally, darker 
skin colour burns less and has a better ability to tan, whereas pale skin or white skin burns 
easily and tans slowly and poorly (29).  The biggest difference resulting from sun 
exposure is visible in moderately brown skin, the change is dramatically visible as tan 
lines, where part of the skin which is tanned is delineated from unexposed skin (30).  The 
Fitzpatrick classification of skin-photo types based on sunlight sensitivity is shown in 
Table 1.1.  
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Table 1.1: Fitzpatrick sun-reactive skin types (31).  
Skin type Natural skin 
colour 
Skin reaction to solar 
radiation 
Examples  
I Pale white Always burns, peels and 
never tans. 
People with blue eyes, 
often freckled. Northern 
European/British.  
II Fair white Burns easily, peels and 
tans minimally. 
People with red or 
blonde hair, blue eyes. 
European/Scandinavian. 
II Light brown Burns moderately, tans 
uniformly. 
People with brown eyes, 
dark hair. Southern or 
central European. 
IV Moderate brown Burns minimally, tans 
easily. 
People with dark brown 
hair, dark eyes. 
Mediterranean, Asian or 
Latino. 
V Dark brown Rarely burns, tans easily 
and substantially. 
People with dark eyes, 
dark hair. East Indian, 
Native American, Latino 
or Africa. 
VI Black Almost never burns, tans 
readily and profusely. 
Dark eyes, dark hair. 
African or Aboriginal 
ancestry. 
 
Skin-types I-III are melanocompromized.  These skin types have a risk of developing skin 
cancer following sun exposure.  On the other hand, skin types IV-VI, which are 
melanocompetent, have a tendency to an overactive production of melanin following sun 
exposure, which can lead to melasma.  Therefore, all skin-types advisedly should use 
appropriate sunscreens to protect themselves from harmful UV rays due to the serious 
damage induced by extreme sun exposure, such as uneven skin tone, premature ageing, 
and possible skin cancers. 
Other skin classification systems are based on factors such as lipid content and hydration 
of the skin, rather than the sensitivity to sunlight or the effect of UV radiation.  In the 
report by Mercurio et al. (32), they scientifically classify skin into six types based on 
secretory characteristics.  These include eudermic (healthy skin), oily, alipic, hydrated 
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and combination.  Skin-types can change over time. An instance is younger people being 
more likely to have a normal skin than older people.  
 
1.3  Melanin and pigmentation 
Melanin is a large bio-aggregate composed of subunits of different pigment species 
formed by oxidation and cyclisation of the amino acid tyrosine.  Skin complexion and 
UV-sensitivity is determined by the amount and type of epidermal melanin (33-35).  
Melanin exists in two main chemical forms, eumelanin, a dark pigment found abundantly 
in the skin of heavily pigmented individuals, and pheomelanin, a light-coloured sulfated 
pigment resulting from the incorporation of cysteines into melanin precursors (36).  The 
efficiency of eumelanin to block UV photons is greater than that of pheomelanin, 
therefore the more eumelanin in the skin, the less UV-permeable is the epidermis (37).  
The levels of pheomelanin are similar between dark-skinned and light-skinned 
individuals, and it is the amount of epidermal eumelanin that determines skin complexion, 
UV sensitivity and cancer risk (38).  
Over production or too little production of melanin brings about uneven pigmentation 
known as skin pigmentation disorder. Overproduction of melanin brings about 
hyperpigmentation, often referred to as melasma, chloasma or solar lentigines (39).  
Melasma is a general term describing darkening of the skin.  Chloasma is generally used 
to describe skin discolouration caused by hormones.  These hormonal changes are usually 
the result of pregnancy, birth control pills or oestrogen replacement therapy.  Solar 
lentigines are the technical term for darkened spots on the skin caused by the sun. Solar 
refers to sunlight and lentigines describes a darkened area of skin.  These spots are most 
common in adults with a long history of unprotected sun exposure.  Hyperpigmentation, 
aside from sun exposure and hormones, can also be trigged by skin damage such as 
remnants of blemishes, wounds or rashes. This is usually observed with darker skin tones 
(40). 
The inability of melanocytes to produce melanin or properly transport melanosomes 
results in hypopigmentation.  Vitiligo is an example of hypopigmentation, which is 
characterised by patches of unpigmented skin (often surrounded by a heavily pigmented 
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border).  Vitiligo affects all skin types and is generally considered a cosmetic condition, 
but it can cause significant psychological distress, particularly to some black patients (41).  
Despite the controversy surrounding the use of SLPs, they have shown to effectively 
correct specific zones of abnormal high pigmentation on the skin. Thus, SLPs can help 
remove a tan or discoloration due to some pigments in the top layer of the skin, but cannot 
make a dark person fair (42). 
 
1.3.1  Biosynthesis of melanin 
The initial step of melanin biosynthesis begins from either the hydroxylation of L- 
phenylalanine to L-tyrosine (noncompulsory step, operative in vivo) or directly from L-
tyrosine which is then hydroxylated to L-dihydroxyphenylalanine (L-DOPA), which is an 
obligatory step both in vitro and vivo.  L-DOPA serves as a precursor to both melanins 
and catecholamines, acting along separate pathways (Figure 1.1).  Oxidation of L-DOPA 
to dopaquinone, represents the next step, which is common to both eu- and 
pheomelanogenic pathways (43).  
Further transformation of dopaquinone to leukodopachrome, followed by a series of 
oxidoreduction reactions with the production of the intermediates dihydroxyindole (DHI) 
and DHI carboxylic acid (DHICA), that undergo polymerization to form eumelanin, is 
referred to as eumelanogenesis (44, 45).  Pheomelanogenesis also begins  with dopaquine; 
this is conjugated to cysteine or glutathione to yield cysteinyldopa and glutathionyldopa, 
which further transform into pheomelanin (43, 44).  Eu- and pheomelanin are contained 
in mixed melanin.  L-DOPA generation of catecholamines requires its enzymatic 
decarboxylation, hydroxylation, and methylation to produce dopamine, norepinephrine, 
and epinephrine, respectively.  All of these catecholamines can potentially convert into 
neuromelanin through several oxidation/reduction reactions in vitro (Figure 1.1) (35).  In 
vivo, the only primary precursors to pigment are dopamine and cysteinyldopamine (46-
48).  Thus, melanin pigments have a similar arrangement of several units linked by 
carbon-carbon bonds, but the chemical composition, structural and physical properties 




















Figure 1.1. Synthesis of melanins.  Adapted from (35). 
GSH, glutathione; Cys, cysteine. 1: phenylalanine hydroxylation;  2: tyrosine 
hydroxylation;  3: DOPA oxidation;  4: dopachrome tautomerization;  5a: DHICA 
oxidation;  5b: DHI oxidation;  a: hydrolysis of glutathionyldopa;  b: oxidation of 
cysteinyldopa;  c: intramolecular cyclization of cysteinyldopaquinone;  I: DOPA 


















































































































1.3.2  Melanin pathway inhibitors (tyrosinase inhibitors) 
Different steps of the melanin pathway can be interrupted, depending on the mechanistic 
reaction of the inhibitors involved (49).  The most common approach in skin-lightening 
is the inhibition of the enzymatic reaction of tyrosinase (49, 50). The active compounds 
used in cosmetic products and traditional preparations to inhibit melanin production are 
either of synthetic, natural or botanic sources.  
SLAs can be classified into four types depending on the mechanism of tyrosinase 
inhibition.  These include competitive inhibitors, uncompetitive inhibitors, mixed type 
(competitive/uncompetitive) inhibitors and non-competitive inhibitors (51).  Table 1.2 
lists several tyrosinase inhibitors and gives their classification.  A competitive inhibitor 
tends to combine with a free tyrosinase and therefore hinders substrate binding.  A 
competitive inhibitor could be tyrosinase-substrate analogues, copper ion chelators, or 
derivatives of L-tyrosinase or L-Dopa.  An uncompetitive inhibitor binds only to the 
tyrosinase-substrate complex.  The mixed-type inhibitor binds with both a free tyrosinase 
and the tyrosinase-substrate complex.  The equilibrium binding constants for free 
tyrosinase and the tyrosinase-substrate complex differ for most mixed-type inhibitors.  
For non-competitive inhibitors, the free tyrosinase and the tyrosinase-substrate complex 




Table 1.2: Some tyrosinase inhibitors derived from synthetic and natural sources.* 
Synthetic sources Natural sources 
Inhibitor  Type of 
inhibition 
Inhibitor Type of 
inhibition 
Benzoic acid Mixed Arbutin Competitive 
Benzaldehyde Noncompetitive Aloesin Noncompetitive 
Cupferron Competitive Anacardic acid Competitive 
Cinnamaldehyde Noncompetitive Anisaldehyde Noncompetitive 
Cinnamic acid Mixed Anisic acid Uncompetitive 
Captopril Noncompetitive Agaritine Uncompetitive 
Citral Noncompetitive Cumic acid Noncompetitive 
Dimethyl sulfide Competitive Cuminaldehyde Noncompetitive 
Methimazole Mixed p-Coumaric acid Mixed 
Kojic acid Mixed (-) Epicatechin-3-O-
gallate (ECG) 
Competitive 







Tropolone Competitive Oxyresveratrol Noncompetitive 
2-Methoxycinnamic 
acid 
























Competitive   
*Adapted from (52). 
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However, competitive inhibitors of tyrosinase are the most commonly used skin-
lightening agents.  They include phenolic compounds, non-phenolic compounds and the 
combination formula (53).  Phenolic compounds consist of compounds such as 
hydroquinone and its derivatives, for example, monobenzyl ether of hydroquinone, 
phenol and its compounds such as 4-methoxyphenol, 4-isopropylcatechol, 4-
hydroxyanisol, and N-acetyl-4-S-cystaininylphenol. Kojic acid, azelaic acid, N-
acetylcysteine, tretinoin, and L-ascorbic acid represent the non-phenolic compounds.  The 
combination of hydroquinone and various other active lightening agents in different 
concentrations often describe the combination formula. The combination formulas often 
used are Kligman’s formula (hydroquinone 5%, tretinoin 0.05–0.1%, dexamethasone or 
betamethasone valerate 0.1% in hydro-alcoholic base cream or ointment base), Pathak’s 
formula (2% hydroquinone, tretinoin 0.05–0.1% in hydro-alcoholic base cream or 
ointment base) and Westerhofs formula (N-acetylcysteine 3%, hydroquinone 2%,  
hydrocortisone 1% in ointment base) (53). Other active compounds that have proven to 
have a strong inhibitory effect on melanin synthesis include resorcinol and its derivatives 
(4-butylresorcinol, 4-phenyl-ethylresorcinol), steroids and mercury (10, 50, 52, 54). 
Furthermore, a myriad of plant extracts contain active compounds mainly flavonoids, 
gentisic acid, niacinamide, licorice, arbutin, aleosin and polyphenols, that have shown to 
inhibit melanogenesis, without melanocyte cytotoxicity or mutagenicity (55).  
 
1.4   Skin-lightening agents 
Currently, there are a plethora of skin depigmentation formulations available 
commercially which contain one or several active compounds.  They may serve as 
prescription drugs and over-the-counter products.  Others tend to be uncontrolled, 
traditional or prohibited products.  Most skin-lightening formulations contain a 
combination of compounds in order to provide better potency via supplementary or 
synergistic actions.  These include compounds like hydroquinone, mercury, 
corticosteroids, kojic acid, arbutin and many more.  These agents expose users to certain 
additional health risks since the comparative clinical efficacy and safety regulations of 
the agents are not usually met (9).  The following is a review of the most used and popular 
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SLAs reported in the literature, their known mechanism of action and potential side-
effects.  The structures of these compounds are shown in Figure 1.2.  
 
1.4.1   Hydroquinone 
Hydroquinone (structure shown in Figure 1.2) is known to be a dihydric phenol with two 
derivatives, viz. monobenzyl and monomethyl ether of hydroquinone (40).  It is also 
known under different synonyms such as benzohydroquinone, p-benzenediol, 1,4-
dihydroxybenzene, β-quinol, 1,4-diol/quinol, 1,4-benzenediol, p-hydroxyphenol, p-
dioxobenzene, hydrochinone or tecquinol.  Hydroquinone occurs naturally in tea, red 
wine, coffee beans, wheat and leaves of berries.  Despite the inconsistent effects and 
safety concern of hydroquinone, it is still the most prescribed SLA worldwide and is the 
gold standard for skin-lightening (31, 56-59).  Hydroquinone was initially believed to act 
mainly by inhibition of tyrosinase due to its structural analogy to melanin precursors (60).  
But, the inhibition of DNA and RNA synthesis, degradation of melanosomes and 
destruction of melanocytes, are other putative mechanisms of hydroquinone action (61).  
The clinical efficacy of hydroquinone is gauged based on its concentration, nature of the 
vehicle and stability of the formulation.  It is mostly used at a concentration of 1.5-5% 
(9).  Several clinical studies have established the beneficial therapeutic effect of 
hydroquinone in the treatment of melasma and other pigmentary disorders.  In a report, 
2% of hydroquinone was found to produce a decrease in hyperpigmentation, which was 
as good to excellent in 14-17% of treated patients (62-64).  Hydroquinone at high 
concentration showed more effectiveness but there were associated augmented side-
effects, consisting mainly of irritation at the sites of application (53).  The inclusion of 
antioxidants, in the form of sodium bisulfate or ascorbic acid, enhance the stability of 
hydroquinone by minimising its oxidation (53).  Hydroquinone undergoes oxidation to 
benzoquinone.  Both hydroquinone and benzoquinone are metabolites of each other, these 
makes the toxicity observed with one of the two also relevant for the other, although it 
may vary in potency (65).  Hence, SLPs which contain hydroquinone may very likely 




In Europe, most available commercial formulations contain 2% hydroquinone, which is 
considered safe and effective (53).  High concentrations of hydroquinone are highly 
discouraged due to its side-effects (9).  The US FDA proposed a maximum of 1.5-2.0% 
hydroquinone as an active ingredient in over-the-counter cosmetics, while the National 
Food and Drug Agency of Nigeria (NAFDAC) had initially allowed a maximum of 2% 
hydroquinone in lightening creams in Nigeria, but later banned hydroquinone due to the 
side-effects associated with prolonged usage and non-compliance with safety regulations 
(40).  Likewise, the use of hydroquinone in over-the-counter SLPs is also completely 
banned in South Africa (66) 
Prolonged and high concentrations of hydroquinone usage have proven to cause multiple 
cutaneous and systemic-side effects (67).  Irritant contact dermatitis is the most common 
acute complication of hydroquinone, followed by post-inflammatory hyperpigmentation, 
hypopigmentation, and allergic contact dermatitis (67-69).  Chronic exposure to 
hydroquinone results in nail discolouration (70-72), or pseudo yellow nail syndrome (40).  
Other side-effects include conjunctival pigmentation (73), corneal melanosis and 
degeneration (7, 73, 74), decreased skin elasticity (40), peripheral neuropathy (75), 
impaired wound healing, and wound dehiscence (40, 76), specifically after abdominal 
surgeries such as caesarian section or hysterectomy.  Trimethylaminuria or fish odour 
syndrome is another unique side-effect of chronic hydroquinone use. It is characterised 
by a rotten fish body odour caused by excretion of trimethylamine in the saliva, sweat, 
urine, and vagina (77).  
The most severe complication of chronic hydroquinone use is known as exogenous 
ochronosis (67, 78), with at least 789 reported cases, 756 of which occurred in Africa 
(79).  Ochronosis can exist both in the form of endogenous and exogenous.  Endogenous 
ochronosis is related to alkaptonuria, an autosomal recessive disorder which is 
characterised by the absence of homogentisic acid oxidase in 1 out of 25,000 of the 
population (80), while exogenous ochronosis is attributed typically to hydroquinone-
containing compounds (67, 78).  Pick (81) reported the first case of exogenous ochronosis 
in 1901, in a patient with prolonged exposure to phenols.  The first cases of hydroquinone 
induced exogenous ochronosis were reported in 1975 by Findlay and colleagues (78), in 
35 South African Bantu women with high hydroquinone exposure (3.5-7%) for many 
years.  Exogenous ochronosis is characterised by grey-brown or blue-black macules 
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coalescing into patches, accompanied occasionally by pinpoint, dark brown, and caviar-
like papules (78, 82, 83).  Although, several attempts have been made experimentally to 
treat exogenous ochronosis, the results have not been satisfactory (84).  Occasionally, 
hydroquinone discontinuation might undo hyperpigmentation, but this can take several 
years (78, 85). 
Concern exists on the possible carcinogenicity of hydroquinone but studies need to be 
carried out to determine the risk of skin cancer in hydroquinone users (86, 87). 
 
1.4.2   Benzoquinone 
Benzoquinone is a poorly water soluble crystalline substance which can be produced in 
large amounts by oxidation of aniline or phenol (88).  It can also occur naturally in small 
amounts in a variety of arthropods as it is excreted and synthesised by many insects (89).  
Other synonyms for benzoquinone include cyclohexa-2,5-diene-1,4-dione, 1,4-
benzoquinone, p-benzoquinone, p-quinone or quinone.  When present in aqueous 
solution, benzoquinone is susceptible to both redox and acid-based transformation, 
resulting in the formation of hydroquinone, semiquinone and reactive oxygen species (88, 
90, 91). 
Studies have shown benzoquinone to be readily absorbed from the gastrointestinal tract 
and subcutaneous tissue and excreted partly unchanged and partly as hydroquinone.  Most 
of it is eliminated as its conjugates (88, 92).  Results emanating from various animal 
studies described benzoquinone to be a skin sensitizer.  It was reported to induce skin 
lesions and irritation when injected subcutaneously in guinea pigs (93).  The acute toxicity 
carried out on animals indicates various neurological symptoms, including loss of 
reflexes, writhing and paralysis of the hind limbs (94, 95).  In humans, high level exposure 
of benzoquinone in air may result in irritation of the eyes (94, 96) while dermal exposure 
may result in discolouration, dermatitis, severe irritation, erythema, swelling, and the 
formation of papules and vesicles (97, 98).  The carcinogenicity studies of benzoquinone 
still remain unsatisfactory, although benzoquinone is classified in category 3B for 
carcinogenicity and cell germ mutagenicity in Germany (65).  The America Conference 
of Governmental Industry Hygienists (ACGIH) established in 2001 a threshold limit 
16	
	
value (TLV) for exposure to benzoquinone of 0.44 mg m-3 as the 8 hours time weighted 
average (94). 
 
1.4.3   Kojic acid 
Kojic acid is a hydrophilic fungal derivative obtained from aspergillus and penicillium 
species, and is chemically known as 5-hydroxymethyl-4H-pyrane-4-one.  It is used as an 
antioxidant by the cosmetics industry and is the second most effective over-the-counter 
SLA used as an alternative to hydroquinone in skin-lightening.  It is also a popular agent 
used for the treatment of melasma (99).  Despite being purported to have skin-lightening 
credentials, it is not currently approved by the US FDA for such use in over-the-counter 
pharmaceutical products (100).  
Kojic acid is found to be a skin sensitizer and has proven to be mutagenic in cell culture 
studies (54).  It is characterised by the ability to prevent tyrosinase activity by binding to 
copper (101).  According to a survey conducted by the Personal Care Products Council 
of the United States, kojic acid is used at a concentration ranging from 0.1 to 2%, with 
the maximum concentration found in face and neck creams, lotions, and powders.  In a 
report submitted by Health Canada’s Cosmetics Notification System, 148 products were 
found to contain kojic acid, with uses in skin care products (100).  It summarized the 
concentration ranges for kojic acid use in Canada to be 0.1% or less in 37 products, 0.1 
to 0.3% in 11 products, 0.3 to 1% in 34 products, 1 to 3% in 45 products, 3 to 10% in 14 
products, and 10 to 30% in 3 products.  However, it is widely reported to be used in a 
concentration of 1 to 4% in Asia (102). 
Based on a margin of safety calculation, the European Commission’s Scientific 
Committee on Consumer Products (SCCP) concluded that the use of kojic acid at a 
maximum concentration of 1% in skin care formulations poses a risk to human health due 
















Mequinol Soy protein 
  
Glycolic acid Flavonoid 
  
Azelaic acid Monobenzyl ether of hydroquinone 
 
Figure 1.2: Chemical structures of common skin-lightening agents.  Adapted from 



















































1.4.4   Niacinamide 
Niacinamide is the amide form of vitamin B3.  It acts by inhibiting the transfer of 
melanosomes to the epidermal keratinocytes.  Reports have shown that niacinamide is of 
benefit in the treatment of melasma, and pustular acne (103).  The efficacy of niacinamide 
was confirmed in one study where 3.5% niacinamide plus retinyl palmitate were used in 
the treatment of hyperpigmentation (104). 
 
1.4.5   Arbutin 
Arbutin (hydroquinone-B-D-glucopyranoside) and methyl arbutin are referred to as skin-
lightening glucosides derived from bearberry fruit (Arctostaphylos uva ursi).  Arbutin is 
also found in certain herbs and pear trees.  Arbutin acts by inhibiting melanosomal 
tyrosinase activity.  A 1% concentration of arbutin has been cited as effective for 
depigmentation by SLP manufacturers (102).  However, 3% arbutin is also available, but 
a controlled study on the possible side-effects has not been carried out (102).  Arbutin has 
been shown to be effective in treating solar lentigines and melasma, but a high 
concentration can bring about hyperpigmentation (103).  
 
1.4.6   Glycolic acid 
Glycolic acid is derived from sugarcane.  It is an α-hydroxy-acid, which in low 
concentration produces rapid desquamation of pigmented keratinocytes, and in high 
concentration results in epidermolysis.  In the removal of superficial layers of the 
epidermis with glycolic acid peels, a concentration of 30 to 70% is used and these can 
further enhance the penetration of other skin lighteners like hydroquinone (105).  In the 
treatment of post-inflammatory hyperpigmentation, glycolic acid is usually used at a low 






1.4.7   Mequinol 
Mequinol is chemically known as 4-hydroxyanisole, methoxyphenol, or monomethyl 
ether of hydroquinone.  It is a substrate for tyrosinase; it acts as a competitive inhibitor in 
the formation of melanin precursors but the exact mechanism of action accounting for its 
skin-lightening attributes is unknown.  It is the primary lightening alternative to 
hydroquinone approved for use in Europe and the United States.  In the United States, 
mequinol is available at 2% concentration and can only be sold as a prescribed skin-
lightener in combination with 0.01% tretinoin.  Unlike hydroquinone, mequinol does not 
damage the melanocyte but has been noticed to cause longstanding depigmentation, 
though, this longstanding depigmentation generally repigments with time (54). 
 
1.4.8   Azelaic acid 
Azelaic acid is regarded as a naturally occurring non-phenolic, saturated, 9-carbon 
dicarboxylic acid.  It is isolated from cultures of pityrosporum ovale and is associated 
with the hypomelanosis seen in tinea versicolor (53). In vitro, azelaic acid interferes with 
the function of tyrosinase and may also inhibit DNA synthesis and mitochondrial 
oxidoreductase (106), but does not seem to affect normal melanocytes (107).  
Therapeutically, azelaic acid has shown to have beneficial effects in acne and vulgaris 
and certain pigmentary disorders, such as melasma and lentigo maligna (53).  In the 
treatment of melasma and post-inflammatory hyperpigmentation, azelaic acid is used at 
a concentration of 15 to 20% (108).  At these concentrations, azelaic acid is tolerated in 
humans, but mild pruritus, transient erythema, irritation and scaling tend to be its adverse 
reactions (107, 102). 
 
1.4.9   Retinoids (Topical) 
Retinoids such as tretinoin and retinol are obtained from vitamin A.  The efficacy of these 
products has been proven in the treatment of melasma, post-inflammatory 
hyperpigmentation, and other pigmentation disorders (102).  Retinoids have been used as 
pigment lightening agents both directly and indirectly.  For direct improvement in skin 
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pigmentation, the prescribed retinoids are tretinoin and tazarotene (109, 110).  Retinol 
compared to tretinoin or tazarotene is less effective and less irritating.  Retinol is mostly 
found in a variety of moisturisers and anti-aging products sold over the counter (102).  
Retinol has been shown to convert to retinoic acid in the skin in a two-step oxidation 
process (111).  The main challenge to retinol formulations is its lack of stability at high 
concentration (54) . 
Retinoids when use indirectly to lighten dyspigmentation serve as penetration enhancers. 
A side-effect of retinoids is irritant dermatitis which is characterised by erythema, 
dryness, and scaling (112, 113). These cutaneous changes damage the skin barrier, 
allowing easy penetration of other pigment-lightening agents such as hydroquinone and 
mequinol, to the melanocytes. 
 
1.4.10   Resorcinol  
Resorcinol and its derivates, such as rucinol (4-n-butylresorcinol), are known tyrosinase 
and TRP-1 inhibitors (50).  They are considered as antibacterial, anti-acne and potent 
topical disinfectants in a concentration of 1 - 3%.  In the treatment of moderate to severe 
facial dyschromia, acne, oily skin, texturally rough skin, fine wrinkle and 
pseudofolliculitis, 14% resorcinol is often combined with 14% salicylic acid and 14% 
lactic acid (114).  A prolonged exposure to resorcinol can lead to thyroid dysfunction 
(115).  Resorcinol is banned in over-the-counter SLPs in South Africa (66). 
 
1.4.11   Aleosin 
Aleosin, a low-molecular-weight glycoprotein, is derived from the aloe vera plant.  It acts 
by inhibiting tyrosinase by competitive inhibition at the dihydroxyphenylalanine 
oxidation site (116, 117).  Unlike hydroquinone, it is not characterised by cell 
cytotoxicity.  Due to its hydrophilic nature, it has limited ability to penetrate the skin.  
Aleosin is commonly used in combination with arbutin or deoxyarbutin, and, these 




1.4.12   Soy proteins 
Soy protein is a commonly used SLA in cosmeceutical moisturisers (54).  It contains 
small serine proteases such as Bowman Brik inhibitor (BBI) and Soybean trypsin 
inhibitor (STI) which inhibit the protease activated receptor-2 (PAR-2) pathway 
expressed on keratinocytes (118).  The PAR-2 pathway, can be inhibited after 3 weeks of 
raw soy milk application (54), resulting in diminished melanin transfer (119, 120). Thus 
far, soy extract has been shown to have minimal side-effects and has an excellent safety 
profile (54). 
 
1.4.13   Flavonoids 
Flavonoids belong to the group of plant polyphenols.  They are classified into six major 
groups, which include flavanols, flavones, flavonols, flavanones, isoflavones, and 
anthocyanidins.  Reports have shown flavonoids to inhibit enzymes due to their ability to 
chelate copper at the active site (121).  In a recent fluorescence quenching study, the 
dihydroxy substitutions in both the A and B rings of flavonoids (see Figure 1.2) have been 
shown to be crucial in inhibiting tyrosinase activity (122). 
 
1.4.14   Steroids 
In dermatology, steroid preparations are pharmaceutical products usually prescribed for 
the treatment of inflammatory conditions.  They are also called corticosteroids, 
glucocorticoids, or “cortisone”.  Steroids are referred to as “systemic” if taken by mouth 
or given by intramuscular injection, or “topical” if absorbed through the skin.  Topical 
steroids are categorised as mild, moderate, potent and very potent.  Both mild and 
moderate topical steroids rarely cause side-effects, while potent and very potent topical 
steroids are very toxic as they are more absorbed through the skin and into the blood 
system.  Betamethasone, clobetasol, fluocinonide, and triamcinolone acetonide are among 
the strongest topical steroids found in bleaching creams.  They exert their depigmenting 
effects by inhibiting epidemic melanogenesis (123).  Steroid formulations have been 
found to improve therapy for psoriasis conditions when prescribed in a concentration of 
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0.025 to 0.5% (m/m) (124).  Sometimes, the efficacy of steroids is increased when 
combined with other SLAs.  The chemical structures of commonly used topical steroids 






Figure 1.3:  Chemical structures of topical steroids mostly present in skin-lightening 
products.  Adapted from http://www.chemicalbook.com/ (Accessed on 28 June 2016). 
Betamethasone dipropionate 0.05% Clobetasol propionate 0.05% 
Fluocinonide 0.05% Triamcinolone acetonide 0.05% 
Betamethasone valerate 0.1% Hydrocortisone valerate 2% 










































































The use of topical steroids is associated with multiple dermatological and systemic side-
effects, especially when used incorrectly (123, 40, 76, 125, 126). Acne vulgaris (12, 76), 
allergic contact dermatitis (127, 128), hypertrichosis (76, 126), skin atrophy (129, 11, 
130), perioral dermatitis (130), rosacea (40), striae atrophica (12, 11), and telangiectasias 
(126, 129), are among the common cutaneous complications associated with topical 
steroid application.  Topical steroid use is also known to cause systemic complications 
such as hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing syndrome (76, 
131, 132), diabetes mellitus (126), and hypertension (133). 
Steroid addiction syndrome is the adverse effect from the chronic daily use of a potent 
topical steroid, which is associated with intense burning and potentially permanent 
erythema due to the withdrawal of vasodilatation.  Ophthalmological conditions such as 
cataracts and glaucoma, also fall among complications associated with chronic topical 
steroid use (40). 
 
1.4.15   Mercury 
Mercury is a known melanotoxin.  Mercury exists primarily in elemental, or in organic 
and inorganic forms.  Elemental mercury is mostly used as a liquid metal in thermometers 
and is also still used in dental amalgams.  Organic mercury compounds like thiomersal, 
methylmercury, and ethylmercury are used as preservatives.  Mercury salts such as 
mercuric amidochloride or ammoniated mercury, mercuric chloride, and mercurous 
chloride or calomel are the kind of mercury commonly added to SLPs (134).  Mercury is 
a highly volatile element with a long atmospheric half-life.  As a result of these physical 
properties, it is present in every environment and exposure is not an isolated concern but 
rather a global concern to human health.  In recent years, research has shown that even 
chronic exposure to very low concentrations has the ability to cause long-lasting 
neurological and kidney impairment (135). 
Mercury compounds, when used to lighten skin pigment, have recorded varying success. 
The mercury ion is thought to act by inhibiting the synthesis of melanin (136).  Inhibiting 
melanin production makes the skin more susceptible to skin cancer (137).  When mercury 
is applied to the skin, it reacts with ultra-violet light and reoxidizes.  This leads to more 
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pigmentation and premature ageing.  However, further application of mercury in an 
attempt to correct the skin will lead to a darker blotchy appearance (40). 
Chronic usage of mercury-containing skin-lightening preparations has led to the 
deposition of mercury in the body after absorption through the skin, especially in the 
tubular region of the kidney, giving rise to the occurrence of severe reactions (138-140).  
Studies have shown increased accumulation of mercury in the brain, kidney and liver 
tissues of both albino and pigmented mice when absorbed through the skin (141), and it 
was found to be highest in the kidney and lowest in the brain (142).  Research has also 
shown that women using mercury-containing soaps and creams tend to attain mercury 
concentrations from 0.03 to 0.15 mg L-1 in their urine.  At this concentration, the central 
nervous system, and kidneys are at major risk of negative effects, since such effects have 
been shown at a concentration of 0.02 to 0.5 mg L-1 (143). 
The common cutaneous complications of mercury use are allergic contact dermatitis, 
flushing, erythroderma, purpura, nail discolouration, and gingivostomatitis (144, 145, 
59).  Paradoxic hyperpigmentation is a consequence of the chronic use of mercurial skin 
lighteners, which might be caused by dermal deposition of mercury-containing granules 
(123).  The use of mercury cosmetics during pregnancy has also been shown to result in 
prenatal and postnatal intoxication, as mercury can cross the placenta (59).  The amount 
of mercury applied to the skin is proportional to the amount excreted by the kidney as 
shown by Cole and colleagues (146). 
 
1.5   Clotrimazole 
Clotrimazole is a broad-spectrum topical antifungal drug which belongs to the azole class.  
The azole class can be further subdivided into two classes, namely, imidazole and 
triazoles (147).  Clotrimazole and other class members, econazole and miconazole (see 
Figure 1.4), fall into the imidazole sub-class and can be used for the topical treatment of 
tinea pedis (athlete’s foot), tinea cruris and tinea corporis (148).  It is also popularly used 
in the topical treatment of vulvovaginal and oropharyngeal candidiasis (147). 
The mono-preparations of clotrimazole are generally available over-the-counter, but if 
present in a combined preparation will necessitate prescription.  Clotrimazole is usually 
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at 1% (m/m) in a combined formulation (147).  Treatment with a clotrimazole formulation 
does not usually exceed one week of application, especially if found in combination with 
topical steroids so as to avoid unwanted side-effects.  The addition of clotrimazole to 
SLPs is very unconventional and should be a cause for concern since SLPs are used over 
a long period of time. 
The side-effects resulting from clotrimazole application include burning, stinging, 
swelling, irritation, redness, pimple-like bumps, tenderness or flaking of the skin (149).  
Serious allergic reactions of clotrimazole-containing creams include rash, 




















Figure 1.4: Chemical structures of some imidazole fungicides.  Adopted from 


















1.6   Heavy metals in cosmetics and their health complications 
Heavy metals are any metallic chemical elements that have a relatively higher density of 
at least five times greater than that of water (1 g cm-3).  They are naturally occurring in 
the environment, in rocks, soil, and water.  They may also be found in pigments and other 
raw materials in all industries with no exception to the cosmetics industry.  Examples of 
metals considered as heavy metals include antimony, arsenic, bismuth, cadmium, 
chromium, cobalt, copper, gallium, gold, iron, lead, manganese, mercury, nickel, 
platinum, selenium, silver, tellurium, thallium, tin, uranium, vanadium, and zinc (150). 
Heavy metals are naturally occurring in the environment and make their way in trace 
quantities into raw materials and finally end up in the finished products we use and 
consume every day.  These substances enter into the human body mainly through diet, 
inhalation, and skin exposure to soil and/or medication.  Dermal exposure represents the 
most significant route for cosmetic products, as most of the cosmetics are applied directly 
on the skin (4, 151). 
The intentional use of heavy metals and their compounds as active ingredients in cosmetic 
products has been banned by the US FDA unless they occur as impurities (150).  Their 
presence in products is therefore a cause for concern if not well controlled.  Annex 11 of 
Directive 76/7681/EEC of the European Union lists more than 1000 chemical substances 
that must not be included in the composition of cosmetic products due to their toxicity 
(152).  In that list, heavy metals such as antimony (Sb), arsenic (As), cadmium (Cd), 
chromium (Cr), cobalt (Co), mercury (Hg), nickel (Ni) and lead (Pb) in cosmetics are 
banned as they are considered unsafe. 
Long-term exposure to heavy metals can result in their accumulation in organisms as they 
are difficult to metabolise.  From studies, metal ions, when bound to proteins, enzymes, 
and nucleic acids, are absorbed and form complexes with the carboxylic acid (-COOH), 
amine (-NH2), and thiol (-SH) groups of proteins resulting in malfunctioning or death of 
cells (153, 154). 
The use of cosmetic products often represents a possible source of long-term exposure to 
a myriad of chemicals (155).  Some of these ingredients in cosmetic products can 
penetrate the skin and reach vital internal organs via the systemic circulation, as they are 
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applied to the skin (156).  Unlike other cosmetic products that are applied to restricted 
parts of the body, the application of body creams is over the entire body surface, and 
hence, exposure to contaminants in these products is much greater (152). 
Low-level exposure to Pb can result in disorders such as behavioural abnormalities, 
permanent neurological damage, decreased learning and hearing, and may also have 
diverse effects on the reproductive, hepatic and renal systems.  Cadmium is a cell poison. 
It causes several damages, including cell death or an increase in cell proliferation.  Due 
to the toxic nature of cadmium, it has been categorised as a group 2A carcinogen by the 
International Agency for Research in Cancer (IARC) (157). 
Arsenic has a pronounced affinity for skin and keratinizing structures including the hair 
and nail. Acute overexposure to arsenic can bring about skin eruptions, alopecia and 
characteristic striation of the nails (158).  Overexposure to antimony and it compounds 
can also adversely affect the skin, liver, lungs and cardiovascular system (159). 
Other heavy metals such as Cu, Cr, Fe, Ni, Mn and Zn are not completely harmful to 
humans as they are involved in many biological processes, even though Cr still has some 
controversies surrounding it.  For instance, iron plays a vital role in oxygen transport and 
storage, and electron transport, in hydrogenase and other redox active enzymes.  
Manganese is present in superoxide dismutases and also in catalases.  Cobalt, a vitamin 
B12 component, is essential in various rearrangement and methylation reactions. Copper 
is important in electron transfer (azurin and plastocyanin), oxygen atom transfer 
(oxygenases), and also respiration (cytochrome C oxidase).  Nickel is required for the 
function of acetyl coenzyme synthesis, ureas, and various hydrogenases.  Zinc plays an 
essential role in many enzymes including anhydrase and a group of proteases, such as 
carboxypeptidase A.  Zinc is also involved in the transfer of genetic information via the 
zinc finger protein.  Despite the essential nature of some of these heavy metals to humans 
and other organisms, they still can cause serious health challenges when present in 
cosmetics products, one of which is an allergy.  Chromium, cobalt, and nickel are well-
known allergens, while copper, manganese and zinc are referred to as weak allergens 
(152). 
In the present study, 12 elements: As, Al, Cd, Co, Cr, Cu, Fe, Hg, Mn, Ni, Pb, and Zn 
were investigated for their presence in the studied SLPs. 
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1.7   Dermatological effects of skin-lightening products 
The occurring side-effects associated with skin bleaching depend on the nature and 
concentration of the SLPs used (15, 11).  This is complicated when the actual 
concentrations of the active ingredients listed on the product labels are not consistent 
(160). Further contributing factors include the concurrent use of several depigmenting 
products, application of products over a wide spread of the body, and longtime use of the 
products (123). The most reported side-effects include exogenous ochronosis, allergic 
contact dermatitis, skin atrophy or thinning, acne, erythema, pigmented colloid milia, 
straie atrophicans, nail discoloration, skin peeling and redness, patchy hyperpigmentation 
and hypopigmentation, cushing syndrome, pityriasis, bleached panda effect, eczema, 
wrinkles, rosacea, and tinea (59).  Thus, a knowledge of the concentration of SLAs in 
SLPs is essential.  In Figure 1.5 are shown some photographs of patients diagnosed with 












Figure 1.5: Photographs of patients diagnosed with various skin conditions arising from 
the improper use of skin-lightening products.  (Source: Prof N Dlova, Nelson Mandela 
School of Medicine). 
  
Permanent ochronosis Acne vulgaris 
Patchy pigmentation Permanent stretch marks 
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1.8   Methods of analysis of skin-lightening agents 
Before now, mercury and hydroquinone were the most frequently analysed SLAs found 
in lightening creams since their side-effects where recorded first.  Currently, a myriad of 
SLPs containing newly introduced SLAs are available in the market.  This development 
has led to the constant demand of new analytical procedures capable of quantifying such 
compounds.  Methods that have been used over time to analyse SLAs include thin layer 
chromatography (TLC), capillary electrophoresis (CE), capillary electrochromatography 
(CEC), micellar electrokinetic chromatography (MEKC), electrochemistry, differential 
pulse voltammetry (DPV), gas chromatography (GC) and high performance liquid 
chromatography (HPLC) (161-163).  Mass spectrometry coupled with either HPLC or 
GC is also used for the analysis of SLAs (162).  
Among the methods listed above, the HPLC method was chosen in this study to analyse 
the selected SLAs present in the studied SLPs.  HPLC represents one of the most reliable 
techniques regularly used in the analysis of SLAs since it can handle a wide range of 
target compounds.  For instance, Gaudiano et al. reported an isocratic HPLC method for 
the determination of six glucocorticoids in whitening creams.  The method employed a 
C18 column, a mobile phase of water/acetonitrile (50:50) and detection was done at a 
wavelength of 240 nm.  The method was reported to be robust, linear, accurately sufficient 
and precise (161). 
Huang et al. developed an HPLC method for the simultaneous determination of five 
whitening agents (magnesium ascorbyl phosphate, ascorbyl glucoside, kojic acid, arbutin 
and hydroquinone decomposed from arbutin in cosmetics).  The method used a Cosmosil 
C18-AR-II column, a mobile phase of 0.05 M KH2PO4 buffer solution (pH 2.5) and 
methanol (99:1), with detection wavelength set at 280 nm (164). 
Balaquer et al. developed a HPLC method referred to as environmental friendly for the 
determination of ascorbic acid (vitamin C) and its derivatives (ascorbyl phosphate (as 
magnesium or sodium salts), ascorbyl palmitate, and ascorbyl glucoside) in skin-
whitening cosmetics.  The method made use of a C18 column and a mobile phase gradient 
of ethanol:50 mM phosphate buffer at different pHs (containing 0.1 M NaCl).  Detection 
was carried out with a UV-visible detector set at different wavelengths.  The method was 
reported to be robust (165). 
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Reepmeyer et al. developed a reversed-phase and a normal phase HPLC method for the 
detection of clobetasol propionate in some formulations.  A NOVA-Pak C18 column and 
a mobile phase of acetonitrile-water (1:1) was used for the reversed phase 
chromatography, while a Chromegasphere SI 60 column and a mobile phase of 
isopropanol-heptane (1:4) was used for the normal phase chromatography. The 
chromatogram was monitored at 240 nm and the signal was scanned from 200 to 350 nm 
in order to record the UV spectra (166). 
More studies have employed HPLC when investigating SLPs due to the complex matrices 
that require a variety of ingredients to be separated and quantified. 
 
1.9   Methods of analysis of heavy metals 
Typical examples of instrumentation methods used for heavy metal analysis include 
atomic absorption spectrometry (AAS), inductively coupled plasma-optical emission 
spectrometry (ICP-OES), inductively coupled plasma-mass spectrometry (ICP-MS), 
neutron activation analysis (NAA), X-ray fluorescence (XRF), and ion chromatography 
(IC) (167-171).  However, the AAS, ICP-OES and ICP-MS are the most common 
instrumentation methods used when analysing the heavy metal content in cosmetic 
products. 
For instance, Iwegbue et al. evaluated the levels of heavy metals present in commonly 
used moisturising and skin-lightening creams in Nigeria by means of AAS.  The metals 
quantified included Al, Cd, Cr, Cu, Co, Fe, Mn, Pb and Zn (152).  Similarly, Al-Salah et 
al. used the AAS method to investigate the presence of trace metals such as As, Cd, Cr, 
Hg, Ni, and Sb in lipsticks (172).  Nnorom also used the AAS method to determine the 
presence of metals such as Pb, Cd, Co, and Cr in talcum powders (173).  More studies 
have used the AAS technique when measuring the content of heavy metals in cosmetics 
products (4, 150).  The AAS technique is easy to use, fast and cheap, but the technique is 
disadvantaged with moderate detection limits, element limitations and lack of screening 
ability. 
The ICP-OES and ICP-MS are the most favoured techniques for heavy metal analysis.  
They have the advantage of multi-element analysis, high productivity, economical for 
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many samples and/or elements, few chemical interferences, excellent screening abilities, 
total dissolved solids and can handle both inorganic and organic samples (174). 
Al-Qutob et al. reported the use of ICP-MS for the determination of heavy metals such as 
Ag, Al, Ba, Bi, Cd, Cr, Co, Cu, Mn, Mo, Ni, Pb and Zn in cosmetics products (168).  
Similarly, Bocca et al. used the ICP-MS to determine the presence of metals such as Cd, 
Co, Cr, Cu, Hg, Ir, Mn, Ni, Pb, Pd, Pt, Rh, and V in commercial body creams (175).  Zeo 
et al. also used the ICP-MS for measurement of metals like Cr, Cd, Pb, Hg, As, Se, and 
Sb in cosmetic products such as lipsticks, nail polishes and skin creams (176). 
Alquadami et al. used the ICP-OES to determine the presence of heavy metals such as 
As, Bi, Cd, Hg, Pb and Ti in some skin-whitening cosmetic creams (167).  Likewise, 
Mayildurai et al. used the ICP-OES to investigate the presence of metals such as As, Cd, 
Cr, Hg, Ni, Pb, Co, Cu, in a deodorant, eyeshadows, a face cream, a hair dye, kohl, soap 
and talcum powder (177).  Sabah et al. also used ICP-OES to quantify metals such as As, 
Cd, Pb, and Hg in face make-ups (178). 
Furthermore, Emad et al. used both the ICP-MS and ICP-OES for the determination of 
elements in cosmetic products like eye-shadow, lipsticks, lip-gloss, eye-liners, mascaras, 
fairness products, kohl, hair dyes, foundations and hennas.  Twenty three trace elements 
(Ag, As, Ba, Be, Cd, Co, Cr, Cu, Mn, Mo, Ni, Pb, Sn, Sr, Ti,Tl, U, Zn, Zr, Nb, Rb, Sb, 
and Se) were studied by using ICP-MS and twenty two elements (Al, Ba, Bi, Ca, Cd, Co, 
Cr, Cu, Fe, K, Mg, Mn, Na, Ni, P, Pb, Si, Sr, Th, Ti, U, and V) were studied by using 
ICP-OES (179). 
Both the ICP-OES and ICP-MS are an excellent choice when analysing the heavy metal 
content of cosmetic products as they can measure a wide range of elements with good to 
excellent detection limits, but are associated with possible limitations of spectral 
interferences (174). 
For mercury determination in cosmetic products, the cold vapour atomic absorption 
spectroscopy (CV-AAS) technique is one of the most widely used techniques and has 
been reported in a number of studies (137, 180).  
In this study, the CV-AAS and ICP-OES methods were used to quantify the levels of 
mercury and other heavy metals respectively.  
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1.10   Quantitation methods 
Basically, there are three different calibration methods that can be utilised in quantitative 
analysis; namely, external standard, internal standard and the standard addition method. 
The external standard method is the basic quantification method in which both the 
calibration solutions and unknown samples are analysed under the same conditions.  The 
accuracy of this method is affirmed when there is reproducibility of the injection volume.  
The external standard method is performed by preparing calibration standard solutions of 
known concentration of the analyte of interest, and making sure the concentration of 
unknown samples fall within the range bracket of the calibration solutions.  A fixed 
amount of the calibration solutions and unknown samples are injected, and the peak 
heights or areas obtained for the calibration solutions are then plotted against the 
concentration of the analyte, giving a linear calibration plot passing through the origin.  
The resulting peak heights or areas from the unknown samples are then related to those 
of the calibration solutions, by using the calibration plot to estimate the amount of the 
unknown (181, 182). 
The internal standard method is performed by adding a known amount of a compound 
different from the analyte of interest to the unknown sample and the calibration standards.  
The internal standard chosen must be chemically similar to the analyte of interest.  The 
accuracy of this method is dependent on the stability of the internal standard and it must 
not in any way interfere with any of the sample components.  With this method extraction 
efficiency can be evaluated if the internal standard is added before preparation of the 
sample.  Quantification by using the internal standard method is achieved by using the 
ratio of peak height or area of the standard solution to the internal standard to calculate a 
response factor.(181).  This response factor is then used to calculate the concentration of 
the unknown. 
The standard addition method is most useful for samples with complex matrices and with 
potential to cause adverse effects to the signal (matrix effect), making it unreliable to 
relate the signal between the sample and standard by using the traditional calibration plot 
approach.  In the standard addition method, known quantities are added directly to an 
unknown and the analyte concentration is determined from the increased signal (183). 
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In this study, the external standard method was employed to carry out quantitative 
analysis of the selected SLAs and heavy metals.  When analysing samples with complex 
matrices like SLPs, which require a variety of ingredients to be quantified, the external 
standard approach is more suitable so as to avoid introduction of further interferences in 
the samples.  The external standard method helps to calibrate the instrument and can be 
applied to a wide variety of methods. 
 
1.11   Problem statement 
The problem to be addressed in this research is the fact that some SLPs contain 
compounds which are illegal and harmful to the skin.  Another problem area is that the 
active SLAs present in the products may be present at concentrations greater than allowed 
by regulatory control limits.  All SLPs should have the active ingredients listed on the 
package labels and the actual contents should be consistent with those listed on the 
product labels.  It is a concern that not all SLPs available on the market specify the 
composition and active ingredients in detail as would be informative to the end-user.  
Some products are labelled in a language that is confusing or difficult to understand.  It 
is therefore of great importance for public health that the contents of commonly used 
SLPs be known. 
 
1.12   Motivation 
Considering the toxic effects of some SLAs, such as hydroquinone, mercury, and steroids, 
the practice of skin-lightening in an attempt to beautify and accomplish a light 
complexion, is worrisome. The NAFDAC had initially allowed a maximum of 2% 
hydroquinone in lightening creams in Nigeria, but due to the side-effects associated with 
prolonged use of hydroquinone and also the lack of compliance with content and labelling 
requirements, all forms of bleaching agents were prohibited in cosmetics and toiletries 
(40). In view of the increasing incidents of undesirable side-effects such as exogenous 
ochronosis, contact dermatitis, hyperpigmentation and hypopigmentation, nail 
discoloration, nephrotic syndrome and other health complications reported to be 
associated with the practice skin-lightening, it is necessary to investigate whether 
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prohibited additives such as hydroquinone and other toxic elements and compounds are 
still among the ingredients found in commercial SLPs on the Nigerian market.  This work 
is of great importance for public awareness and safety.  
 
1.13   Aim and objectives 
The aim of this research work was to identify and quantify commonly used organic SLAs 
and heavy metals present in some selected SLPs sampled from Ilorin State in Nigeria. 
This study had the following specific objectives: 
I. To develop an extraction method for the selected SLAs. 
II. To develop and validate a high-performance liquid chromatography (HPLC) 
method for the identification and quantification of the selected SLAs in the studied 
SLPs.  
III. To extract trace amounts of heavy metals present from the SLPs by means of 
microwave-assisted digestion. 
IV. To quantitatively determine the presence of mercury in the studied SLPs by means 
of cold vapour atomic absorption spectroscopy (CV-AAS). 
V. To quantitatively determine the presence of other heavy metals in the studied 
SLPs by means of inductively coupled plasma-optical emission spectroscopy 
(ICP-OES). 
VI. To evaluate the exposure risk derived from the heavy metal content in these 
products. 
Chapter 2 of this dissertation provides the experimental procedures undertaken to achieve 
these objectives.  The results of these experiments are presented and discussed in Chapter 






This chapter describes the analytical techniques used for the analysis of some commonly 
used skin-lightening products (SLPs) in Nigeria.  It also provides the materials and 
instruments used to carry out these analyses.  
 
2.1   Materials 
A total of 35 products were purchased from various stores in Ilorin, Nigeria.  All the 
samples were stored at room temperature away from sunlight.  The samples were stored 
in the refrigerator after extraction and before analysis.  All samples were investigated for 
both the presence of organic active skin-lightening ingredients and heavy metals.  A list 
of all the products investigated including their brand names, cost, ingredients listed on the 
label, company of production, and country of manufacture, can be found in Table 2.1. 
The list of chemicals used are provided in Appendix A, together with their chemical 
grades and manufacturers. The reagents used were all of analytical grade.  The solvents 
used, for example, methanol and acetonitrile, were of HPLC grade.  The water used was 
purified with a Millipore Elix 5 UV water purification system. 
 
2.2   Equipment 








Table 2.1: List of skin-lightening products investigated in this study. 







4000 Anivat  
Lightening 
Lotion 
Aqua (water), Glyceryl Stearate, 
Parafinum, Liquidum (mineral 
oil), Isopropyl Myristate, 
Cetostearyl Alcohol, Cetearch 20 
& 25, Triethanolamine Puriss, 
Sodium Lauryl Sulfate, 
Butyrospermum parkii, 
Glycyrrhiza Globra, Murus Alba, 
Ascorbic Acid, Citric Acid, 
Methyl Paraben, Parfum 








3500 Make Me 
White Fade 
Milk 









3500 Nature White 
Whitening 
Milk 
Water (Aqua), Cetearyl Alcohol, 
Cetearesth 20, Canola oil, 
Glycerin Glycol Stearate, PEG-4, 
Lactic Acid, Kojic Acid, 
Propylene Glycom, Mulberry 
(Morou Bom Bycis) Root Extract, 
Bearberry (Arctostaphylos 
Uvayrsil) Extract, Licorice 1 
















Aqua, Polysorbate 60, Glycerine, 
A.H.A, Glyceryl Monostearate, 
Cetyl Alcohol, Vitamin C, Stearic 
Acid, Paraben Complex, 
Carbomer, Triethanolamine, 
Vitamin E, Acetate, Fruity 




















oil), Glycerin, Cetearyl Alcohol 
and Ceteth-20 Phosphate and 
Dicetyl Phosphate, Di-PPG-2 
Myreth-10 Adipate, Cetearyl 
Alcohol, Phenoxy-ethanol and 
methylparaben and ethylparaben, 
and propylparaben and 










butylparaben, Lanolin Alcohol, 
Carbomer, Parfum (fragrance), 
Sodium Hydroxide, 
Caprylic/Capric Triglyceride 
Diacetyl Boldine, Disodium 
EDTA, CI 45430, Alpha-Hexyl 
Cinnamic Aldehyde (HCA), 







300 Clair Express Aqua, Plant Extracts, Paraffinum 
Liquidum, Glycerin, Refined 
Palm, Stearin, Fragrances, 
Carbomer, Methylparaben, Propyl 











Aqua (water), Glycerystearate, 
Parafinum Liquidum (mineral oil, 
Isopropyl Myristate, Cetosearyl 
Alcohol, Cetearch 20 & 25, 
Triethanolamine Puriss, Sodium 
Lauryl Sulfate, Butyrospermum 
Parkii, Glycyrthiza Globra, 
Murus Alba, Ascorbic Acid, 
Citric Acid, Methylparaben, 












Eau Purfiee BP, Parafine Oil 
USP, Dimethicone BP, Isopropyl 
Myristate BP, Propylene Glycol 
BP, Methyl Paraben BP, Propyl 
Paraben BP, Clobetasol 
Propionate USP 0.05%w/w, 













Deionised Water, Isopropyl 
Palmitate, Ceteareth-6 (and) 
Stearyl Alcohol, Stearic Acid, 
Glycerol, Cetostearyl Alcohol, 
Lanolin, Hydroquinone (2.0%), 
Hydrogenated Castor Oil, 
Fragrance, Silicon Fluid, Carboxy 
Methyl Cellulose, Octyl Methoxy 
Cinamate, Aloe Vera, Collagen, 
Allantoin, Vitamin c, Citric Acid, 
Triclosan, Vitamin E, Methyl 
Paraben, Propyl Paraben, Sodium 










Deionised Water, Cetostearyl 
Alcohol, Isopropyl Palmitate, 
Stearic Acid, Glycerol, Lanolin, 
Hydroquinone, Hydrogenated 
Castor Oil, Fragrance, Silicon 
Fluid, Carboxy Methyl Cellulose, 
Benzophenone-3, Sodium Lauryl 
Sulphate, Aloe Vera, Collegen, 






Vitamin E, Irgasan DP300, 
Methyl Paraben, Propyl Paraben, 
Sodium Sulphite, Sodium 
Metabisuphite, FD &C Yellow 








Isopropyl, Myristate, Deionised 




Carboxy Methyl Cellulose, Octyl 
Methoxycinnamate, Anhydrous 
Lanolin, Methyl Paraben, Propyl 
Paraben, Sodium Sulphite, 
Sodium Metabisulphite, Stearic- 
Acid, Vitamin A, Vitamin E, 
Citric Acid, Ascorbic Acid 
(Vitamin –C), Niacinamide 










650 Beauty Fair 
Supa Tona 
Stabilized Aloe-Vera Gel, 
Deionized Water, Glycerin, 
Stearic Acid, Propylene Glycol, 
C12-C13 (Alky Benzoate), 
Hydrogenated Poly sobutene, 
Isopropyl Myrestate, Collegen, 
D-Penthanol (Pro Vitamin B5), 
Vitamin-C, Vitamin-E, Kojic 
Acid Dipalmitate (K.A.D), 







Kernel Oil, Sodium Metabisulfite, 
Sodium Sulfite, Propyl Paraben, 





600 Ken Perfect 
Action White 
Deionized Water, Cosmowax, 
Cetyl Alcohol, Stearic Acid, 
Glycerin, Mineral Oil, Isopropyl 
Myristate, Alph Hydroxy Acid 
with Kolic Acid (AHA-K), Citric 












Water, Mineral Oil, Petrolatum, 
Lanolin, Stearic Acid, Cetyl-
Stearylic Alcohol, Isopropyl 
Myristate, Tocopheryl Acetate, 
BHT, Methyl Paraben, Propyl 
Paraben, Sodium Lauryl Sulfate, 
Sodium Metabisulfite, Sodium 
Ssulfite, Citric Acid, Propylene 
Glycol, AHA (Alpha-
Hydroxyacid), Allantoin, Lecithin 








600 Skin Magnet 
Whitening 
Lotion 
Aqua (water), Glyceryl Stearate, 
Cetostearyl, Alcohol, Avocado 
Oil, Isopropyl Myristate, 
Glycerine, Allantoin, Ascorbic 








 Sodium Sulphite, Fragrance, 
Sunscreen, Arbutin, Carrot 










Peg-7 Glycerylcacoate, Bearberry 
Extracts, Mulberry Extracts, 
Licorice Extracts, Lemon 
Extracts, Kojic Acid, PPG-1-
PEG-9 Lauryl Ether, Fragrance.  




500 So White 
Skin 
Perfector Gel 
Propylene Glycol, Cetearyl 
Alcohol, Hydroxy Phenol,Castor 




(Fragrance), Sodium Sulfite, 
Sodium Metabisulfite, CI14700. 











Vaseline, Huile De Vaseline, 
Acide Stearique, Glycerine, 
Acides De Fruits (AHA), Acide 
Kojique, Allantoine, Huile De 
Silicone, BHT, Lorol C16, Lorol 









450 Rapid Clair 
Gel Cream 
Plus 
Eau Purfiee BP, Parrafine Oil 
USP, Dimethicone BP, Isopropyl 
Myristate BP, Propylene Glycol 
BP, Sorbic Acid BP, Clobetasol 
Propionate USP 0.05%w/w, 












Deionosed Water, Ceteareth-6 
(and) Stearyl Alcohol, Cetostearyl 
Alcohol, Isopropyl Palmitate, 
Glycerol, Stearic Acid, Lanolin, 
Hydroquinone (2%), 
Hydrogenated Castor Oil, 
Fragrance, Sillicon Oil, Escalol 
557, Aloe Vera, Collegen, D-
Panthenol, Citric Acid, Vitamin 
E, Vitamin C, Methyl Paraben, 
Propyl Paraben, Sodium Sulphite, 














Petrolatum, Mineral Oil, Stearic 
Acid, Cetearyl Alcohol, Isopropyl 
Myristate, Glycerin, Methyl & 
Propyl Paraben, Huile De 
Carotte, Vitamin E(0.2%), 













Water, Cetyl Stearylic Alcohol, 
Stearic Acid, Petrolatum, Mineral 
Oil, Isopropyl Myristate, 
Propylparaben, BHT, UVA, 
UVB, Tocopheryl Acetate, 
Polysorbate 60, Methylparaben, 
Sodium Sulfite, Sodium 
Metabisulfite, Propylene Glycol, 
Ascorbic acid, Allantoin, Carrot 
Oil, Collagen, Hydroquinone 2%, 
Fragrance. 




350 Venus Skin 
Toning 
Cream 
Water, C12-15 Alkyl Benzoate, 
Mineral Oil, Octyl Stearate, 
Polyglyceryl-3 Methyl Glucose 




Glyceryl Stearate, Tocopheryl 





Acrylates/C10-30 Alkyl Acrylate 
Crosspolymer, Disodium EDTA, 







SLP 25 250 Euro White 
Cream 
100g Contain Clobetasol 





SLP 26 250 Labidjanaise 
Carrot 
Cream 
100 g Contiennet Clobetasol 





SLP 27 250 Applevet 
Lightening 
Cream 
Clobetasol Propionate B.P 0.05 % 




SLP 28 250 Xtra White 
Gel 
100 g Contiennet Betamethasone 






SLP 29 250 Amos White 
Gel 






SLP 30 200 Janet Gel 
Plus 
100 g Contain Clobetasol 





SLP 31 200 Tempovate 
Gel 






SLP 32 200 Visible 
Difference 
Cream 






















SLP 33 200 Clear White 
Moon 
Clobetasol Propionate U.S.P. 0.05 
% w/w Excipient q.s. 
 India 
SLP 34 150 Esapharma 
Movate 
Cream 
100 g Contiennet: Clobetasol 
Propionate 0.05 g, Excipient: 1,2- 
Propandiol, Dyoxyde De Titane, 






SLP 35 150 Beneks’ 
Fashion Fair 
Gel Plus 
100 g Contient: Betamethasone 







2.3   HPLC analysis of skin-lightening agents 
Chromatography still represents the most commonly used technique for the determination 
of SLAs in cosmetic products including SLPs.  It is categorised by the type of mobile 
phase used, as liquid, gas, or supercritical chromatography.  A number of reports describe 
various HPLC methods used for the qualitative and quantitative determination of SLAs 
in SLPs.  These were discussed in Section 1.8. 
In this study, a reversed-phase HPLC technique was employed to separate, identify, and 
quantify the SLAs present in the studied SLPs.  Reversed-phase HPLC is far superior to 
other HPLC modes in the variety of target compounds it can handle.  The HPLC technique 
has a unique advantage in terms of the column and mobile phase interaction, or 
mechanism of separation, and the selectivity.  It allows for the separation of high 
molecular mass and high polarity compounds and also gives one liberty to accomplish 
very difficult separations at low levels of detection, with high precision and accuracy.  
 
2.3.1   Theory of HPLC 
Chromatography is based on the partitioning of solutes between two phases and is, 
therefore, related to simple liquid–liquid extraction.  In HPLC, however, one phase (the 
mobile phase) is in constant movement relative to the other one (the stationary phase).  
The sample molecules are partitioned between the phases; those in the stationary phase 
are retained, whereas those in the mobile phase move.  The interaction between the solutes 
and the stationary phase is most often based on adsorption.  During an HPLC separation, 
a solute normally partitions between the phases many thousand times.  The basis of 
separation is that different kinds of molecules on average spend different amounts of time 
in the stationary phase.  Due to a large number of partitioning steps, chromatography has 
enormous resolving power and can separate mixtures of components with very similar 
physical properties.  In the common HPLC format, the stationary phase is a highly porous 
solid material packed inside a cylindrical column, whereas the mobile phase is a liquid.  
If a successful separation has been made of a binary sample, this will in the ideal case 




2.3.2   Components of an HPLC system 
A typical HPLC instrument has five main units.  These are the mobile phase reservoir, 
pump, column, injector system, and detector (Figure 2.1).  A recorder and a waste unit 








Figure 2.1: Components of an HPLC instrument (185). 
The mobile phase reservoir is an inert container for mobile phase storage and transport.  
Generally, transparent glass bottles are used so as to facilitate visual inspection of the 
mobile phase level inside the container.  Stainless steel particulate filters are placed inside 
the containers for removal of particulate impurities in the mobile phase, if any. 
The column is a stainless steel tube packed with stationary phase, with the option of 
different lengths, bore sizes and packing materials, and is held in place by the column 
hardware.	Columns are available in different dimensions including preparative, normal-, 
micro- and mini-bore, and capillary columns.  The most widely used packing materials 
for HPLC separations are silica-based. The most popular material is octadecyl-silica 
(ODS-silica), which contains C18 coating, but materials with C1, C2, C4, C6, C8 and 
C22 coatings are also available.  Other types of substances used as column packing 
materials include zirconia, polymer-based and monolithic columns.  The right choice of 
column length combined with the correct packing material in correlation with the 
appropriate mobile phase is what determines an effective separation in HPLC.  The two 
most commonly used modes of separation in HPLC are the reversed-phase and normal-
phase.  Reversed-phase columns contain a non-polar stationary phase (such as C18) and 
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are mostly used for non- or mildly polar organic compounds, and are typically paired with 
a polar mobile phase.  Normal-phase columns contain a polar stationary phase and are 
mostly used to separate polar molecules in combination with a non-polar mobile phase. 
An injector or auto-sampler is used to provide a constant volume injection of the sample 
into the mobile phase stream.  Inertness and reproducibility of injection are necessary to 
maintain a high level of accuracy. 
The detector measures either the absorbance, fluorescence, conductivity or refractive 
index of the mobile phase.  When a compound elutes from the column, a peak is observed.  
The retention time of the peak is used to identify the compound.  The peak height (or 
area) is proportional to the amount of the compound in the sample.  Some detectors 
provide the ability to obtain a spectrum of the eluting species.  Detector choice depends 
on the properties of the compound being analysed.  A UV detector or photodiode array 
(PDA), fluorescence detector and refractive index detector (RI) are the most widely 
available detectors for use in HPLC.  When analysing a wide variety of substances that 
can absorb light within the ultraviolet to visible region (190-900 nm) a PDA detector is 
commonly used.  The PDA detector allows simultaneous monitoring of more than one 
absorbing component at different wavelengths which is an advantage in terms of less 
solvent usage and time-saving.  A mass spectrometer is the ultimate detector for liquid 
chromatography (LC-MS).  It significantly enhances the application range for HPLC in 
terms of sensitivity and selectivity and its detection pattern is based on fragmentation of 
a molecule by an electric field and separation on the basis of mass to charge ratio of the 
fragmented molecule.  
The pump or solvent delivery system serves to provide a pulse-free flow of the mobile 
phase through the column under constant pressure.  Variations in the flow rates of the 
mobile phase affect the elution time of sample components and result in errors.  The 
composition of the mobile phase can be kept constant during the separation (isocratic 
mode) or can be changed during the gradient separation mode.  Gradient elution is 
employed when trying to resolve components which do not separate and elute under 
isocratic conditions.  There are two options for gradient operation: high-pressure mixing 
(which requires a pump for each solvent) and low pressure mixing (which requires one 
pump).  A control program is required for gradient operation. 
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The recorder reads out information from the detector.  It interprets and records detected 
compounds by means of peaks and produces chromatograms as relevant.  The analysed 
solutions flowing from the detector output make their way to the waste unit.  Tubing lines 
and fittings serve to interconnect the pump, injector, column, and detector components in 
order to form an entire channel for the mobile phase, sample, and separated compounds.  
Modern HPLC systems are computer-based and software controls the operational 
parameters and also the acquisition and treatment of data. 
 
2.3.3   Identification of skin-lightening agents 
Identification of selected SLAs in the analysed products was done by comparing the UV 
spectra and retention times of pure analytes with those of the sample analytes.  The HPLC 
detector used in this study was a photodiode array detector which has the ability to provide 
a UV spectrum for each individual peak in the chromatogram.  With the help of UV-
visible spectrophotometry, the wavelength of maximum absorption for each of the 
selected SLAs was obtained.  By using these wavelengths that the selected SLAs absorb, 
one can differentiate the components separated based on their UV spectra and retention 
times with HPLC.  The wavelengths of maximum absorption are also used to select 
appropriate detection wavelengths for collection of the chromatograms so that all analytes 
can be detected.  Below is a brief introduction on UV-visible spectrophotometry and the 
spectral information of the selected SLAs detected in the analysed products.  
 
2.3.3.1   Theory and instrumentation for UV-visible spectrophotometry 
Ultraviolet and visible (UV-Vis) absorption spectroscopy is the measurement of the 
attenuation of a beam of light after it passes through a sample or after reflection from a 
sample surface.  It measures the intensity of light as a function of its wavelength.  Single-
beam and double-beam are the two major classes of spectrophotometers.  In single-beam 
spectrophotometers, all the light passes through the sample.  To measure the intensity of 
the incident light the sample must be removed so that all the light can pass through.  In a 
double-beam spectrophotometer, before the light reaches the sample, the light source is 
split into two separate beams.  One beam passes through the sample and the second one 
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is used for reference.  This gives an advantage because the reference reading and sample 
reading can take place at the same time. 
Different analytes, such as transition metal ions, biological macromolecules, and highly 
conjugated organic compounds, can be analysed by UV-Vis spectroscopy.  Organic 
compounds absorb light in the UV or visible region of the electromagnetic spectrum.  
Compounds that absorb visible light (400-780 nm) are coloured, whereas those that 
absorb UV light (190-400 nm) do not need to be coloured, which is in our case.  
The wavelength at which an organic compound absorbs depends on how its electrons are 
tightly held in a molecule, but the wavelength of this light is inversely proportional to the 
energy of the radiation as explained by the equation below: 
E = hc/λ. 
E is the energy of electromagnetic radiation being absorbed, h is Plank’s constant, c is the 
speed of light and λ is the wavelength of absorption. 
As energy is absorbed in the UV region, there occur changes in the electronic energy of 
the molecule.  Once a molecule absorbs energy, an electron is promoted from an occupied 
molecular orbital (usually a non-bonding n or bonding π orbital) to an unoccupied 
molecular orbital (an antibonding π∗ or σ* orbital) of greater potential energy.  The lowest-
energy occupied molecular orbitals for most molecule are σ orbitals (see Figure 2.2), 
which correspond to σ bonds and the π orbitals lie at relatively higher energy levels than 
σ orbitals.  The non-bonding orbitals that hold unshared pairs of electrons lie at even 

















σ → σ* π → σ
* n → π
 * 
π → π* 
n → σ* 
σ → π* 
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To determine the concentration of an absorbing species in a solution with a fixed path 
length by UV-visible spectroscopy, the Beer-Lambert law comes into play.  It states that 
the absorbance of a solution is directly proportional to the concentration of the absorbing 
substances in the solution and the path length, which is written symbolically as   
A = log Іₒ ⁄ І = log 100 ⁄ T = ε c b 
where A is the absorbance (no unit of measurement), ε is the molar absorptivity (dm3 mol-
1 cm-1), c is the molar concentration (mol dm-3), and b is the path length (cm).  The 
concentration of the samples must be low in order to obey the Beer-Lambert law. 
The minimum requirements of an instrument to study absorption spectra (a 
spectrophotometer) include a source, a monochromator, sample compartment and a 
detector (see Figure 2.3).  The commonly used light sources, such as a tungsten halogen 
lamp (˃ 350 nm) and a deuterium lamp (˂ 350 nm), are required to be stable during the 
measurement period, i.e. the intensity of the emitted radiation should not fluctuate, and 









Figure 2.3: Schematic of a double-beam UV-visible spectrophotometer (186). 
The function of a monochromator is to produce a beam of monochromatic (single 
wavelength) radiation that can be selected from a wide range of wavelengths.  The 
essential components are the entrance slit, collimating device (to produce parallel light), 
a wavelength selection or dispersing system, a focus lens or mirror, and an exit slit.  The 
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sample compartment serves to accommodate the cuvette that carries the sample solution.  
The detector, which servers to measures the absorbance of samples, is usually a 
photomultiplier, silicon diode, or diode array. 
In this study, a PerkinElmer Lambda 25 double-beam UV-visible spectrophotometer 








Figure 2.4: A photograph of the PerkinElmer Lambda 25 double-beam UV-visible 
spectrophotometer used for measuring the UV spectra of the selected SLAs. 
 
2.3.3.2   Determination of UV absorbance of skin-lightening agents 
In order to carry out the UV analysis, pure standards of selected SLAs, which included 
clobetasol propionate, betamethasone dipropionate, clotrimazole, hydroquinone, 
benzoquinone, kojic acid, niacinamide and arbutin, were dissolved in methanol.  The UV 
analysis of the SLAs was done by using 1 cm path length quartz cuvettes and methanol 
as the blank in the reference beam.  Their UV absorption bands were obtained over the 
wavelength range of 190 nm to 400 nm.  The spectra of the SLAs are shown in Figures 










































































































































































































































































































Table 2.2: The wavelength of maximum absorption for each skin-lightening agent 
obtained by UV-visible spectrophotometry. 
Active ingredients Wavelength of maximum absorption/nm 
Clobetasol propionate (CP) 238 
Betamethasone dipropionate (BD) 238 
Clotrimazole (CT) 204 
Hydroquinone (HQ) 293 
Benzoquinone (BQ) 242 
Kojic acid (KA) 269 
Niacinamide (NC) 262 
Arbutin (ARB) 286 
 
2.3.4   HPLC method development 
The selection of the appropriate HPLC column and mobile phase, and optimisation of 
other operational parameters are what defines the method development.  The process is 
typically influenced by the nature of the sample and analytes involved.  
However, certain precautions need to be taken during the HPLC method development so 
as to consistently obtain reproducible results.  This includes the use of HPLC-grade 
solvents and ultrapure water obtained from a Milli-Q unit for preparation of all solutions 
including the mobile phase.  The mobile phase is one of the most important factors in 
HPLC method development and if it contains water it should be prepared fresh daily.  It 
must be filtered through Millipore 0.45 µm HV organic aqueous filters for removal of any 
particulates before degassing with high purity helium at a rate of 100 mL min-1 for 5 
minutes prior to use.  The process of degassing serves to prevent a change in PDA signal 
to noise ratio caused by light scattering which can be due to air bubbles in the eluent.  
When using acidic or basic mobile phases, the column must be confirmed to be 
compatible with the pH range and should be immediately flushed out thoroughly after use 
with the appropriate solvent so as to avoid precipitation of salts that could damage and 
score the moving parts of the pump. 
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In order to clear the entire system lines of air bubbles and previously used solvent, the 
HPLC pumps should be left over a long time to pump at a rate of 0.2 ml min-1 with the 
mobile phase of interest.  This is referred to as purging and is done without the column 
so as to avoid its contamination.  Before use, the column should be equilibrated by 
allowing at least ten column volumes of mobile phase to pass through the column with 
the pressure of the pumps not exceeding the maximum pressure allowed for the 
instrument.  This reduces the problems of pressure fluctuations and noisy baseline which 
can result in inconsistent retention times.   The lamp of the PDA detector should be 
warmed-up for a period of 30 minutes before use. 
In order to avoid the introduction of any particulate matter onto the column all samples 
must be filtered through 0.45 µm Millex HV solvent resistant syringe filters.  Carry-over 
of samples between injections is checked with blank injections in between samples. 
 
2.3.4.1   Determination of optimum separation method 
Separation in HPLC is dependent upon the physical and chemical interactions between 
the analyte and the mobile and stationary phases.  Each of these factors may be altered in 
order to change or optimise the selectivity of an HPLC separation.  
To achieve optimum separation by isocratic elution, the studied SLAs were grouped into 
two so as to avoid co-elution.  The first group consisted mainly of steroid compounds 
such as clobetasol propionate, betamethasone dipropoinate and clotrimazole.  The test 
separations were performed on the mixed standard solutions on a Brownlee analytical 
C18 (100 × 4.6 mm, 3 µm) column.  Several mobile phases were tested in order to find 
the best separation.  The mobile phases included a mixture of methanol and water (50:50, 
v/v), methanol and water (60:40 v/v), methanol and 0.2% acetic acid in water (70:30, v/v), 
and methanol and water (80:20, v/v).  The mobile phase flow rate was altered between 
0.5, 0.8, and 1.0 mL min-1 while the injection volume was 10 µL.  The column 
temperature was kept at ambient throughout. 
The second group of SLAs, which included hydroquinone, benzoquinone, kojic acid, 
niacinamide and arbutin, were separated under different liquid chromatographic 
conditions since the method chosen for the first group of SLAs proved unsuccessful for 
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these analytes.  Just like for the first group of SLAs, trial separation experiments were 
done by using pure standard solutions.  Here the stationary phase used was an SGE C18 
(250 × 4.6 mm, 5 µm) column, as it is known that a change in column is one of the most 
popular ways to alter the selectivity of a separation.  The mobile phases which were tried 
included a mixture of methanol and 0.05 M KH2PO4 at a pH of 2.5 (70:30, v/v), methanol 
and 0.05 M K2HPO4.3H2O at a pH of 3.0 (80:20, v/v), methanol and 0.2% acetic acid in 
water (90:10, v/v), and 0.5% orthophosphoric acid in methanol and 0.5% orthophosphoric 
acid in water (5:95, v/v).  The mobile phase flow rate was varied between 0.3, 0.5, 0.8, 
1.0, and 1.2 mL min-1 and the injection volume of the studied analytes was 10 µL. The 
column temperature was varied between 25 °C and 35 °C.  The result of these various 
trials are presented and discussed in Section 3.1.3. 
 
2.3.4.2   Determination of optimum extraction method 
The extraction of SLAs in the studied SLPs is an important factor for their quantitative 
analysis.  The extraction method must be good enough to extract the maximum amount 
of SLAs in the SLPs.  This required a preliminary extraction test so as to determine the 
best solvent to be used.  Four solvents were tested as the extractant, namely, methanol, 
acetonitrile, 50% methanol in water, and a mixture of 50% acetonitrile and 50% methanol.   
The extraction method for the sample preparation was studied with eight SLA standards 
and the analysis was done by HPLC with the columns described in Section 2.3.4.1 for the 
two groups of SLAs. 
In order to optimise extraction of SLAs from the cream formulations, 0.05 g of a SLP 
containing none of the studied SLAs was weighed into a glass flask, after which a known 
amount of a mixture containing the same concentration of each of the SLAs was 
immediately added and then diluted with 4 mL of the extraction solvent.  The solution 
was stirred for a few minutes to allow for proper mixing before being placed in an 
ultrasonic water bath at 40 °C for 20 minutes.  After ultrasonication, the solution was 
allowed to cool down and was then quantitatively transferred into a 10 mL volumetric 
flask and made up to the mark with the extractant.  This method was repeated for each of 
the four extractants on both groups of SLAs.  The resulting solutions were analysed by 
HPLC with the folowing chromatographic conditions: a Brownlee analytical C18 (100 × 
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4.6 mm, 3 µm) column, mobile phase of methanol and water (80:20, v/v), injection 
volume of 10 µL, flow rate of 0.8 mL min-1, and ambient column temperature for the first 
group of SLAs and an SGE C18 (250 × 4.6mm, 5 µm) column, mobile phase of 0.5% 
orthophosphoric acid in methanol and 0.5% orthophosphoric acid in water (5:95, v/v), 
injection volume of 10 µL, flow rate of 1.0 mL min-1 and a column temperature of 35 °C 
for the second group of SLAs.  The results of the extraction test are presented and 
discussed in Section 3.1.4. 
 
2.3.4.3   Standard solution preparation and analysis 
A 1000 mg L-1 standard stock solution was prepared for each of the SLAs by dissolving 
0.025 g of the pure materials with methanol in 25 mL volumetric flasks.  The solutions 
were then placed in an ultrasonic bath for 10 minutes so as to completely solubilise the 
solutes present in them.  The solutions were subsequently made up to the mark with 
methanol.  For each SLA, the standard stock solutions were prepared in triplicate, from 
which a 100 mg L-1 multi-standard working stock solution was prepared for clobetasol 
propionate, betamethasone dipropionate, clotrimazole, and a 400 mg L-1 multi-standard 
working stock solution for hydroquinone, benzoquinone, kojic acid and niacinamide.  In 
the case of arbutin, a 100 mg L-1 standard working stock solution was prepared separately 
as it always co-elutes with kojic acid.  
From these working stock solutions of standards, another set of dilute working standard 
solutions was prepared by serial dilution with methanol.  For clobetasol propionate, 
betamethasone propionate and clotrimazole, eight different concentrations of working 
standard solutions were prepared in the range of 0.2 – 60.0 mg L-1.  In the case of 
hydroquinone, benzoquinone, kojic acid, niacinamide and arbutin seven different 
concentrations of working standard solutions were prepared in the range of 0.5 – 400 mg 
L-1, 0.2 – 20 mg L-1, 0.5 – 90 mg L-1, 0.8 – 110 mg L-1, and 1.0 – 20 mg L-1 respectively.  
Aliquots of each of the standard solutions were subjected to HPLC analysis so as to 
generate calibration curves for quantification of the SLAs. 
Certain chromatographic conditions were set during the analysis.  The autosampler was 
set to perform three injections per standard solution, with a blank injection of methanol 
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in between each injection so as to avoid any carry-over from the previous injection into 
the column.  The injection volume was 10 µL throughout and the flow rate was set at 0.8 
mL min-1 for the first group of SLAs and 1.0 mL min-1 for the second group of SLAs.  
The column temperature was room temperature for the first group of SLAs and 35 °C for 
the second group of SLAs.  Chromatograms were collected at detection wavelengths of 
225 nm, 240 nm, 270 nm and 289 nm so as to observe all SLAs optimally and the 
maximum run time was 20 minutes. 
 
2.3.4.4   Sample preparation and analysis 
A mass of 0.05 g of each SLP was accurately weighed into a glass flask in which 4 ml of 
methanol was added and properly shaken for 5 minutes.  The flask was then placed in an 
ultrasonic water bath set at 40 °C for 20 minutes.  After ultrasonication, the sample was 
allowed to cool to room temperature and then quantitatively transferred into a 10 mL 
volumetric flask and made up to volume with methanol.  The sample was filtered through 
a 0.45 µm Millipore syringe filter to remove all particulate matter that could clog the 
column before being transferred into the HPLC injection vials.  Three replicates were 
prepared for each of the SLPs for HPLC analysis.  The analysis was carried out by using 
the same precautions and chromatographic conditions as described in Section 2.3.4.3. 
Both samples and standard solutions were analysed on a Brownlee analytical C18 (100 × 
4.6 mm, 3 µm) column for the first group of SLAs and a SGE C18 (250 × 4.6 mm, 5 µm) 
column for the second group of SLAs with a mobile phase composed of methanol : water 
(80:20, v/v) and 0.5% orthophosphoric acid in methanol : 0.5% orthophosphoric acid in 
water (5:95, v/v) for the first and second groups of SLAs respectively.  
All HPLC analyses were carried out on a Shimadzu Prominence UFLCXR instrument (see 
Figure 2.13) (Shimadzu Corporation, Japan) with the following components: a DGU-
20A3 degasser, LC-20AD XR binary pumps, SIL-20A XR autosampler, SPD-M20A 
diode array detector, CTO-20A column oven, CBM-20A communicator bus module, 












Figure 2.13: A photograph of the Shimadzu Prominence UFLCXR instrument used for the 
determination skin-lightening agents in this study. 
 
2.3.4.5   Recovery analysis 
Recoveries were performed in order to determine the accuracy of the methods developed.  
This was done by spiking samples with a known amount of the SLA standards.  The 
samples used were previously analysed to ensure that they did not contain any of the 
SLAs under investigation.  Two spiked solutions of different concentration were prepared 
for each of the studied SLAs.  This was done by pipetting 1 mL and 5 mL of clobetasol 
propionate, 1 mL and 5 mL of betamethasone propionate, 1 mL and 5 mL of clotrimazole, 
1 mL and 2 mL of hydroquinone, 1.5 mL and 2 mL of benzoquinone, 0.8 mL and 2 mL 
of kojic acid, 1 mL and 2 mL of arbutin, and 1.5 mL and 2 mL of niacinamide from a 100 
mg L-1 of their respective standard stock solutions to a mass of 0.05 g of the SLA-free 
sample and made up to volume with methanol in a 10 mL volumetric flask.  The spiked 
sample solutions were then shaken vigorously for 5 minutes and placed in an ultrasonic 
water bath at 40°C for 20 minutes.  After this, the spiked sample solutions were allowed 
to cool and filtered through a 0.45 µm Millipore syringe filter into an HPLC injection vial 
for analysis.  The entire procedure was performed in triplicate and analyses were carried 
out following the methods described in Sections 2.3.4.3 and 2.3.4.4.  The results obtained 
from the recovery analysis are presented and discussed in Section 3.2.2. 
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2.3.4.6   Intra-day and inter-day analysis 
Intra-day and inter-day analyses were carried out in order to determine the precision of 
the method.  This was done by a repeated analysis of the studied SLA standards. Three 
different standard solutions were prepared for each of the SLAs, which included 2, 10, 
and 20 mg L-1 for hydroquinone; 2, 8, and 20 mg L-1 for benzoquinone; 1, 10, and 20 mg 
L-1 for kojic acid; 5, 10, and 20 mg L-1 for niacinamide; 2, 12, and 20 mg L-1 for arbutin 
and the same concentrations of 1, 4, and 8 mg L-1 for clobetasol propionate, 
betamethasone dipropionate, and clotrimazole.  The entire procedure was completed in 
triplicate.  The HPLC methods described in Sections 2.3.4.3 and 2.3.4.4 were used to 
analyse the standards. 
The intra-day analysis was done by repeated analysis of the three standards three times a 
day over a time interval of three hours, while the inter-day analysis was done by repeated 
analysis of the three standards over a period of 24 hours for three consecutive days.  The 
results of the intra-day and inter-day analyses are given and discussed in Section 3.2.3. 
 
2.4   Analysis of heavy metal content 
The qualitative and quantitative analysis of heavy metals in various types of samples has 
been carried out by using different analytical techniques.  These were discussed in Section 
1.9.  Usually, the choice of technique is dependent on cost, run-time, sensitivity (LOD), 
physical state of the matrix and instrument availability. 
In the present study, ICP-OES was employed as it was the best available option at our 
disposal.  This technique allows multi-element determination and also permits the 
scanning of liquid samples in order to obtain overall information on the inorganic 
composition of the sample under study.  The technique involves short-run times, has high 
sensitivity and is relatively free from complex matrices.  For mercury determination, cold 





2.4.1   Extraction of heavy metals 
An acid digestion procedure was employed in this study for the extraction of heavy metals 
in the studied SLPs.  This was achieved by dissolving the samples in a mixture of acids 
and heating until complete decomposition of the matrix, while avoiding loss or 
contamination of the analytes before introduction into the ICP-OES or CV-AAS in liquid 
form for analysis. 
Open acid digestion and closed acid digestion are the two types of acid digestion 
procedure.  Both are carried out with the aid of a wide variety of reagents.  Aside from 
mineral acids, such as nitric acid, hydrochloric acid, nitro-hydrochloric acid, hydrofluoric 
acid, or sulfuric acid, other reagents, such as hydrogen peroxide, potassium peroxide 
sulfate, boric acid and many more, are also employed.  However, the selection of specific 
reagents or the preparation of the reagent mixture depends on the sample to be digested. 
The open acid digestion method is carried out either with a reflux system or in a beaker 
on a laboratory hot plate.  This method is challenged with temperature limitations as a 
consequence of the solution boiling point and the risk of contamination from the air.  A 
volatile element like mercury may be lost during the digestion process, leading to lower 
results.  Generally, the quality of digestion is mostly unsatisfactory despite the long 
digestion times of 2 – 15 hours. 
For the present study, the closed acid digestion method was used.  With this method, the 
temperature limitation can be overcome by working with a closed pressure vessel since it 
allows temperatures in the range of 200 – 260 °C to be reached.  This results in a dramatic 
increase in the reaction kinetics, allowing acid digestion to be carried out in a matter of 
20 – 40 minutes if microwave heating is employed.  However, one can conclude that 
temperature represents what is actually the most important reaction parameter.  It is the 
ultimate determinant of digestion quality, but also results in a pressure increase in the 
vessel as the reaction between the acid and sample takes place, making it a potential safety 
hazard.  Thus, the pressure must ultimately be closely monitored. Section 2.4.1.1 





2.4.1.1   Microwave-assisted digestion 
Microwave-assisted digestion involves irradiation of the sample with microwave 
electromagnetic radiation of a high-frequency electric field to achieve fast heating of the 
sample through the direct absorption of microwave radiation.  This allows for an 
extremely rapid, simultaneous heating of about 8-12 sample solutions which represents 
another advantage of microwave heating.  Once the setpoint temperature is reached, the 
decomposition reaction of the sample solutions proceeds at the same rate. 
As mentioned earlier, the combination of acids during digestion depends on the matrix of 
the sample.  A combination of nitric acid, hydrochloric acid, and/or hydrofluoric acid has 
been reported to provide better recoveries for digestion of some cosmetics such as 
lipsticks, eye shadows and eyeliners in a closed system (187).  Such a reagent mixture 
was not suitable for use for SLP digestion as it would explode (188).  Thus, nitric acid 
alone was chosen for the digestion of SLPs in this study as it is known to be a strong 
oxidising agent. 
A sample of each SLP of a mass of a 0.250 g was placed into a high-pressure resistant 
TFM-vessel to which 10 mL of conc. nitric acid was added.  The samples were allowed 
to pre-digest for 30 minutes in the fume hood uncovered, after which the vessels were 
sealed and subjected to microwave irradiation in a Mars 6 microwave digestion system 
(see Figure 2.14).  The temperature was gradually increased from room temperature to 
200 °C in a time frame of 15 minutes before the vessels were held at this temperature for 
a period 20 minutes and then cooled down to ± 65 °C over a period of 15 minutes.  After 
cooling to room temperature, the vessel modules were disassembled and both the lids and 
vessels were rinsed with double distilled water and the rinse solutions collected with the 
digest.  The samples were subsequently filtered through a 11 µm grade one Whatman 
filter paper into 50 mL volumetric flasks and then made up to mark with double distilled 
water.  Filtration of samples was necessary in order to avoid any residue that could clog 
the instrument lines or result in data fluctuation.  Both the samples and blanks were 












Figure 2.14: A photograph of the Mars 6 microwave digestion device and the XP-1500 
TFM reaction vessels used for digestion of skin-lightening samples in this study. 
 
2.4.2   Inductively coupled plasma-optical emission spectrometry 
Inductively coupled plasma-optical emission spectrometry (ICP-OES) is one of the most 
powerful and popular analytical tools for the determination of metals in a variety of 
different sample matrices.  The technique is based on the spontaneous emission of 
photons from atoms and ions that have been excited in a radio-frequency discharge.  Thus, 
the wavelength of the photons emitted is used to identify the elements from which they 
originated. The total number of photons is directly proportional to the concentration of 
the originating element in the sample. 
The ICP-OES instrument has two main parts: the torch, and the optical spectrometer 
(Figure 2.15).  The ICP torch is made up of three concentric quartz glass tubes.  Part of 
this quartz torch is surrounded by the work coil of the radio-frequency generator.  Argon 
gas typically serves in creating the plasma.  When the torch is turned on, an intense 
electromagnetic field is created within the coil by the high power radio-frequency signal 
flowing in the coil.  This radio-frequency signal is created by the radio-frequency 
generator which is, effectively, a high power radio-transmitter driving the work coil the 
same way as a typical radio transmitter drives a transmitting antenna.  Typical ICP-OES 
instruments run at either 27 or 40 MHz.  The argon gas flowing through the torch is ignited 
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with a Tesla unit that creates a brief discharge arc through the argon flow to initiate the 
ionisation process.  Once the plasma is "ignited", the Tesla unit is turned off.  The argon 
gas is ionised in the intense electromagnetic field and flows in a particular rotationally 
symmetrical pattern towards the magnetic field of the radio-frequency coil.  A stable, 
high-temperature plasma of about 7000 K is then generated as the result of the inelastic 










Figure 2.15: Schematic of an ICP-OES instrument (189). 
A peristaltic pump delivers an aqueous or organic sample into the analytical nebuliser 
where the sample is changed into mist and introduced directly inside the plasma 
discharge.  The sample components immediately collide with the electrons and charged 
ions in the plasma and are broken down into charged ions.  The various molecules break 
up into their respective atoms, which then lose electrons and recombine repeatedly in the 
plasma, giving off radiation at the characteristic wavelengths of the elements involved. 
In this work a PerkinElmer Optima 5300 DV simultaneous ICP-OES spectrometer (see 




2.4.2.1   Preparation of standard solutions of heavy metals 
All standard solutions were prepared from 1000 mg L-1 analytical grade stock solutions 
of the respective metals.  From the stock solutions, a multi-element working standard 
solution of 5 mg L-1 for each component was prepared for Al, Cr, Cu, Fe, Mn, Ni, Pb, and 
Zn in a 100 mL volumetric flask.  This was done by first placing 10 mL of concentrated 
nitric acid in the volumetric flask and then transferring an aliquot of 0.5 mL of each metal 
ion into the flask before making it up to the mark with double distilled water.  The essence 
of the nitric acid was to minimise matrix effects.  From here, further dilution was made 
with double distilled water to prepare nine different concentrations for each of the metals 
and these more dilute solutions were used for the construction of calibration curves.  The 
concentration range was 0.01 – 1.6 mg L-1 for all the metals. 
Standard solutions were not prepared for As, Cd and Co since the rough scan run on all 
the samples did not indicate their presence. 
 
2.4.2.2   Determination of heavy metals 
All samples were analysed for As, Al, Cd, Co, Cr, Cu, Fe, Mn, Ni, Pb, and Zn.  Certain 
operational conditions were set on the ICP-OES instrument before the analysis began, 
which included generator power, 1000 W; plasma gas flow rate, 12 L min-1; nebuliser 
pressure, 3 bars; and sample flow rate, 1 mL min-1.  
A scan run was initially performed on all the sample solutions to confirm the presence or 
absence of the targeted elements.  This was helpful in knowing what metal standards to 
prepare and their concentration ranges.  Also, three different analytical wavelengths were 
preselected for each element out of which one of these wavelengths with high intensity, 
low detection limits and minimal impact on the background of an emission line were 
chosen for each element for further quantitative determinations.  The wavelengths chosen 
for use in this study for each metal ion analysed are listed in Table 2.3.  To begin the 
analysis, standard solutions and samples were allowed to aspirate for 60 seconds before 











Figure 2.16: A photograph of the PerkinElmer Optical 5300 DV simultaneous ICP-OES 
device used for the determination of heavy metals in this study. 
 
Table 2.3: Emission wavelengths used for analysis of heavy metals by ICP-OES. 
Element Wavelength/nm 
Arsenic (As) 188.979 
Aluminium (Al) 396.153 
Cadmium (Cd) 214.440 
Cobalt (Co) 228.6116 
Chromium (Cr) 267.716 
Copper (Cu) 324.752 
Iron (Fe) 259.939 
Manganese (Mn)  257.610 
Nickel (Ni) 231.604 
Lead (Pb) 217.000 





2.4.3   Cold-vapour atomic absorption spectrometry 
Atomic absorption spectrometry is an analytical technique used to determine the presence 
and concentration of metals in liquid samples.  Samples are atomised by a flame or 
graphite furnace and light of a specific wavelength, from a hollow cathode lamp or an 
electrodeless discharge lamp, is passed through the atomic vapour of the element of 
interest, and measurement is made of the attenuation of the intensity of the light as a result 
of absorption by free ground-state atoms of the element in the sample.  In the case of 
mercury, free mercury atoms can exist at room temperature and consequently this metal 
can be analysed by atomic absorption spectrometry without employing a flame or graphite 
furnace.  The technique used for the analysis of mercury is what is referred to as cold-
vapour atomic absorption spectrometry (CV-AAS).  
In the cold vapour technique, mercury is reduced chemically to the free atomic state with 
a strong reducing agent solution like stannous chloride (SnCl2) or sodium borohydride 
(NaBH4) in a closed reaction system.  The reaction quantitatively releases mercury from 
the sample solution and the mercury atoms are carried by a stream of air, nitrogen or 
argon through a quartz absorption cell placed in the light path of the spectrometer.  A 
manually operated accessory, such as the MHS 15 mercury hydride system, is required 
for vapour generation when carrying out mercury analysis with an atomic absorption 
spectrometer.  The pneumatic system of the MHS 15 accessory is described by Figure 
2.17.  The MHS 15 unit is composed of a reaction assembly (a reaction flask, reservoir 
bottle and carrier gas pipelines) and a quartz tube atomiser (QTA) assembly.  Hence, the 
efficacy of this technique is dependent upon the proper connection of the MHS 15 unit to 
the gas supply and the spectrometer. 
When SnCl2 is used as the reductant during the analysis of mercury, the inert gas from 
the pressure reducer comes via restrictor F2 and line b to the changeover valve, and then 
travels via line e to the reaction flask.  The gas pressure applied by means of ports 1 to 4 
and then through line g, forces the transfer of SnCl2 reductant solution through line h into 
the reaction flask.  The mercury vapour is then transported by the combined gas streams 














Figure 2.17: Schematic of the PerkinElmer MHS 15 mercury hydride pneumatic system 
(190). 
 
2.4.3.1   Preparation of reagents and standard solutions 
A 5% (m/v) SnCl2·2H2O (reductant solution) solution was prepared by dissolving 50 g of 
the salt in 100 mL of hot conc. HCl and then diluted to 1 L with double distilled water.  
A dilute nitric acid solution of 1.5% was also prepared which served as the diluent 
throughout the analysis.  To prepare a stock solution of 1000 mg L-1 mercury, a mass of 
0.135 g mercury chloride (HgCl2) was accurately weighed and dissolved in 25 mL of 
double distilled water and the solution was diluted to 100 mL in a volumetric flask with 
double distilled water.  After this a 1 mg L-1 mercury working standard solution was 
prepared.  This was done by pipetting a volume of 100 µL of the 100 mg L-1 stock solution 
into a 100 mL volumetric flask and then diluted to the mark with double distilled water.  
From here, lower concentrations of mercury working standards were prepared for 




2.4.3.2   Determination of mercury 
Mercury determination was carried out with a PerkinElmer Analyst 200 atomic 
absorption spectrometer fitted with a mercury (Hg) lamp at a wavelength of 253.7 nm and 
a PerkinElmer MHS 15 system was also connected to the instrument for vapour 
generation.  The instrument set-up is shown in Figure 2.18. 
 
Figure 2.18: A photograph of the PerkinElmer MHS 15 mercury hydride system 
connected to the PerkinElmer Analyst 200 atomic absorption spectrometer instrument and 
gas supply during mercury determination in this study. 
 
During analysis, 10 mL of the diluent (1.5% HNO3) was transferred into the reaction 
flask, to which aliquots of 100, 200, 300, 400, 500, 600, 700, and 800 µL of a 1 mg L-1 
mercury working stock solution were added sequentially to generate mercury calibration 
curves by mass.  These aliquots correspond to 100, 200, 300, 400, 500, 600, 700, and 800 
ng of mercury respectively.  Once the reagent reservoir and reaction flask were attached 
to the reactor assembly, the extractor was then switched on and the argon gas was allowed 
to flow through the immersion tube placed into the reaction flask.  While the plunger 
(multipath valve) is manually depressed and held between 20 to 30 seconds, an argon 
stream transports the reducing agent (SnCl2) from the reagent reservoir into the reaction 
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flask to reduce mercury either in the standard or sample resulting in mercury vapour 
which is driven out through the immersion tube to the QTA.  The special conical form of 
the immersion tube and reaction flask provides excellent mixing of the standard or sample 
and SnCl2, guaranteeing a spontaneous reaction.  As the mercury vapour passes into the 
QTA, the measured absorbance gradually increases and then decreases as the mercury 
diminishes.  It was ensured that the reaction flask and the outside of the immersion tube 
were rinsed with the diluent after every single measurement.  The maximum absorbance 
detected for each measurement was recorded and the absorbance for the standard 
solutions was used to plot the calibration curve.  Both standard solutions and digested 
samples were analysed in triplicate. 
 
2.4.4   Validation of heavy metal and mercury analyses 
The accuracy of both the analytical techniques, namely, ICP-OES and CV-AAS, was 
verified by using spike recovery methods.  A known amount of each element under study 
was introduced into an already analysed sample and the sample reanalyzed.  Two spiked 
solutions were prepared for each of the metals by spiking a sample mass of 0.250 g with 
aliquots from two different standard solutions as indicated in Table 2.4.  Thereafter, 10 
mL of concentrated nitric acid was added to the solution and the mixture allowed to 
predigest.  The digest was completely solubilized by the microwave procedure described 
in Section 2.4.1.1.  After microwave-assisted digestion, the digest was filtered, diluted 
into a 50 mL volumetric flask with double distilled water and analysed according to the 




Table 2.4: Details of the solution preparation in 50 mL volumetric flasks for validation of 
heavy metal and mercury analyses. 
Metal Standard 
solution/mg L-1 
Aliquot pipetted from 
standard solution/mL 
Spiked concentration in 
sample solution/mg L-1 
Al 10 0.25 0.05 
 20 3.0 1.20 
Cr 10 0.1 0.02 
 20 0.5 0.20 
Cu 10 0.1 0.02 
 20 0.175 0.07 
Fe 10 0.4 0.08 
 20 2.75 1.10 
Mn 10 0.1 0.02 
 20 0.1 0.04 
Ni 10 0.1 0.02 
 20 0.75 0.30 
Pb 10 0.25 0.05 
 20 2.5 1.00 
Zn 10 0.4 0.08 
 20 3.75 1.50 
Hg 1.0 1.25 250 ng 





2.5   Data analysis 
The data obtained in this study were evaluated by using the Microsoft Excel Analysis 
Tool Pak.  Calibration curves were determined by using the linear least-squares regression 
equation given as: 
 
 y = mϰ + c        (2.1) 
 
where y is the HPLC peak area or corrected intensity or absorbance, ϰ is the concentration 
of analyte, m is the slope, and c is the intercept.  By assuming that c = 0 at the 95% 
confidence level, only m needs to be determined to establish the calibration line taking 
into account the error in each yo c and m, and thereby to produce an estimated standard 
deviation SDϰo for the point estimate ϰo = (yo - c)/m.  The correlation coefficient (R2) 
measures the degree of linear association between the peak area, or corrected intensity or 
absorbance, and the concentration of each analyte. 
The slope and standard error (SE) of the calibration line (for each analyte) was used to 
calculate the limit of detection (LOD) and the limit of quantitation (LOQ).  This is given 
by the equation: 
 
LOD = 3#$ %        (2.2) 
 
(SE is the standard error of the slope and m is the slope of the calibration line) and the 
limit of quantitation was calculated as: 
 




The accuracy of the method developed is expressed in terms of the percent recovery and 
estimated by using equation (2.4): 
 
% Recovery = ()*+	-.	.-/+0	1-+1)+23*24-+
5647)0	1-+1)+23*24-+
×100  (2.4) 
 
The precision of the method developed is expressed in terms of percent relative standard 
deviation and estimated by using the following equations: 
 
% R.S.D. = 52*+0*30	0)94*24-+
()*+	1-+1)+23*24-+
×100	   (2.5) 
 
% Accuracy = ()*+	-.	.-/+0	1-+1)+23*24-+
2:)-3)241*;	*(-/+2
×100  (2.6) 
 




×100      (2.7) 
 
where Cs is the concentration of an analyte of interest from the standard curve (mg L-1), 
Vs is the volume of sample extract, Df is the dilution factor (where applicable), and Ws is 





The risk of human exposure to heavy metals contained in the SLPs was estimated by 
using the uncertainty factor called the Margin of Safety (MoS) in accordance with the 
Scientific Committee on Consumer Safety (SCCS) (191).  This is given by the equation: 
 
MoS = BC D EF
GE?
        (2.8) 
 
NO(A)EL is the no-observed-adverse-effect-level of the contaminant and can be 
estimated by using the formula: 
 
NO(A)EL = RFD × UF × MF    (2.9) 
 
UF and MF are the uncertainty factor and the modifying factor with default values of 100 
and 1 respectively.  RFD is the oral reference dose, which is an estimate of daily exposure 
of the metals to the human population, including sensitive sub-groups.  The RFD values 
(in mg g-1 day-1) for each metal are as follows: Al (1.0 × 10-1) (192), Cr (3.0 × 10-3), Cu 
(4.0 × 10-2), Fe (7.0 × 10-1), Mn (1.4 × 10-1), Ni (2.0× 10-2), Pb (4.0 × 10-3), Zn (3.0 × 10-
1) (193), and Hg (5.0 × 10-4) (194). 
A minimum MoS value of 100 has been proposed by the World Health Organization 
(WHO) as acceptably safe for the product to be used on the human body (191). 
SED is the systemic exposure dosage.  Certain factors need to be considered in order to 
obtain information on the SED for cosmetics.  This includes the amount of cosmetic 
applied to the body per day, the applied surface area, the concentration of the metal in the 
cosmetic under investigation, the dermal absorption of the particular contaminant and a 
human body weight value (191).  Thus, SED can be estimated by using equation (2.10): 
 
SED (mg kg-1 bw day-1) =  	?Dа	×	GGD	×	I	
JA
×10-3  (2.10) 
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DAa is the dermal absorption reported as µg/cm2.  It is the amount of ingredient absorbed 
per square centimeter, resulting from an assay under an in-use mimicking condition.  In 
case no dermal absorption data is available, 100% dermal absorption is used (191).  DAa 





       (2.11) 
 
Cs is the concentration of the particular metal in the product (mg kg-1); AA is the amount 
of cosmetic product applied per day (7.82 g for body cream); SSA is the surface area of 
the skin onto which the cosmetic is applied (15670 cm2 for body cream); F is the 
frequency of application (2.28/day for body cream);  BW is the body weight (60 kg for 
default body weight) and 10-3 is the unit conversion factor (191). 
The results obtained following the procedures described in this chapter are presented and 






RESULTS AND DISCUSSION 
The results of the experiments described in Chapter 2 are presented and discussed in this 
chapter.  This chapter is divided into two main parts as described below. 
The first part discusses the results obtained for the identification and quantification of the 
organic SLAs such as clobetasol propionate (CP), betamethasone propionate (BD), 
clotrimazole (CT), hydroquinone (HQ), benzoquinone (BQ), kojic acid (KA), 
niacinamide (NC), and arbutin (ARB) in the 35 Nigerian commercially available SLPs.  
The second part of the chapter present the results obtained for the heavy metal content of 
these same products and also provides an assessment of the possible exposure risk through 
the use of these products from the heavy metal content. 
 
3.1   HPLC method development for the determination of organic skin-
lightening agents 
In order to determine the active organic ingredients in the studied samples, a suitable 
HPLC method was developed for the separation, identification, and quantification of the 
selected SLAs.  The HPLC instrument (Shimadzu Prominence) used for the analysis 
consisted of a binary solvent manager, autosampler, and a PDA detector.  Separation was 
performed in an isocratic mode with a Brownlee analytical C18 column (100 × 4.6 mm, 
3 µm) and a SGE C18 column (250 × 4.6mm, 5 µm) for the two groups of SLAs as 
described in Section 2.3.4.1.  
 
3.1.1   Optimum detection wavelengths 
For skin-lightening active ingredients to be detected by an HPLC instrument equipped 
with a PDA detector, optimum detection wavelengths must be set.  The UV spectra and 
the wavelength of maximum absorption for each of the SLAs were first obtained by means 
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of UV-visible spectrophotometry. The optimum wavelength for detection was selected 
based on the wavelength that gives the highest sensitivity.  The wavelength of maximum 
absorption identified for each SLA was provided in Table 2.2.  The UV spectrum for each 
SLA obtained from a UV-visible spectrophotometer (provided in Section 2.3.3.2) was 
used to confirm the UV spectra generated by the PDA detector in HPLC. 
The PDA detector was set to acquire chromatograms at 225 nm for CT, 240 nm for CP, 
BD and BQ, 270 nm for KA and NC, and 289 nm for HQ and ARB, as their highest 
sensitivity was observed at or close to these wavelengths and these would enhance the 
quantitation of the SLAs.  For CT its wavelength of maximum absorption of 204 nm could 
not be used since many other analytes as well as the solvent absorb close to this 
wavelength.  Hence, four UV absorption wavelengths (225, 240, 270 and 289 nm) were 
selected for the SLA analysis in this study and the HPLC chromatograms were acquired 
simultaneously at these wavelengths with the PDA detector. 
 
3.1.2   Identification of skin-lightening agents 
Since each component has its own distinct UV-visible spectrum and retention time at 
which it elutes, identification of the SLAs in all samples was achieved by comparing the 
HPLC-UV-visible spectra and retention times of the pure analytes (standards) with those 
of the sample analytes.  It must be borne in mind that there is a slight variability in the 
retention time for each of the SLAs as indicated in Table 3.1 but an acceptable range is 




Table 3.1: Retention times and detection wavelengths for the skin-lightening agents 




Clobetasol propionate 2.80-3.00 240 
Betamethasone dipropionate 3.50-3.70 240 
Clotrimazole 4.50-4.80 225 
Hydroquinone 7.90-8.10 289 
Benzoquinone 15.45-15.70 240 
Kojic acid 6.15-6.30 270 
Niacinamide 2.60-2.70 270 
Arbutin 6.0-6.15 289 
 
3.1.3   Optimum separation conditions 
Obtaining optimum resolution and separation in a minimum time is the most important 
aspect in HPLC .  This is achieved by first knowing the chemistry of the analytes in 
question, and also the use of the best mobile phase combination and stationary phase.  
Since most of the studied SLAs are relatively polar molecules, the use of polar solvents 
such as methanol and acetonitrile as constituents of the mobile phase and a non-polar 
stationary phase in a reversed phase HPLC separation seems appropriate.  Therefore, in 
order to obtain a good separation for the simultaneous analysis of the studied SLAs, 
mobile phases with different compositions of methanol, acids, buffers and water, with 
flow rates varying between 0.3-1.2 mL min-1 on a Brownlee analytical C18 column (100 
× 4.6 mm, 3 µm) and a SGE C18 column (250 × 4.6 mm, 5 µm) were tried in an isocratic 
mode.  
The pure standards of each SLA were first analysed individually to obtain the retention 
times.  These were then mixed to prepare a multicomponent standard solution that could 
be used to check for proper resolution and separation of the compounds.  Two 
multicomponent standard solutions were prepared.  The first included steroid compounds, 
such as CP, BD and CT, and their separation was effected on a Brownlee analytical C18 
column (100 × 4.6 mm, 3 µm).  When a mobile phase consisting of either 50 or 60% (v/v) 
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methanol in water was used at flow rates of 0.5, 0.8 and 1.0 mL min-1, all three SLAs 
were separated but the peak for CT was very broad.  In an attempt to correct the CT 
broadened peak, 70% methanol in water containing 0.2% acetic acid at flow rates of 0.5, 
0.8 and 1.0 mL min-1 was used.  The introduction of acetic acid was meant to change the 
pH of the mobile phase which in turn would alter the degree of ionisation of some analytes 
by affecting their hydrophobicity.  Nevertheless, it was observed that all three SLA peaks 
clustered together at flow rates of 0.8 and 1.0 mL min-1.  However, with a lower flow rate 
of 0.5 mL min-1, all three SLA peaks were separated but the CT peak still remained broad.  
With the first group of SLA, it was generally observed that an increase in the percentage 
of methanol in the mobile phase caused the analytes to elute faster with well resolved 
peaks but the peaks co-eluted or broadened when the wrong flow rate was chosen.  The 
three SLAs were finally well resolved and separated when 80% (v/v) methanol in water 
was used at a flow rate of 0.8 mL min-1.  The total run time was 10 minutes and the column 
temperature was kept at ambient.  Figure 3.1 shows the optimum chromatogram for the 
separation of the first group of SLAs which includes CP, BD and CT.  The first two 
chromatograms (A and B) shown in Figure 3.1 clearly show the effect of the detection 
wavelength, particularly for CT.  The peak for CT is much more prominent when detected 
at 225 nm which is close to its wavelength of maximum absorption, namely 204 nm, than 
in the case of detection at 240 nm.  The third chromatogram (C) shows an example of one 


















Figure 3.1: Chromatogram for the separation of active ingredients CP, BD and CT, 
obtained at detection wavelengths of (A) 240 nm, (B) 225 nm and (C) 240 nm.  The 
chromatographic separation was achieved on a Brownlee analytical C18 column (100 × 
4.6 mm, 3 µm), with a mobile phase of MeOH-H2O 80:20 (v/v), an injection volume of 





As seen in chromatogram (C) of Figure 3.1, there is good resolution and separation of the 
peak of the steroid compound (CP) at a retention time of 2.908 minutes when the optimum 
conditions used for separating the steroid standard mixture were applied on the sample.  
It can also be observed that there are peaks of other analytes on the chromatogram which 
are not of interest.  These peaks can be found, if not all, but at least some, in all the steroid 
containing samples analysed.  They have consistent retention times of approximately 0.8, 
1.3, 1.6 and 2.0 minutes as shown in Appendix E, Figures E25 – E37.  The peaks of these 
undesired analytes were confirmed not to belong to any of the other SLAs investigated in 
this study when comparison of their UV–visible spectra was made (see Figure 3.2).  
However, these peaks are suspected to be those of paraben preservatives (methyl, propyl, 
ethyl and butyl paraben) judging from their UV–visible spectra.   Just like most of the 
SLAs investigated in this study, paraben preservatives are also polar compounds and 
could easily have been extracted from the samples during the extraction process of the 
SLAs with 100% methanol.  Moreover, separation of parabens have been reported to be 
carried out in a reversed-phase HPLC with a similar mobile phase combination (methanol 
















Figure 3.2: Comparison of the UV–visible spectra of other SLAs investigated in this study 




The second group of SLAs, which included HQ, BQ, KA, NC and ARB were separated 
on a SGE C18 column (250 × 4.6 mm, 5 µm).  When the column and conditions used to 
separate the first group of SLAs was used for these analytes, a poor separation resulted.  
This then led to a change in the stationary phase, which is one of the effective ways of 
altering the selectivity of the separation in HPLC.  When a mobile phase consisting of 
either 70% methanol with 0.05 M KH2PO4 at a pH of 2.5, or 80% methanol with 0.05 M 
K2HPO4 at a pH of 3.0, was used at flow rates of 0.3, 0.5, 0.8, 1.0 and 1.2 mL min-1, the 
peak for NC was separated, but the peaks for HQ and BQ co-eluted and likewise for KA 
and ARB.  By using 90% methanol in water containing 0.2% acetic acid as the mobile 
phase, at different flow rates, all the SLAs were found to elute earlier than before but the 
peaks were clustered at very close retention times.  With the second group of SLAs, it 
was generally observed that an increase in the percentage of methanol in the mobile phase 
led to early elution of all the analytes at flow rates above 0.8 mL min-1, causing the 
analytes to co-elute.  Whereas with flow rates ranging between 0.3 to 0.8 mL min-1, the 
elution times of all analytes are increased and the separation improved but the peaks were 
broadened.  This indicated that a mobile phase containing far less methanol was needed 
for optimal separation. 
Separation of the second group of SLAs was best achieved when 5% methanol containing 
0.5% orthophosphoric acid and 95% water containing 0.5% orthophosphoric acid was 
used as a mobile phase. The flow rate was set at 1.0 mL min-1 and the total run time was 
20 minutes. Figure 3.3 shows the chromatograms for the separation of the second group 
of SLAs, which included NC, KA, HQ, BQ and ARB.  ARB was removed from the 
standard mixture and was analysed separately with the same optimum conditions used for 
these SLAs as it co-eluted with KA.  Moreover, the column temperature was set at 35 °C.  
An increase in temperature was observed to reduce tailing in some of the analyte peaks.  
Again the effect of detection wavelength is particularly evident in the case of NC and BQ 
in their chromatograms acquired at different detection wavelengths of 270 and 240 nm 
respectively in Figure 3.3.  Chromatogram (E) of the same figure shows the separation of 

































Figure 3.3: Chromatograms for the separation of active ingredients NC, KA, HQ, BQ and 
ARB obtained at detection wavelengths of (A) 289 nm, (B) 270 nm, (C) 240 nm (D) 289 
nm and (E) 270 nm.  The chromatographic separation was achieved on a SGE C18 column 
(250 × 4.6 mm, 5 µm) with a mobile phase of 0.5% orthophosphoric acid in methanol and 
0.5% orthophosphoric acid in water 5:95 (v/v), an injection volume of 10 µL, a flow rate 
of 1.0 mL min-1 and a column temperature of 35 °C. 
 
3.1.4   Optimum extraction solvent for sample preparation 
In order to determine the optimum extraction method for the studied SLAs, four different 
solvents were examined.  This was done following the experimental method described in 
Section 2.3.2.4.  The peak areas of the SLAs obtained were plotted and served as a direct 
reflection of the solvent extraction strength.  
When solutions of the SLAs were ultra-sonicated in a water bath at 40 °C for 20 minutes, 
the best extraction solvent was found to be 100% methanol.  When 100% acetonitrile and 
a 1:1 (v/v) mixture of methanol and acetonitrile were used, a similar extraction result was 
obtained for both solvents but with less efficacy than 100% methanol.  A 1:1 (v/v) mixture 
of methanol and water was found to be the solvent with the least extraction strength 
among those examined as shown in Figure 3.4.  Thus, 100% methanol was used in this 








Figure 3.4: Optimisation of four different solvents for the extraction of CP, BD, CT, HQ, 
BQ, KA, NC, and ARB: a) methanol (100%), b) acetonitrile (100%), c) 
methanol:acetonitrile (1:1, v/v), and d) methanol:water (1:1, v/v).  The optimum HPLC 
conditions described in Section 3.1.3 were used to obtain the peak areas. 
 
3.2   Validation of HPLC analytical method 
Analytical method validation is an important requirement in any HPLC analysis.  The 
validation of an analytical method must demonstrate the fulfilment of all the analytical 
conditions required to ensure the reliability of the results.  For this reason, the 
adequateness of the HPLC method developed in this study was tested for linearity, 
accuracy, precision, and limits of detection and quantitation.  
 
3.2.1 Linearity of calibration curves and limits of detection and 
quantitation 
An external standard calibration method was used to assess the linearity of the calibration 
curves used for quantitation of the SLAs identified in the sample products.  A minimum 
of seven different concentrations in three replicates were prepared for each of the active 
ingredients and the calibration curves were determined in triplicate.  Linear regression 
analysis (at the 95% confidence level) of the calibration data for each SLA was performed 
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constructed by plotting a graph of the HPLC peak areas against concentration.  Moreover, 
equation (2.1) given in Section 2.5 was used for the quantitation of the studied SLAs in 
the sample products.  The calibration data used to construct the linear regression curves 
are given in Appendix C while the corresponding calibration curves and residual plots for 
each of the studied SLAs are shown in Appendix D. 
Good linearity was observed for all the SLA standards over the concentration range tested 
and was confirmed from the correlation coefficient R2 values which were greater than 
0.990.  Table 3.2 gives the results of the linear regression analysis, and the limits of 
detection and limits of quantitation.  The lowest correlation coefficient value for the 
studied SLAs was found to be 0.9942 and the highest value was 0.9995.  The LOD values 
were found to be in the range of 0.007 – 0.029 mg L-1 and the LOQ values ranged from 




Table 3.2: Results of the linear regression analysis of the calibration curves for the skin-lightening active ingredients analysed by HPLC. 
Parameters CP BD CT HQ BQ KA NC ARB 
Maximum absorption/nm 239 238 205 293 242 269 262 286 
Detection wavelength/nm 240 240 225 289 240 270 270 289 
Calibration range/mg L-1 0.2-60 0.2-60 0.2-60 0.5-400 0.2-20 0.5-90 0.8-110 1.0-20 
Slope/L mg-1  22293 20003 27456 11708 38293 27397 11327 2310.5 
Standard error of slope 63.099 52.915 69.235 113.883 326.682 124.798 58.988 9.047 
Correlation Coefficient (R2) 0.9994 0.9995 0.9995 0.9942 0.9955 0.9987 0.9983 0.9991 
LOD/mg L-1 0.008 0.007 0.007 0.029 0.026 0.014 0.016 0.012 
LOQ/mg L-1 0.028 0.026 0.025 0.097 0.085 0.046 0.052 0.039 
Limit of Detection (LOD)/mg L-1 = (3 × standard error of slope)/slope. 




3.2.2   Accuracy 
The accuracy of the quantitation method was examined by performing a recovery test.  
By using a sample free of the active ingredients, two solutions of different concentration 
were prepared with known amounts of the pure active ingredients added.  These were 
extracted and the extracts injected in triplicate on the HPLC.  The percent recoveries of 
the spiked active ingredient were then calculated.  No interferences were observed 
throughout the test.  The results of the accuracy studies are summarised in Table 3.3 and 
it is evident that the method is accurate within the acceptable recovery range of 80 to 
120% (197).  The percent recoveries obtained ranged from 84.23 to 110.33% and the 
percent relative standard deviation (%R.S.D.) ranged from 0.11 to 3.93%. 
 





Found/mg L-1 %Recovery %R.S.D. 
CP 10 8.42±0.03 84.23 0.41 
 50 49.58±0.21 99.17 0.44 
BD 10 9.33±0.04 93.36 0.44 
 50 47.09±0.08 94.19 0.18 
CT 10 9.35±0.07 93.49 0.80 
 50 49.03±0.14 98.07 0.28 
HQ 10 11.030.20 110.33 1.84 
 20 20.150.48 100.73 2.39 
BQ 15 14.860.58 99.09 3.93 
 20 19.630.02 98.15 0.11 
KA 8.0 7.270.02 90.83 0.21 
 20 19.160.07 95.80 0.37 
NC 15 14.330.36 95.56 2.49 
 20 19.130.12 95.67 0.62 
ARB 10 10.030.28 100.29 2.84 
 20 19.610.26 98.07 1.37 
Recovery (%) = (mean of found concentration/spiked concentration) × 100. 




3.2.3   Precision 
The precision of analysis measures the degree of repeatability of an analytical method 
and is normally expressed as the percent relative standard deviation for a significant 
number of samples with different ranges of concentration.  The precision of the method 
was determined from the intra-day (same day) and inter-day (over a period of three days) 
analysis.  Three different standard solutions were prepared for each of the active 
ingredients and analysed following the method described in Section 2.3.4.6. 
The results obtained from the intra-day and inter-day precision analysis are summarised 
in Table 3.4.  The percent relative standard deviation (%R.S.D.) for the intra-day precision 
ranged from 0.17 to 8.16% while that of the inter-day precision ranged from 0.14 to 
4.78%.  Likewise, the % accuracies obtained from the precision analysis fell within an 
acceptable range.  The intra-day analysis % accuracy ranged from 83.1 to 114.2% and the 





















CP 2.80-3.00 1.0 0.940.004 0.39 94.1 0.94±0.007 0.79 94.3 
  4.0 3.740.025 0.67 93.5 3.76±0.023 0.61 93.9 
  8.0 7.820.042 0.54 97.7 7.950.033 0.41 99.4 
BD 3.50-3.70 1.0 0.920.005 0.59 91.9 0.92±0.012 1.27 91.7 
  4.0 3.720.006 0.17 93.1 3.73±0.019 0.52 93.2 
  8.0 7.830.098 1.25 97.9 7.920.038 0.48 99.0 
CT 4.50-4.80 1.0 0.830.029 3.55 83.1 0.84±0.024 2.81 84.2 
  4.0 3.650.137 3.76 91.1 3.74±0.026 0.69 93.5 
  8.0 7.960.024 0.29 99.5 7.980.011 0.14 99.7 
HQ 7.90-8.10 2.0 2.180.112 5.15 109.2 2.140.100 4.69 106.9 
  10 11.480.087 0.76 114.2 11.40.087 0.76 114.4 
  20 18.710.191 1.02 93.5 18.830.227 1.21 94.2 
BQ 15.45-15.70 2.0 1.910.066 3.46 95.7 1.960.026 1.35 97.8 
  8.0 7.740.064 0.83 96.8 7.720.091 1.18 96.5 
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  20 19.170.067 0.35 95.8 19.190.069 0.36 95.9 
KA 6.15-6.30 1.0 0.940.077 8.16 94.4 0.940.045 4.78 93.9 
  10 10.130.054 0.53 101.3 11.150.111 0.99 111.5 
  20 18.080.126 0.69 90.4 18.160.064 0.35 90.8 
NC 2.60-2.70 5.0 4.570.078 1.71 91.5 4.590.042 0.93 91.9 
  10 9.660.129 1.34 96.6 11.00.093 0.85 110.1 
  20 19.810.066 0.33 99.1 19.90.063 0.32 99.6 
ARB 6.0-6.15 2.0 1.930.116 5.99 96.4 1.960.091 4.63 97.9 
  12 12.050.245 2.03 100.4 12.190.216 1.77 101.6 
  20 19.320.147 0.76 96.6 19.420.322 1.66 97.1 




3.3 Amount of skin-lightening agents detected in skin-lightening 
products 
A total of 35 cream samples were prepared and quantitatively analysed for the presence 
of SLAs, such as CP, BD, CT, HQ, BQ, KA, NC, and ARB, following the HPLC method 
developed.  It was found that out of the 35 cream samples analysed, 32 contained at least 
one of these eight agents (see Table 3.5).  The HPLC chromatograms of these cream 
samples are shown in Appendix E and the peak areas obtained for the detected SLAs are 
given in Appendix F. 
Fifteen out of the thirty-five cream samples analysed contained HQ in the range of 0.017 
– 7.096% (m/m).  Of these, only five cream samples listed HQ in the ingredients with 
four stating the content percentage to be 2%.  Two more cream samples (SLP 12 and 18) 
were found to indicate HQ in the list of ingredients but as p-hydroxyphenol.  This can be 
perceived as deliberately misleading since this is an unpopular name for HQ among users 
of skin bleaching creams.  As seen in Table 3.5, two cream samples contain HQ below 
1.0% (m/m) (0.017 – 0.924% m/m), nine cream samples have HQ above 1% (m/m) (1.024 
– 1.916% m/m) and four cream samples have HQ above 2% (m/m) (2.429 – 7.096% m/m) 
which counters the proposed US FDA ruling of 2% HQ in marketing over-the-counter 
skin-lightening creams.  Six cream samples containing HQ were found to also contain 
BQ. This can be attributed to the hydrolysis of HQ into BQ as it is usually unstable in 
some formulations.  The BQ concentration in our cream samples was found to be in the 
range of 0.005 – 0.015% (m/m).   
For the purpose of dermatological therapy, HQ was one of the most prescribed agents for 
treating hyperpigmentation until 2006 when the US FDA placed a ban on over-the-
counter HQ products due to its toxicity (16).  Currently, products containing HQ above 
2% are only sold by prescription in the US.  Reports have revealed the health risks 
associated with the use of high concentrations of HQ and its long-term exposure.  They 
include irritant contact dermatitis, allergic contact dermatitis, nail discolouration, 
decreased skin elasticity, trimethylaminuria, exogenous ochronosis and much more (59).  
In contrast to the US FDA, the Nigerian Food and Drug Agency (NAFDAC) and the 
South Africa government have placed a total ban on any amount of HQ in over-the-
counter products (40, 198).  This is also the case in the UK and EU (16).  Of great concern 
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is that the cream sample (SLP 18) with the highest amount of HQ (7.096% m/m) was 
found to be manufactured in one of the EU countries which could imply that the inclusion 
of HQ as an active ingredient in over-the-counter SLPs is permitted for export only in 
some EU countries.  From the results obtained, it shows that despite the bans, products 
containing high concentrations of HQ are still available and sold illegally in the Nigerian 
market.  Regulations on the quality of import products is weak or not there at all. 
KA was found in nine cream samples ranging from 0.017 – 1.412% (m/m), with only 
three of the creams indicating KA among their ingredients.  Only one of the nine cream 
samples (SLP 15) was found to contain KA above 1% (m/m).  The allowed amount of 
KA is still not unanimously agreed on but according to reports from the Personal Care 
Product Council (100), KA is commonly used at a concentration of 0.1 – 2.0 %.  However, 
based on the margin of safety calculation, KA at a maximum concentration of 1% is 
considered unsafe (100).  Nevertheless, KA is still to be approved by the US FDA in over-
the-counter products (100) and has been reported to be banned in Japan due to its 
mutagenicity concerns (9).  Thus, going by the afore-mentioned reports, it is safer to avoid 
over-the-counter SLPs with KA as the active ingredient. 
NC was also identified in four cream samples ranging from 0.029 – 1.827% (m/m).  Only 
one of the four cream samples (SPL 24) indicated NC in the list of ingredients.  NC was 
also listed in another of the cream samples (SLP 12) but was not detected from the 
analysis.  The amount of NC allowed in SLPs is still to be established and this could be 
the reason why some manufacturers introduce the use of NC and some other bleaching 
agents with unknown safety profiles in over-the-counter SLPs. 
One cream sample (SLP 16) was indicated to contain ARB in the list of ingredients but 
upon analysis, this agent could not be detected.  However, ARB has been shown to be a 
safer SLA in comparison with HQ (102). 
Steroid compounds, such as CP, BD and CT, were detected in 13 cream samples with two 
of the samples (SLP 9 and 20) containing both CP and CT.  The steroid compounds were 
all indicated in the list of ingredients, stating their content percentage (see Table 2.1).  
Although one of the cream samples (SLP 25) claimed to contain CP, it was found to 
contain BD instead.  Ten of the cream samples contain CP in the range of 0.007 – 0.035% 
(m/m), three contained BD in the range of 0.019 – 0.027% (m/m) and two contained CT 
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in the range of 0.007 – 0.012% (m/m).  Hence, all the steroid compounds contained in the 
cream samples do not exceed the allowed limits of 0.05% (m/m) CP, 0.065% (m/m) BD 
and 1.0% (m/m) CT for medical use.  However, these cream samples are all sold as over-
the-counter products for skin bleaching purposes.  Ideally, any cream containing steroid 
compounds should be considered a pharmaceutical product and should only be sold as a 
prescription drug or when sold as an over-the-counter product should only be used within 
seven days under medical supervision.  Failure to observe this can be very detrimental to 
the users’ health.  The addition of steroid compounds in skin bleaching creams has been 
seriously warned against by the US FDA irrespective of the potency or amount due to 
their severe side-effects (16).  Steroids can be absorbed systematically and result in 
several detrimental health effects such as acne vulgaris, allergic contact dermatitis, 
Cushing syndrome, diabetes mellitus, steroid addiction syndrome, ophthalmological 
conditions such as cataracts and glaucoma, and many more (59). 
Samples 6, 7 and 16 were found to contain none of the studied SLAs in this study.  Thus, 
in this selection of Nigerian SLPs, the most prevalent SLAs were HQ, BQ, KA, NC, CP, 
BD and CT as shown in Figure 3.5.  As shown in bar graph (A) it can be observed that 
HQ, the gold standard for skin-bleaching, is the most detected SLA in the studied SLPs 
followed by KA, BQ and then NC.  Whereas in SLPs containing steroid compounds (see 





















Figure 3.5: Prevalence of skin-lightening agents detected in the investigated products. 
 
Each of the SLPs analysed in this study has its own purchase price (see Table 2.1) and 
these can actually be a deciding factor on their sales.  Looking at the price range (4000-
150 Naira) of the studied SLPs, it is only ideal for one to assume that the more expensive 
products might be the safer products to use in terms of the type or level of SLAs they 
contained.  Figure 3.6 relates the cost of each of the studied SLPs to the level of their 
detected SLAs in order to confirm if the most expensive products are actually safer in 



































Figure 3.6: Levels of SLAs detected in the studied SLPs compared to their cost. 
 
For the purpose of this study, SLPs above 1000 Naira are considered expensive, those 
above 500 Naira are considered moderately cheap and those below 500 Naira are 
considered cheap since most of the population can afford SLPs at this cost. 
As shown in bar graph (A) of Figure 3.6, the cost of the SLPs ranged from the most 
expensive sample (4000 Naira) to the cheapest sample (350 Naira).  It can be observed 
that all the expensive SLPs have HQ below the 2% proposed limit by the US FDA.  
Nevertheless, the expensive SLPs were observed to contain more than one SLA.  This 
can be HQ combined with either KA or NC or all the three SLAs together.  There are no 
established guide-lines for KA and NC, but KA is still to be approved by the US FDA for 
use in over-the-counter products due to its mutagenic concerns (100).  In assessing other 
SLPs that fall in the range of moderately cheap to cheap it can be observed that most of 
these samples have HQ in line with the proposed US FDA regulations too, except in the 
case of some samples (SLP 14, 18, 22, and 23) containing HQ above 2%.  Another notable 
observation with SLPs in this range is the unstable nature of HQ in them.  The presence 
of BQ in some of these cheaper products proves that HQ has been oxidised.  This means 
HQ is unstable in the formulation. 
As observed in bar graph (B) of Figure 3.6, only SLPs containing steroid compounds were 

















































750-150 Naira.  It can be seen that the sample that cost most contained the highest amount 
of CP.  Here, there is no significant difference in relation to the levels of SLAs detected 
and the purchase price of the SLPs except in the case of SLP 30 with a lower level of CP. 
Judging from the results of this study, there is no convincing proof to show that the more 
expensive SLPs are actually safer than the cheaper SLPs.  One can only make reference 
to some of the moderately cheap and cheap SLPs (SLP 14, 18, 22, and 23) as the most 
unsafe products in this study since many other cheaper SLPs have similar levels of 
detected SLAs as the expensive ones.  It is also important to note that most of the so called 
‘expensive SLPs’ analysed in this study declared none of the SLAs detected or false 
ingredients on their labels.  However, some of the investigated SLAs were positively 
detected.  This is a clear tactic of luring users to buy the expensive products. 
 
Table 3.5: Levels of active ingredients detected (n = 3). 




Mean concentration /%(m/m) 
± confidence interval 
SLP 1 —— HQ 1.205±0.228 
 —— KA 0.442±0.025 
 —— NC 0.029±0.035 
SLP 2 —— HQ 0.924±0.227 
 —— KA 0.245±0.025 
 —— NC 0.063±0.035 
SLP 3 KA KA 0.530±0.025 
 —— HQ 1.741±0.229 
 —— NC 0.049±0.035 
SLP 4 —— HQ 1.024±0.227 
 —— KA 0.476±0.025 
SLP5 —— HQ 1.916±0.229 
 —— KA 0.155±0.025 
SLP 8 —— HQ 0.017±0.226 
 —— KA 0.786±0.026 
SLP 9 CP CP 0.035±0.008 
 CT CT 0.012±0.007 
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SLP 10 HQ HQ 1.6350.229 
SLP 11 HQ HQ 1.5920.228 
SLP 12 HQ HQ 1.1110.227 
 —— BQ 0.0150.011 
SLP 13 —— HQ 1.7290.229 
 —— BQ 0.0070.011 
SLP 14 —— HQ 2.4290.231 
 —— BQ 0.0090.011 
SLP 15 —— KA 1.4120.028 
SLP 17 KA KA 0.0170.025 
SLP 18 HQ HQ 7.0960.265 
 —— BQ 0.0060.011 
SLP 19 KA KA 0.6630.025 
SLP 20 CP CP 0.029±0.008 
 CT CT 0.007±0.007 
SLP 21 HQ HQ 1.8890.229 
SLP 22 HQ HQ 4.1290.240 
 —— BQ 0.0050.011 
SLP 23 HQ HQ 3.7000.238 
 —— BQ 0.0090.011 
SLP 24 NC NC 1.8270.039 
SLP 25 CP BD 0.019±0.007 
SLP 26 CP CP 0.032±0.008 
SLP 27 CP CP 0.033±0.008 
SLP 28 BD BD 0.026±0.007 
SLP 29 CP CP 0.021±0.008 
SLP 30 CP CP 0.007±0.008 
SLP 31 CP CP 0.024±0.008 
SLP 32 CP CP 0.032±0.008 
SLP 33 CP CP 0.027±0.008 
SLP 34 CP CP 0.019±0.008 




3.4   Validation of ICP-OES and CV-AAS methods 
The MHS 15 mercury hydride system together with a PerkinElmer Analyst 200 AAS and 
a PerkinElmer Optical 5300 DV ICP-OES were used to determine the levels of mercury 
and other heavy metals in the studied SLPs respectively.  The linearity and accuracy of 
the techniques used were determined by using the external standard calibration method 
and recovery studies.  The results of these validations are provided in Sections 3.4.1 and 
3.4.2 respectively.  The problem of spectral interference which usually occurs for 
elemental analysis with ICP-OES was well minimised by choosing detection wavelengths 
where minimal interference occurred.  
 
3.4.1   Linearity of calibration plots for heavy metal analysis 
An external standard method was used to obtain nine-point calibration curves for each of 
the metals.  The curves were plotted by using the data generated from the standard 
solutions.  The standard solutions were prepared in three replicates for each of the metals 
following the procedure described in Section 2.4.2.1 and were measured in the same way 
to obtain three data points.  The calibration data for the metals is given in Appendix G 
and the calibration curves with their corresponding residual plots are shown in Appendix 
H. 
Linear regression analysis (at the 95% confidence level) of the calibration data for the 
metals was performed by using Microsoft Excel 2013 Analysis Tool Pak.  The LOD and 
LOQ of each metal was estimated from the slope and standard error of the calibration 
curves by using equation (2.2) and (2.3) given in Section 2.5 respectively.  As seen in 
Table 3.6, the method had LODs in the range of 0.007 – 0.011 mg L-1 and LOQs in the 
range of 0.025 – 0.088 mg L-1.  Likewise, acceptable correlation coefficient (R2) values 




Table 3.6: Results from the linear regression analysis of the calibration data for heavy metals. 
Parameters Al Cr Cu Fe Mn Ni Pb Zn 
Calibration range/mg L-1 0.01-1.6 0.01-1.6 0.01-1.6 0.01-1.6 0.01-1.6 0.01-1.6 0.01-1.6 0.01-1.6 
Slope/L mg-1 59756 38901 219185 59962 285242 19683 1165.3 36679 
Standard error of slope 215.7 91.6 1170.7 526.1 1154.5 62.9 4.2 92.1 
Correlation Coefficient (R2) 0.9997 0.9999 0.9993 0.9980 0.9996 0.9997 0.9997 0.9998 
LOD/mg L-1 0.011 0.007 0.016 0.026 0.012 0.009 0.011 0.008 





The results of the linear regression analysis for mercury are given in Table 3.7.  An 
acceptable correlation coefficient, R2, value of 0.9989 was obtained from the calibration 
curve of mercury and the LOD and LOQ values were less than 0.025 and 0.08 ng 
respectively. 
 
Table 3.7: Results from the linear regression analysis of the calibration data for the 
determination of mercury. 
Parameters Value 
Calibration range/ng 100-800 
Slope/ng 7.334  10-4 
Standard error of slope 5.184  10-6 




3.4.2   Accuracy 
Recovery tests were carried out so as to check the accuracy of the methods used for 
quantitation of metals.  This was done by spiking cream samples with known amounts of 
the element of interest as described in Section 2.4.4.  The results obtained from the 
recovery tests are summarised in Table 3.8.  The mean percentage recovery for all the 
metals analysed ranged from 95.6 – 112.7% and the percent relative standard deviation 




Table 3.8: Recovery data for heavy metal quantification in skin-lightening products          
(n = 3). 
Element Spiked amount  
/µg g-1 
Found/µg g-1 Recovery % Standard  
deviation 
%R.S.D. 
Al 0.05 0.049 98.14 0.0004 0.89 
 1.20 1.181 98.39 0.0092 0.78 
Cr 0.02 0.020 100.24 0.0002 0.99 
 0.20 0.219 109.51 0.0091 4.17 
Cu 0.02 0.019 99.3 0.0009 4.89 
 0.07 0.068 98.28 0.0018 2.62 
Fe 0.08 0.079 99.07 0.0007 0.88 
 1.10 1.083 98.43 0.0013 0.12 
Hg 0.25 0.282 112.76 2.974 1.05 
 0.45 0.496 110.26 2.182 0.44 
Mn 0.02 0.019 99.17 0.0011 5.64 
 0.04 0.038 95.63 0.0005 1.23 
Ni 0.02 0.019 98.07 0.0002 1.22 
 0.30 0.299 99.87 0.0023 0.76 
Pb 0.05 0.049 97.43 0.0008 1.59 
 1.0 0.978 97.83 0.0023 0.23 
Zn 0.08 0.078 97.75 0.0008 1.08 





3.5   Levels of mercury and heavy metals detected in skin-lightening 
products 
A total of 35 SLPs were investigated for the presence of 12 heavy metals (As, Al, Cd, Co, 
Cr, Cu, Fe, Mn, Ni, Pb, Zn and Hg) in this study.  As seen in Table 3.9, only nine of the 
metals (Al, Cr, Cu, Fe, Mn, Ni, Pb, Zn and Hg) were detected in the studied SLPs.  
Arsenic, cadmium and cobalt could not be detected.  
Aluminium was detected in all the cream samples investigated at concentrations ranging 
from 0.039 to 0.354 µg g-1.  Among the cream samples analysed, SLP 12 was found to 
contain the highest level of Al but this value is much lower than the level found in 
Brazilian make-up products (199).  Although, no guideline has yet been established for 
Al in cosmetic products, studies have shown it to cause changes in some biological 
processes.  It is suggested that Al at high concentration can result in a decreased rate of 
DNA synthesis, an increase in DNA replication errors and affinity of linker histones for 
DNA (200). 
Chromium was detected in 21 cream samples.  The concentration of Cr found ranged 
from 0.010 to 0.217 µg g-1.  The levels of Cr found in the cream samples were similar to 
some of those found in body creams from Dubai, India, and Pakistan (201), and some 
personal care products in Nigeria (4).  The level of Cr in the cream samples was found to 
be lower than the reported value capable of inducing immediate side-effects.  This could 
imply that continued or long-term exposure to cosmetic products with a low level of Cr 
is unsafe too.  Side-effects, such as skin rashes, kidney and liver damage, lung cancer, 
and respiratory problems, have been reported to be associated with chromium exposure 
(4).  However, complications associated with chromium exposure are dependent upon its 
oxidation state.  In accordance with the IARC classification, Cr(VI) compounds are 
considered carcinogenic to humans while metallic Cr and Cr(III) compounds were not 
classifiable as human carcinogens due to lack of reassuring evidence in humans (202).  
Reports have also shown that Cr(VI) can diffuse through the skin more easily than Cr(III) 
due to its higher solubility (203, 204), with the contact time, sweat at low pH and the 
application of a cleanser being contributing factors (205). 
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Lead was detected in all the studied cream samples, however, at low concentration.  The 
concentration of Pb ranged from 0.012 to 0.026 µg g-1.  The concentrations of Pb in the 
cream samples are lower than the concentrations found in some cosmetic products in 
Nigeria (150).  Pb concentrations in the cream samples were below the 10 µg g-1 limit 
that was established for Pb in specified cosmetics by Health Canada (206) and the 20 µg 
g-1 limit established as an impurity in colour additives in cosmetics for external use (207).  
However, even at low concentration, Pb has been indicated as a cause for concern since 
it can be absorbed through the skin especially after long-term exposure (208).  Hence, the 
concentrations of Pb in the studied cream samples do not indicate an immediate health 
concern. 
Nickel was detected in 26 cream samples with concentrations ranging from 0.010 to 0.433 
µg g-1.  The levels of Ni in the studied cream samples were similar to those found in 
moisturising and skin-lightening creams in Nigeria (152).  Ni with other metals, such as 
Cr and Co, are known inducers of allergic contact dermatitis both at occupational and 
environmental levels (175).  However, the levels of Ni in our cream samples were below 
the 5 µg g-1 limit proposed by scientific literature as a good manufacturing practice and 
an ultimate target level of 1 µg g-1 in order to minimise the risk of sensitization for very 
sensitive individuals (209). 
The copper concentrations ranged from 0.017 to 0.050 µg g-1 and copper was detected in 
all the studied cream samples.  The level of Cu in the cream samples is very low to cause 
any immediate health concerns.  However, cases of immune reactions, as a result of Cu 
exposure from intra-uterine devices or handling of euro coins, have been reported (152). 
Iron and manganese are two essential elements involved in a number of biological 
processes.  They are both reported to have relatively low toxicity.  Neurological disorders, 
such as anger, aggression, and criminality, are said to be associated with Mn exposure 
(210) and the cumulative effect of long-term exposure to low levels of Fe may result in 
cellular death or colorectal cancer (211, 212).  The concentration of Fe in the studied 
cream samples ranged from 0.112 to 1.252 µg g-1 which is lower than those reported in 
moisturising and skin-lightening creams in Nigeria (152).  Fe was detected in all the 
cream samples.  Low levels of Mn were detected in 22 of the studied cream samples.  The 
concentrations of Mn in the cream samples ranged from 0.012 to 0.053 µg g-1. 
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Zinc was detected in all the studied cream samples, with SLP 14 (1.535 µg g-1) and SLP 
33 (76.33 µg g-1) having the highest concentrations of Zn.  The concentrations of Zn in 
the cream samples ranged from 0.018 to 76.33 µg g-1.  High levels of Zn have been 
reported in body creams in Dubai, India, and Pakistan (201) and in personal care products 
in Nigeria (4).  Cream samples found to have a high concentration of Zn may serve in the 
form of ZnO as a broad spectrum inorganic ultraviolet (UV) radiation filter in creams.  
Despite the importance of Zn to the body, cumulative effects of high concentration 
dosages can cause brittle nails, neurological abnormalities, as well as gastrointestinal 
disorders and convulsions (152). 
Mercury was detected in only one of the studied cream samples (SLP 6) at a concentration 
of 69.86 µg g-1.  Under conditions of good manufacturing practice, trace amounts of 
mercury in cosmetics are unavoidable and it has been established by the US FDA that 
mercury in cosmetics should be less than 1 µg g-1 (213).  The concentration of Hg in 
cream sample SLP 6 is far above the allowed limit of 1 µg g-1 by the World Health 
Organization (WHO) (214) and the 3.0 µg g-1 limit allowed by Health Canada (206).  
High concentrations of Hg have been reported in skin-lightening creams in Syria and 
extremely high concentrations of Hg in Mexican facial whitening creams (215).  Hg can 
be absorbed through the skin and can accumulate in the brain, kidney, and liver tissues 
(141).  This may result in several health issues such as psychological, neurological, and 
immunological conditions and much more (137).  Cream SLP 6 was not found to contain 
any other SLA (see Section 3.3).  Thus, the high amount of Hg found here is indicative 
that it was not an impurity from the manufacturing process but that it was added as the 
active SLA.  It is well known that mercury salts bleach the skin (16).  The use of Hg as a 
SLA is banned and should not be found present in SLPs. 
 
3.6   Systemic exposure dosage and margin of safety for metals 
The systemic exposure dosage (SED) and margin of safety (MoS) in this study were 
estimated by using equations 2.10 and 2.8, respectively, as given in Section 2.5.  The 
values of SED and MoS obtained from the use of the studied SLPs are displayed in Tables 
3.10 and 3.11 for 100% dermal absorption respectively.  A minimum MoS value of 100 
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has been proposed by the World Health Organization (WHO) as acceptably safe for a 
product to be used on the human body (191). 
The estimated SED for Al in this study ranged from 1.16 × 10-5 to 1.05 × 10-4 mg kg-1 bw 
day-1.  This does not exceed the provisional tolerable daily intake (PTDI) of 1.43 × 10-1 
mg kg-1 bw day-1 set by the WHO (216).  The estimated SED of Pb from the use of the 
studied SLPs ranged from 3.57 × 10-6 to 1.93 × 10-5 mg kg-1 bw day-1.  A PTDI of 3.6 × 
10-3 mg kg-1 bw day-1 was used as the indicative value for comparing the results, even 
though the existing PTDI has been withdrawn by the combined FOA/WHO in 2011 as it 
could not be considered health protective (217).  The estimated SED values for Ni, Cr 
and Cu of the investigated SLPs ranged from 2.97 × 10-6 to 1.29 × 10-4, 3.86 × 10-6 to 6.45 
× 10-5 and 5.05 × 10-6 to 2.59 × 10-5 mg kg-1 bw day-1, respectively.  They are all below 
their respective recommended daily intake/tolerable intake values of 1.2 × 10-2, 3.3 × 10-
3 and 8.33 × 10-2 mg kg-1 bw day-1 (217).  The recommended daily intake (RDI) for Mn, 
Zn and Fe is set at 1.5 × 10-1 (218), 12.0 and 12.5 mg kg-1 bw day-1, respectively (217).  
Their respective SEDs in the current study ranged from 3.57 × 10-6 to 1.57 × 10-5, 5.65 × 
10-6 to 2.27 × 10-2 and 1.93 × 10-6 to 3.72 × 10-4 mg kg-1 bw day-1.  The SED of Hg in 
sample SLP 6 was 2.07 × 10-2 mg kg-1 bw day-1.  This is above the established WHO 
PTDI value of 7.14 × 10-4 mg kg-1 bw day-1 (194, 219), making the product unsafe for 
use.  The estimated SED for other metals studied were within their respective 
recommended PTDI or RDI values. 
As shown in Table 3.11, the MoS value of Hg (2.4085) in sample SLP 6 is far less than 
the minimum value of 100 proposed by WHO to guarantee product safety.  This should 
be a cause for concern since the safety of the product cannot be guaranteed.  All other 
metals examined in the studied SLPs have MoS values greater than 100.  This makes the 




Table 3.9: Levels of heavy metals detected in different samples of skin-lightening products analysed in this study (n = 3). 
Sample 
codes 
Mean concentration ± SD/µg g-1 
Al Cr Cu Fe Hg Mn Ni Pb Zn  
SLP 1 0.137±0.0005 0.010±0.0003 0.022±0.0003 0.209±0.0059 - 0.013±0.0001 0.017±0.0011 0.022±0.0099 0.030±0.0006 
SLP 2 0.132±0.0008 0.019±0.0006 0.043±0.0001 0.243±0.0021 - 0.012±0.0001 0.064±0.0005 0.014±0.0024 0.023±0.0001 
SLP 3 0.122±0.0031 0.217±0.0016 0.051±0.0010 1.252±0.0108 - 0.053±0.0001 0.433±0.0018 0.020±0.0120 0.023±0.0003 
SLP 4 0.137±0.0009 0.032±0.0001 0.056±0.0005 0.304±0.0010 - 0.015±0.0001 0.069±0.0005 0.020±0.0073 0.018±0.0004 
SLP 5 0.117±0.0014 0.013±0.0002 0.025±0.0003 0.169±0.0003 - <LOD 0.032±0.0001 0.016±0.0016 0.021±0.0005 
SLP 6 0.089±0.0005 <LOD 0.022±0..0001 0.149±0.0001 69.86±0.8921 <LOD 0.018±0.0007 0.020±0.0113 0.021±0.0003 
SLP 7 0.196±0.0010 0.171±0.0009 0.046±0.0004 0.458±0.0016 - 0.026±0.0001 0.166±0.0016 0.022±0.0033 0.145±0.0005 
SLP 8 0.091±0.0047 0.013±0.0007 0.034±0.0034 0.160±0.0060 - 0.012±0.0004 0.061±0.0031 0.017±0.0011 0.070±0.0005 
SLP 9 0.173±0.0025 0.064±0.0003 0.051±0.0003 0.298±0.0009 - 0.017±0.0001 0.059±0.0004 0.024±0.0058 0.113±0.0003 
SLP 10 0.050±0.0001 0.043±0.00004 0.034±0.0001 0.280±0.0003 - 00.023±0.0001 0.145±0.0013 0.025±0.0108 0.019±0.0003 
SLP 11 0.074±0.0003 0.013±0.0005 0.053±0.0002 0.207±0.0007 - 0.017±0.0002 0.035±0.0007 0.024±0.0092 0.032±0.0003 
SLP 12 0.354±0.0019 <LOD 0.035±0.0003 0.150±0.0006 - 0.022±0.0001 0.010±0.0006 0.025±0.0016 0.042±0.0003 
SLP 13 0.118±0.0002 0.033±0.0005 0.018±0.0003 0.252±0.0002 - 0.021±0.0001 0.097±0.0013 0.018±0.0069 0.061±0.0007 
SLP 14 0.243±0.0022 0.021±0.0006 0.037±0.0004 0.135±0.0005 - 0.013±0.0001 0.041±0.0009 0.025±0.0100 1.535±0.0140 
SLP 15 0.073±0.0024 0.032±0.0006 0.024±0.0012 0.147±0.0021 - <LOD 0.010±0.0004 0.018±0.0146 0.059±0.0007 
SLP 16 0.049±0.0010 0.036±0.0002 0.033±0.0002 0.175±0.0007 - 0.015±0.0002 0.059±0.0008 0.012±0.0070 0.030±0.0006 
SLP 17 0.043±0.0003 <LOD 0.026±0.0002 0.127±0.0002 - <LOD <LOD 0.017±0.0088 0.022±0.0002 
SLP 18  0.046±0.0010 <LOD 0.031±0.0001 0.122±0.0006 - <LOD <LOD 0.022±0.0027 0.026±0.0001 
SLP 19 0.061±0.0019 0.030±0.0009 0.035±0.0026 0.315±0.0136 - 0.020±0.0004 0.080±0.0014 0.019±0.0020 0.028±0.0003 
SLP 20 0.075±0.0005 0.115±0.0013 0.047±0.0005 0.218±0.0029 - 0.013±0.0002 0.099±0.0012 0.024±0.0055 0.052±0.0001 
SLP 21 0.104±0.0005 0.017±0.0003 0.050±0.0003 0.225±0.0010 - 0.020±0.0001 0.073±0.0014 0.021±0.0038 0.038±0.0001 
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SLP 22 0.039±0.0008 0.041±0.0004 0.022±0.0002 0.151±0.0008 - 0.012±0.0001 0.030±0.0008 0.023±0.0060 0.019±0.0003 
SLP 23 0.051±0.0007 <LOD 0.019±0.0002 0.120±0.0002 - <LOD 0.032±0.0004 0.023±0.0088 0.026±0.0001 
SLP 24 0.062±0.0008 <LOD 0.018±0.0002 0.124±0.0009 - <LOD <LOD 0.014±0.0037 0.032±0.0004 
SLP 25 0.258±0.0045 0.121±0.0004 0.017±0.0001 0.373±0.0026 - 0.012±0.0001 0.050 ±0.0006 0.015±0.0149 0.041±0.0003 
SLP 26 0.141±0.0081 <LOD 0.023±0.0026 0.122±0.0066 - <LOD <LOD 0.019±0.0018 0.063±0.0003 
SLP 27 0.106±0.0250 <LOD 0.020±0.0017 0.112±0.0051 - <LOD 0.010±0.0004 0.017±0.0026 0.020±0.0002 
SLP 28 0.068±0.0009 <LOD 0.048±0.0005 0.065±0.0004 - <LOD <LOD 0.022±0.0082 0.239±0.0002 
SLP 29 0.304±0.0028 <LOD 0.024±0.0006 0.122±0.0003 - 0.012±0.0001 <LOD 0.019±0.0031 0.074±0.0004 
SLP 30 0.095±0.0027 <LOD 0.035±0.0013 0.139±0.0035 - 0.013±0.0003 0.013±0.0006 0.026±0.0081 0.052±0.0003 
SLP 31 0.302±0.0053 0.090±0.0006 0.051±0.0003 0.285 ±0.0013 - 0.012±0.0001 0.025±0.0012 0.019±0.0062 0.020±0.0001 
SLP 32 0.162±0.0001 <LOD 0.031±0.0002 0.114±0.0002 - <LOD <LOD 0.021±0.0054 0.067±0.0002 
SLP 33 0.050±0.0013 0.014±0.0004 0.024±0.0013 0.136±0.0003 - 0.012±0.0001 0.014±0.0005 0.065±0.0029 76.33±0.3055 
SLP 34 0.060±0.0007 <LOD 0.087±0.0007 0.120±0.0002 - <LOD <LOD 0.013±0.0016 0.035±0.0003 





Table 3.10: Systemic exposure dosage values of metals in skin-lightening products for 100% dermal absorption. 
Sample 
codes 
Systemic Exposure Dosage/mg kg-1 bw day-1 
Al Cr Cu Fe Hg Mn Ni Pb Zn  
SLP 1 4.07 × 10-5 2.97 × 10-6 6.54 × 10-6 6.21 × 10-5 0.00 3.86 × 10-6 5.05 × 10-6 6.54 × 10-6 8.91 × 10-6 
SLP 2 3.92 × 10-5 5.65 × 10-6 1.28 × 10-5 7.22 × 10-5 0.00 3.57 × 10-6 1.90 × 10-5 4.16 × 10-6 6.83 × 10-6 
SLP 3 3.63 × 10-5 6.45 × 10-5 1.52 × 10-5 3.72 × 10-4 0.00 1.57 × 10-5 1.29× 10-4 5.94 × 10-6 6.83 × 10-6 
SLP 4 4.07 × 10-5 9.51 × 10-6 1.66 × 10-5 9.03 × 10-5 0.00 4.46 × 10-6 2.05 × 10-5 5.94 × 10-6 5.35 × 10-6 
SLP 5 3.48 × 10-5 3.86 × 10-6 7.43 × 10-6 5.02 × 10-5 0.00 0.00 9.51 × 10-6 4.75 × 10-6 6.24 × 10-6 
SLP 6 2.64 × 10-5 0.00 6.54 × 10-6 4.43 × 10-5 2.08 × 10-2 0.00 5.35 × 10-6 5.94 × 10-6 6.24 × 10-6 
SLP 7 5.82 × 10-5 5.08 × 10-5 1.37 × 10-5 1.36 × 10-4 0.00	 7.73 × 10-6 4.93 × 10-5 6.54 × 10-6 4.31 × 10-5 
SLP 8 2.70 × 10-5 3.86 × 10-6 1.01 × 10-5 4.75 × 10-5 0.00	 3.57 × 10-6 1.81 × 10-5 5.05 × 10-6 2.08 × 10-5 
SLP 9 5.14 × 10-5 1.90 × 10-5 1.52 × 10-5 8.86 × 10-5 0.00	 5.05 × 10-6 1.75 × 10-5 7.13 × 10-6 3.36 × 10-5 
SLP 10 1.49 × 10-5 1.28 × 10-5 1.01 × 10-5 8.32 × 10-5 0.00	 6.83 × 10-6 4.31 × 10-5 7.43 × 10-6 5.65 × 10-6 
SLP 11 2.19 × 10-5 3.86 × 10-6 1.57 × 10-5 6.15 × 10-5 0.00	 5.05 × 10-6 1.04 × 10-5 7.13 × 10-6 9.51 × 10-6 
SLP 12 1.05 × 10-4 0.00 1.04 ×10-5 4.46 × 10-5 0.00	 6.54 × 10-6 2.97 × 10-6 7.43 × 10-6 1.25 × 10-5 
SLP 13 3.51 × 10-5 9.81 × 10-6 5.35 × 10-6 7.49 × 10-5 0.00	 6.24 × 10-6 2.88 × 10-5 5.35 × 10-6 1.81 × 10-5 
SLP 14 7.22 × 10-5 6.24 × 10-6 1.09 × 10-5 4.01 × 10-5 0.00	 3.86 × 10-6 1.22 × 10-5 7.43 × 10-6 4.56× 10-4 
SLP 15 2.17 × 10-5 9.51 × 10-6 7.13 × 10-6 4.37 × 10-5 0.00	 0.00 2.97 × 10-6 5.35 × 10-6 1.75 × 10-5 
SLP 16 1.46 × 10-5 1.07 × 10-5 9.81 × 10-6 5.20 × 10-5 0.00	 4.46 × 10-6 1.75 × 10-5 3.57 × 10-6 8.91 × 10-6 
SLP 17 1.28 × 10-5 0.00 7.73 × 10-6 3.77 × 10-5 0.00	 0.00 0.00 5.05 × 10-6 6.54 × 10-6 
SLP 18  1.37 × 10-5 0.00 9.21 × 10-6 3.63 × 10-5 0.00	 0.00 0.00 6.54 × 10-6 7.73 × 10-6 
SLP 19 1.81 × 10-5 8.91 × 10-6 1.04 × 10-5 9.36 × 10-5 0.00	 5.94 × 10-6 2.38 × 10-5 5.65 × 10-6 8.32 × 10-6 
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SLP 20 2.23 × 10-5 3.42 × 10-5 1.39 × 10-5 6.48 × 10-5 0.00	 3.86 × 10-6 2.94 × 10-5 7.13 × 10-6 1.55 × 10-5 
SLP 21 3.09 × 10-5 5.05 × 10-6 1.49 × 10-5 6.69 × 10-5 0.00	 5.94 × 10-6 2.17 × 10-5 6.24 × 10-6 1.13 × 10-5 
SLP 22 1.16 × 10-5 1.22 × 10-5 6.54 × 10-6 4.49 × 10-5 0.00	 3.57 × 10-6 8.91 × 10-6 6.83 × 10-6 5.65 × 10-6 
SLP 23 1.52 × 10-5 0.00 5.65 × 10-6 3.57 × 10-5 0.00	 0.00 9.51 × 10-6 6.83 × 10-6 7.73 × 10-6 
SLP 24 1.84 × 10-5 0.00 5.35 × 10-6 3.68 × 10-5 0.00	 0.00 0.00 4.16 × 10-6 9.51 × 10-6 
SLP 25 7.67 × 10-5 3.59 × 10-5 5.05 × 10-6 1.11 × 10-4 0.00	 3.57 × 10-6 1.49 × 10-5 4.46 × 10-6 1.22 × 10-6 
SLP 26 4.19 × 10-5 0.00 6.83 × 10-6 3.63 × 10-5 0.00	 0.00 0.00 5.65 × 10-6 1.87 × 10-5 
SLP 27 3.15 × 10-5 0.00 5.94 × 10-6 3.33 × 10-5 0.00	 0.00 2.97 × 10-6 5.05 × 10-6 5.94 × 10-6 
SLP 28 2.02 × 10-5 0.00 1.43 × 10-5 1.93 × 10-5 0.00	 0.00 0.00 6.54 × 10-6 7.10 × 10-5 
SLP 29 9.03 × 10-5 0.00 7.13 × 10-6 3.63 × 10-5 0.00	 3.57 × 10-6 0.00 5.65 × 10-6 2.19 × 10-5 
SLP 30 2.82 × 10-5 0.00 1.04 × 10-5 4.13 × 10-5 0.00	 3.86 × 10-6 3.86 × 10-6 7.73 × 10-6 1.55 × 10-5 
SLP 31 8.97 × 10-5 2.67 × 10-5 1.52 × 10-5 8.47 × 10-5 0.00	 3.57 × 10-6 7.43 × 10-6 5.65 × 10-6 5.94 × 10-6 
SLP 32 4.81 × 10-5 0.00 9.21 × 10-6 3.39 × 10-5 0.00	 0.00 0.00 6.24 × 10-6 1.99 × 10-5 
SLP 33 1.49 × 10-5 4.16 × 10-6 7.13 × 10-6 4.04 × 10-5 0.00	 3.57 × 10-6 4.16 × 10-6 1.93 × 10-5 2.27 × 10-2 
SLP 34 1.78 × 10-5 0.00 2.59 × 10-5 3.57 × 10-5 0.00	 0.00 0.00 3.86 × 10-6 1.04 × 10-5 





Table 3.11: Margin of safety values of metals in skin-lightening products for 100% dermal absorption. 
Sample 
codes 
Margin of Safety 
Al Cr Cu Fe Hg Mn Ni Pb Zn  
SLP 1 245634.3 100955.7 611852.8 1127097.1 0.00 3624051.3 395904.8 61185.3 3365190.5 
SLP 2 254938.7 53134.6 313040.9 969396.4 0.00 3926055.5 105162.2 96148.3 4389378.9 
SLP 3 275835.3 4652.3 263936.5 188149.6 0.00 888918.2 15543.6 67303.8 4389378.9 
SLP 4 245634.3 31548.7 240370.7 774879.4 0.00 3140844.4 97541.8 67303.8 5608650.8 
SLP 5 287623.1 77658.2 538430.5 1393865.9 0.00 0.00 210324.4 84129.8 4807414.9 
SLP 6 378111.3 0.00 611852.8 1580961.9 2.4085 0.00 373910.1 67303.8 4807414.9 
SLP 7 171693.4 5903.8 292625.3 514330.4 0.00	 1812025.6 40544.5 61185.3 696246.3 
SLP 8 369801.2 77658.2 395904.8 1472270.8 0.00	 3926055.5 110334.1 79180.9 1442224.5 
SLP 9 194519.7 15774.3 263936.5 790480.9 0.00	 2771333.3 114074.3 56086.5 893413.4 
SLP 10 673038.1 23478.1 395904.8 841297.6 0.00	 2048376.8 46416.4 53843.0 5313458.6 
SLP 11 454755.5 77658.2 253976.6 1137987.1 0.00	 2771333.3 192296.6 56086.5 3154866.1 
SLP 12 95061.9 0.00 384593.2 1570422.2 0.00	 2141484.8 673038.1 53843.0 2403707.5 
SLP 13 285185.6 30592.6 747820.1 934775.1 0.00	 2243460.3 69385.4 74782.0 1655011.7 
SLP 14 138485.2 48074.1 363804.4 1744913.6 0.00	 3624051.3 164155.6 53843.0 65769.2 
SLP 15 460984.9 31548.7 560865.1 1602471.7 0.00	 0.00 673038.1 74782.0 1711113.8 
SLP 16 686773.6 28043.3 407901.9 1346076.2 0.00	 3140844.4 114074.3 112173.0 3365190.5 
SLP 17 782602.4 0.00 517721.6 1854829.4 0.00	 0.00 0.00 79180.9 4588896.1 
SLP 18  731563.1 0.00 434218.1 1930846.9 0.00	 0.00 0.00 61185.3 3882912.1 
SLP 19 551670.6 33651.9 384593.2 747820.1 0.00	 2355633.3 84129.8 70846.1 3605561.2 
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SLP 20 448692.1 8778.8 286399.2 1080565.7 0.00	 3624051.3 67983.6 56086.5 1941456.0 
SLP 21 323576.0 59385.7 269215.2 1046948.1 0.00	 2355633.3 92196.9 64098.9 2656729.3 
SLP 22 862869.4 24623.3 611852.8 1560022.1 0.00	 3926055.5 224346.0 58525.1 5313458.6 
SLP 23 659841.3 0.00 708461.2 1963027.8 0.00	 0.00 210324.4 58525.1 3882912.1 
SLP 24 542772.7 0.00 747820.1 1899704.3 0.00	 0.00 0.00 96148.3 3154866.1 
SLP 25 130433.7 8343.4 791809.5 631537.1 0.00	 3926055.5 134607.6 89738.4 2462334.5 
SLP 26 238665.9 0.00 585250.5 1930846.9 0.00	 0.00 0.00 70846.1 1602471.7 
SLP 27 317470.8 0.00 673038.1 2103244.0 0.00	 0.00 673038.1 79180.9 5047785.7 
SLP 28 494880.9 0.00 280432.5 3624051.1 0.00	 0.00 0.00 61185.3 422408.8 
SLP 29 110697.1 0.00 560865.1 1930846.9 0.00	 3926055.5 0.00 70846.1 1364266.4 
SLP 30 354230.6 0.00 384593.2 1694700.2 0.00	 3624051.3 517721.6 51772.2 1941456.0 
SLP 31 111430.1 11217.3 263936.5 826538.0 0.00	 3926055.5 269215.2 70846.1 5047785.7 
SLP 32 207727.8 0.00 434218.1 2066345.0 0.00	 0.00 0.00 64098.9 1506801.7 
SLP 33 673038.1 72111.2 560865. 1732083.3 0.00	 3926055.5 480741.5 20708.9 1322.6 
SLP 34 560865.1 0.00 154721.1 1963027.8 0.00	 0.00 0.00 103544.3 2884448.9 







CONCLUSIONS AND RECOMMENDATIONS 
A number of skin-lightening formulations commonly available in the Nigerian market 
were investigated in this study.  Only 28% of the sample products were manufactured in 
Nigeria.  The remaining 72% of the sample products were either manufactured in 
America, Europe, Asia or other African Countries. 
A total of 35 skin-lightening formulations were analysed for the quantitative 
determination of some selected organic active ingredients and heavy metals.  The organic 
active ingredients were quantified by means of HPLC and the heavy metals were 
quantified by means of ICP-OES and/or CV-AAS.  All analytical methods employed in 
this study were fully validated in terms of precision, detection and quantification limits, 
linearity and recovery. 
Determination of skin-lightening agents by means of HPLC 
The active ingredients investigated in our sample products by means of HPLC included 
clobetasol propionate, betamethasone dipropionate, clotrimazole, hydroquinone, 
benzoquinone, kojic acid, niacinamide and arbutin. 
An external standard method was used to prepare a calibration curve for each active 
ingredient.  The correlation coefficients of all the calibration curves were in the acceptable 
range of a value greater than 0.95.  The hydroquinone standard had the lowest correlation 
coefficient of 0.9942, while both betamethasone dipropionate and clotrimazole had the 
highest correlation coefficient values of 0.9995.  The limits of detection obtained for 
hydroquinone, benzoquinone, kojic acid, niacinamide, arbutin, clobetasol propionate, 
betamethasone dipropionate and clotrimazole were 0.029, 0.026, 0.014, 0.016, 0.012, 
0.008, 0.007 and 0.007 mg L-1 respectively and the limits of quantitation were 0.097, 
0.085, 0.046, 0.052, 0.039, 0.028, 0.026 and 0.025 respectively. 
Intra-day and inter-analyses were used to test the precision of the method.  The percent 
relative standard deviation (%R.S.D.) for the intra-day precision ranged from 0.17 to 
8.16% while that of the inter-day precision ranged from 0.14 to 4.78%.  A recovery 
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analysis was used to test the accuracy of the method.  The calculated recoveries for all the 
active ingredient were within an acceptable range.  The obtained percent recoveries 
ranged from 84.23 to 110.33%. 
Arbutin was not detected in any of the products.  A total number of 32 samples (92%) 
were found to contain at least one or more of the other active ingredients.  Hydroquinone 
was detected in 15 samples with only five of the samples properly labelled.  The 
concentration of hydroquinone in the samples ranged from 0.017 to 7.096%.  Some of the 
samples containing hydroquinone were found to contain benzoquinone.  Hydroquinone 
is usually unstable in some formulations and hydrolyses to benzoquinone.  The six 
samples found to contain benzoquinone ranged from 0.005 to 0.015%.  Kojic acid was 
detected in nine samples in the range of 0.017 to 1.412%.  However, only three samples 
specified kojic acid as an ingredient in the formulations.  Four samples were found to 
contain niacinamide, with only one listing niacinamide on the label.  Although, one more 
sample listed niacinamide among its ingredients, it was not detected after analysis.  The 
concentration of niacinamide in the samples ranged from 0.029 to 1.827%.  Arbutin was 
indicated to be present in one of the sample products but, upon analysis, it was not 
detected.  Steroid compounds were detected in 13 of the studied samples with all the 
samples properly labelled.  Although one sample claimed to contain clobetasol 
propionate, after analysis it was found to contain betamethasone dipropionate.  Eight 
samples were found to contain clobetasol propionate alone, two samples were found to 
contain both clobetasol propionate and clotrimazole, and three samples were found to 
contain betamethasone dipropionate only.  The concentrations of clobetasol propionate, 
betamethasone dipropionate and clotrimazole were found in the range of 0.007 to 0.035, 
0.019 to 0.027 and 0.007 to 0.012% (m/m) respectively. 
Determination of heavy metals by means of ICP-OES and/or CV-AAS 
All skin-lightening formulations were screened for the presence of arsenic, aluminium, 
cadmium, cobalt, chromium, copper, iron, manganese, nickel, lead, and zinc by means of 
ICP-OES and mercury was screened for by means of CV-AAS.   
The correlation coefficients for all the different metal calibration curves ranged from 
0.9980 to 0.9999.  The limits of detection and quantitation of the different metals varied 
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from 0.007 to 0.026 and 0.024 to 0.088 mg L-1 respectively.  The methods were found to 
have good recovery values ranging from 95.6 to 112.7%. 
Arsenic, cadmium and cobalt were not detected in any of the sample products.  
Aluminium was detected in all the samples and the maximum concentration detected was 
0.354 µg g-1.  There is no established guideline for aluminium, but certain health concerns 
have been reported from its high dosage.  Iron, manganese, and copper were detected in 
most of the samples at levels not exceeding 1.252, 0.053, and 0.056 µg g-1, respectively.  
This should not be a threat to the health of users of the products since these are essential 
elements required in a number of biological processes at low concentration.  However, 
cumulative effects of long-term exposure to these elements even at low concentration is 
unsafe.  Zinc was detected in all the samples but was relatively high in one of the samples 
(76.33 µg g-1).  It may have been present in this sample as a sunscreen filter to protect the 
user against the harmful effects derived from solar ultraviolet exposure.  This is 
particularly important in SLPs where the formation of the natural UV filter, melanin, is 
being prevented.  Zinc is a vital element to the body but not required at high concentration.  
Chromium was found in twenty-one samples at a maximum concentration (0.217 µg g-1) 
that cannot induce allergenic contact dermatitis. 
Lead was detected in all samples with concentrations not exceeding 0.026 µg g-1 and 
nickel was detected in 26 samples at a maximum concentration of 0.433 µg g-1.  The levels 
detected for both metals do not exceed the maximum limits allowed as impurities in 
colour additives in cosmetics for external use.  One sample (SLP 6) was found to have a 
relatively high level of mercury (69.86 µg g-1).  This level of mercury in a skin-lightening 
cream is alarming due to its high toxicity.  The severe health implications of mercury are 
why it is completely banned in cosmetics. 
The values of SED and MoS obtained for the studied SLPs show that the level of the 
metal contents detected in these products are safe for use except in the case of the sample 
SLP 6 containing a relatively high level of Hg, where it’s SED and MoS values are outside 
the WHO limits. 
As gathered from the results of this study, the initial concern of some skin-lightening 
formulations commonly available in the Nigerian market containing either banned 
ingredients or exceeding imposed limits of allowed ingredients and improper labelling of 
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these products was justified.  The findings in this study further expose the continued 
inclusion of banned and toxic ingredients, such as hydroquinone, mercury and very potent 
steroids like clobetasol propionate and betamethasone dipropionate, in SLPs.  These 
ingredients are known to be detrimental and pose a serious health risk if the frequency of 
application, the surface area of the body applied, and the duration of practice are 
considered.  Severe and permanent side-effects such as exogenous ochronosis, decreased 
skin elasticity, trimethylaminuria, Cushing syndrome, diabetes mellitus, steroid addiction 
syndrome, gingivostomatitis, paradoxical hyperpigmentation and many more have been 
reported from using SLPs containing these toxic ingredients (59).  
Often, users are advised to double check the labelling of any skin-care product or any 
other cosmetics products before purchase.  However, it is worrisome to know that even 
when users double check the labelling, one cannot be certain of the actual contents of 
these products as evident from some of the findings in this study.  We, therefore, 
discourage the use of these products for skin-lightening purposes.  For skin conditions 
that do require treatment with such products, appropriate consultation from a medical 
practitioner is recommended. 
Furthermore, regulating agencies, especially in a country like Nigeria where skin-
bleaching is fashionable, must establish and enforce more stringent regulations restricting 
the use of banned and harmful ingredients in commercial skin-lightening products.  Such 
regulations should extend to importation or smuggling of skin-lightening or any other 
cosmetic products containing banned or toxic ingredients since 72% of the cream samples 
investigated in this study were found to be manufactured in other countries but are in 
circulation in the study area.  Efforts must also be made by appropriate authorities to 
enlighten users and the general public on the possible dangers associated with skin-
bleaching practices. 
Future work can investigate some newly used plant extracts as active ingredients in skin-
lightening formulations.  Manufacturers have now opted for the inclusion of some plant 
extracts with unknown safety profiles in skin-lightening products not minding the amount 
added as far as the desired effects of skin-lightening are achieved.  Examples of such 
extracts include mulberry root extracts, licorice extracts, lemon extracts, and more.   
Moreover, parabens used as preservatives in skin-lightening products also need to be 
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investigated.  Most of the studied cream samples in this study were found to contain one 
or more of these parabens (methyl, ethyl, propyl, and butyl parabens).  Toxicity concerns 
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This appendix contains the list of chemicals used during the course of this study. 
A1  Chemicals used during the analysis of skin-lightening agents by HPLC 
Chemical Supplier 
Acetonitrile (HPLC grade) Sigma-Aldrich 
Methanol (HPLC grade) Sigma-Aldrich 
Millipore water Millipore Elix 5 UV water purification unit 
Betamethasone dipropionate Sigma Life Science 
Clobetasol propionate (98%) Sigma-Aldrich 
Clotrimazole Sigma-Aldrich 
Hydroquinone (99.09%) Fluka 
Benzoquinone (99.5%) Fluka 
Kojic acid (98%) Fluka 
Niacinamide (99.9%) Supelco Analytical 
Arbutin (96%) Sigma-Aldrich 
Acetic acid (99.9%) BDH Chemicals Limited 
Orthophosphoric acid (98%) Rochelle Chemicals 
Dipotassium hydrogen phosphate BDH Laboratory Supplies  





A2  Chemicals used during the analysis of heavy metals by ICP-OES and CV-AAS 
Chemical Supplier 
Tin chloride dihydrate BDH Laboratory Supplies 
Mercury chloride (HgCl2) Sigma-Aldrich 
Analytical grade nitric acid (69%) Emparta ACS 
Analytical grade hydrochloric acid (32%) B & M Scientific 
Analytical grade, aluminum (Al) 1000 ppm Fluka Chemicals 
Analytical grade, chromium (Cr) 1000 ppm Fluka Chemicals 
Analytical grade, copper (Cu) 1000 ppm Fluka Chemicals 
Analytical grade, iron (Fe) 1000 ppm Fluka Chemicals 
Analytical grade, manganese (Mn) 1000 ppm Fluka Chemicals 
Analytical grade, nickel (Ni) 1000 ppm Fluka Chemicals 
Analytical grade, lead (Pb)  1000 ppm Fluka Chemicals 








This appendix contains the list of instruments and equipment used during the course of 
this study. 
B1  Instruments 
Shimadzu Prominence HPLC equipped with: 
DGU-20A3 Prominence degasser,  
LC-20AD XR Prominence binary pumps,  
SIL-20A XR Prominence autosampler,  
SPD-M20A Prominence diode array detector,  
CTO-20A Prominence column oven,  
CBM-20A Prominence communicator bus module,  
FRC-10A Prominence fraction collector and  
LC/Lab solution system software.  
 
PerkinElmer Lambda 25 UV-VIS dual-beam spectrophotometer 
 
PerkinElmer Optima 5300 DV ICP-OES 
 






B2  Equipment 
CEM Mars 6 microwave digester with a turntable containing 12 reaction vessels (XP-
1500) 
Brownlee HPLC column; C18 (100 × 4.6 mm, 3 µm) 
SGE HPLC column; C18 (250 × 4.6mm, 5 µm) 
Ultrasonic bath (Ultra Manufacturing Company) 
Helium degasser (Sp8700 XR) 
Millipore Elix 5 UV water purification system 
Ministart RC 25 hydrophilic 0.45 µm single use syringe filters 






CALIBRATION DATA FOR SKIN-LIGHTENING AGENTS 
The calibration data for all skin-lightening agents analysed is given in this section. 




































































































Mean 4567.1 10691.7 41366.1 121360.6 226963.4 360742.4 556615.2 1331999 
Std Dev 99.3 258.3 366.9 1118.9 5241.1 4502.5 6643.3 18622.18 
RSD%  2.2 2.4 0.9 0.9 2.3 1.2 1.2 1.4 
  


































































































Mean 4168.4 9520.4 37202 108504.3 201319.7 321682.8 497731.7 1196793 
Std Dev 111.9 130.2 400.4 1046.9 3160.1 4000.9 5372.3 16264.5 






































































































Mean 5172 12815.4 48998.8 141797.2 279250.8 438850.4 679310.2 1645309 
Std Dev 178.7 208.8 1272.3 1530.9 1265.8 5369.4 11281.2 7527.8 
RSD% 3.5 1.6 2.6 1.1 0.5 1.2 1.7 0.5 
 

























































































Mean 4518.2 193655.7 836296.1 1585918 2722978 3292664 5061587 
Std Dev 345.4 2470.2 3297.9 21669.5 18695.3 12433.5 13745.0 
































































































Mean 1295.9 13475 141003 336056.3 577090.9 728377.7 766027.1 
Std Dev 130.9 926.9 3601.4 3259.5 7837.6 9141.4 5431.1 
RSD% 10.1 6.9 2.6 0.9 1.4 1.3 0.7 
 

























































































Mean 12921.2 238422.9 694455.7 1039928 1440049 1891543 2553222 
Std Dev 393.5 2511.9 3801.9 6983.9 10753.2 9920.2 14138.9 
































































































Mean 11266.3 97134.7 304234.8 538375.4 762549.4 1022713 1286549 
Std Dev 273.9 1447.1 3201.4 2580.9 5378.1 20893.6 30888.1 
RSD% 2.4 1.5 1.1 0.5 0.7 2.0 2.4 
 

























































































Mean 1949.9 9520.3 13511.3 22571.2 33403.2 41999.1 47118.4 
Std Dev 16.6 261.2 303.2 665.4 562.1 624.8 1183.7 







CALIBRATION GRAPHS AND RESIDUAL PLOTS FOR SKIN-
LIGHTENING AGENTS 
The calibration curves and residual plots of all skin-lightening agents analysed by HPLC 





















































































































































































































































































































































































































































































HPLC CHROMATOGRAMS OF STANDARD MIXTURES OF 
SKIN-LIGHTENING AGENTS AND SKIN-LIGHTENING 
PRODUCTS 


















Figure E1: Chromatogram for the separation of CP, BD and CT at 240 nm.  The retention 
times were 2.974, 3.702, and 4.766 minutes respectively.  The chromatographic 
conditions used were: Brownlee analytical C18 (100 × 4.6 mm, 3 µm) column; mobile 
phase: MeOH-H2O 80:20 (v/v); injection volume: 10 µL; flow rate: 0.8 mL min-1; and 































Figure E2: Chromatogram for the separation of CP, BD and CT at 225 nm.  The retention 
times were 2.974, 3.702, and 4.766 minutes respectively.  The chromatographic 
conditions used were: Brownlee analytical C18 (100 × 4.6 mm, 3 µm) column; mobile 
phase: MeOH-H2O 80:20 (v/v); injection volume: 10 µL; flow rate: 0.8 mL min-1; and 






























Figure E3: Chromatogram for the separation of NC, KA, HQ, and BQ at 289 nm.  The 
retention times were 2.663, 6.192, 7.926 and 15.432 minutes respectively.  The 
chromatographic conditions used were: SGE C18 (250 × 4.6mm, 5 µm) column; mobile 
phase: 0.5% orthophosphoric acid in methanol and 0.5% orthophosphoric acid in water 
5:95 (v/v); injection volume: 10 µL; flow rate: 1.0 mL min-1; and column temperature:  
































Figure E4: Chromatogram for the separation of NC, KA, HQ, and BQ at 270 nm.  The 
retention times were 2.657, 6.191, 7.926 and 15.458 minutes respectively.  The 
chromatographic conditions used were: SGE C18 (250 × 4.6mm, 5 µm) column; mobile 
phase: 0.5% orthophosphoric acid in methanol and 0.5% orthophosphoric acid in water 
5:95 (v/v); injection volume: 10 µL; flow rate: 1.0 mL min-1; and column temperature:  

































Figure E5: Chromatogram for the separation of NC, KA, HQ, and BQ at 240 nm.  The 
retention times were 2.657, 6.191, 7.923 and 15.462 minutes respectively.  The 
chromatographic conditions used were: SGE C18 (250 × 4.6mm, 5 µm) column; mobile 
phase: 0.5% orthophosphoric acid in methanol and 0.5% orthophosphoric acid in water 
5:95 (v/v); injection volume: 10 µL; flow rate: 1.0 mL min-1; and column temperature:  













II. Chromatograms for the determination of HQ, KA, NC, and BQ in skin-lightening 
products at detection wavelengths of 289, 270, 270 and 240 nm respectively.  The 
chromatographic conditions used were: SGE C18 (250 × 4.6mm, 5 µm) column; 
mobile phase: 0.5% orthophosphoric acid in methanol and 0.5% orthophosphoric 
acid in water 5:95 (v/v); injection volume: 10 µL; flow rate: 1.0 mL min-1; and 















Figure E6: Chromatogram of SLP 1.  The active ingredients detected are NC, KA, and 






























Figure E7: Chromatogram of SLP 2.  The active ingredients detected are NC, KA, and 














Figure E8: Chromatogram of SLP 3.  The active ingredients detected are NC, KA, and 
























Figure E9: Chromatogram of SLP 4.  The active ingredients detected are KA and HQ. 













Figure E10: Chromatogram of SLP 5.  The active ingredients detected are KA and HQ. 






















Figure E11: Chromatogram of SLP 8.  The active ingredients detected are KA and HQ. 














Figure E12: Chromatogram of SLP 10.  The active ingredient detected is HQ. The 






















Figure E13: Chromatogram of SLP 11.  The active ingredient detected is HQ. The 














Figure E14: Chromatogram of SLP 12.  The active ingredients detected are HQ and BQ.  





















Figure E15: Chromatogram of SLP 13.  The active ingredients detected are HQ and BQ.  














Figure E16: Chromatogram of SLP 14.  The active ingredients detected are HQ and BQ.  




















Figure E17: Chromatogram of SLP 15.  The active ingredient detected is KA.  The 













Figure E18: Chromatogram of SLP 17.  The active ingredient detected is KA.  The 






















Figure E19: Chromatogram of SLP 18.  The active ingredients detected are HQ and BQ.  














Figure E20: Chromatogram of SLP 19.  The active ingredient detected is KA.  The 





















Figure E21: Chromatogram of SLP 21.  The active ingredient detected is HQ. The 















Figure E22: Chromatogram of SLP 22.  The active ingredients detected are HQ and BQ.  




















Figure E23: Chromatogram of SLP 23.  The active ingredients detected are HQ and BQ.  













Figure E24: Chromatogram of SLP 24.  The active ingredient detected is NC.  The 










III. Chromatograms for the determination of CP, BD, and CT in skin-lightening 
products at detection wavelengths of 240, 240, and 225 nm respectively.  The 
chromatographic conditions used were: Brownlee analytical C18 (100 × 4.6 mm, 
3 µm) column; mobile phase: MeOH-H2O 80:20 (v/v); injection volume: 10 µL; 
















Figure E25: Chromatogram of SLP 9.  The active ingredients detected are CP and CT.  



























Figure E26: Chromatogram of SLP 20.  The active ingredients detected are CP and CT.  













Figure E27: Chromatogram of SLP 25.  The active ingredient detected is BD.  The 





















Figure E28: Chromatogram of SLP 26.  The active ingredient detected is CP.  The 














Figure E29: Chromatogram of SLP 27.  The active ingredient detected is CP.  The 




















Figure E30: Chromatogram of SLP 28.  The active ingredient detected is BD.  The 














Figure E31: Chromatogram of SLP 29.  The active ingredient detected is CP.  The 




















Figure E32: Chromatogram of SLP 30.  The active ingredient detected is CP.  The 














Figure E33: Chromatogram of SLP 31.  The active ingredient detected is CP.  The 



















Figure E34: Chromatogram of SLP 32.  The active ingredient detected is CP.  The 















Figure E35: Chromatogram of SLP 33.  The active ingredient detected is CP.  The 



















Figure E36: Chromatogram of SLP 34.  The active ingredient detected is CP.  The 














Figure E37: Chromatogram of SLP 35.  The active ingredient detected is BD.  The 











RAW DATA FOR SKIN-LIGHTENING PRODUCTS 
This following tables gives the HPLC peak areas of the detected active ingredients in 
skin-lightening products.  The mass of each product analysed was 0.05 g. 
 

















































































































































































































































































































































































































































































































































CALIBRATION DATA FOR HEAVY METALS 
The calibration data for all the heavy metals analysed is given in this section. 
 
Table G1: Calibration data for the determination of aluminum (Al). 































Mean 384.9 1754.6 3798.9 6014.7 24674.4 41035.7 58216.6 77890.3 96588.4 
Std Dev 32.3 56.1 66.1 33.7 78.7 613.4 796.4 1302.5 467.3 
RSD% 8.4 3.2 1.7 0.6 0.3 1.5 1.4 1.7 0.5 
 
Table G2: Calibration data for the determination of chromium (Cr). 































Mean 287.7 1330.3 2586.0 3996.3 15372.2 27483.3 39154.2 51131.1 61569.2 
Std Dev 11.7 8.6 40.2 18.7 140.6 14.2 146.2 138.8 586.3 
RSD% 4.1 0.6 1.6 0.5 0.9 0.1 0.4 0.3 0.9 
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Table G3: Calibration data for the determination of copper (Cu). 































Mean 2770.9 12125 18235 27901 91718 153581.1 213243.5 293354.7 345907.8 
Std Dev 229.9 450.5 249.4 163.9 645.2 1801.1 1451.6 2334.4 1698.6 
RSD% 8.3 3.7 1.4 0.6 0.7 1.2 0.7 0.8 0.5 
 
Table G4: Calibration data for the determination of iron (Fe). 































Mean 83.5 805.8 2063.6 3545.9 20065.8 39981.5 58238.2 79603.8 97814.5 
Std Dev 4.1 17.1 51.7 10.5 14.3 337.4 165.6 356.6 855.6 
RSD% 4.9 2.1 2.5 0.3 0.1 0.8 0.3 0.4 0.9 
 
Table G5: Calibration data for the determination of manganese (Mn). 































Mean 1672 10897 18062.3 25834 113504 198489 281423 382068 450564 
Std Dev 68.1 92.7 23.1 60.8 686.4 1942.6 730.0 1140.1 4167.2 
RSD% 4.1 0.9 0.1 0.2 0.6 0.9 0.3 0.3 0.9 
184	
	
Table G6: Calibration data for the determination of nickel (Ni). 































Mean 122.3 733.9 1249.9 1952.5 7491.8 13366.5 19376.2 25903.5 31713.6 
Std Dev 6.4 17.5 13.7 35.3 55.5 3.4 150.2 19.2 102.4 
RSD% 5.2 2.4 1.1 1.8 0.7 0.03 0.8 0.1 0.3 
 
Table G7: Calibration data for the determination of lead (Pb). 































Mean 25.1 37.1 68.5 119.2 492.7 814.4 1139.9 1529.7 1862.7 
Std Dev 4.4×10-15 5.1 13.5 9.9 4.8 4.6 14.2 16.1 11.7 
RSD% 1.7×10-14 13.7 19.7 8.3 0.9 0.6 1.2 1.0 0.6 
 
Table G8: Calibration data for the determination of zinc (Zn). 































Mean 379.8 1548.3 2337.8 3737.5 14373 25369.9 36184 48454.4 58581.3 
Std Dev 10.5 18.4 9.2 36.6 18.8 56.7 442.8 64 320.6 













































Mean 0.079 0.146 0.235 0.309 0.381 0.446 0.505 0.567 
Std Dev 0.0015 0.0026 0.0025 0.0031 0.0026 0.0032 0.0035 0.0020 







CALIBRATION CURVES AND RESIDUAL PLOTS FOR HEAVY 
METALS 
The calibration curves and residual plots for all the heavy metals analysed by ICP-OES 
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